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Abstract
Background: The management of rheumatoid arthritis (RA) involves partially 
recursive attempts to make optimal treatment decisions that balance the risks of the 
treatment to the patient against the benefits of the treatment, while monitoring the 
patient closely for clinical response, as inferred from prior and residual disease activity, 
and unwanted drug effects, including abnormal laboratory findings. To the extent that 
this process is logical, based on best available evidence and determined by considered 
opinion, it should be amenable to capture within a Clinical Decision Support Systems 
(CDSSs). The formalisation of logical transformations and their execution by 
computer tools at point of patient encounter holds the promise of more efficient and 
consistent use of treatment rules and more reliable clinical decision making.
Research Setting: The early Rheumatoid Arthritis (eRA) clinic of the Royal Adelaide 
Hospital (RAH) with approximately 20 RA patient visits per week, and involving 160 
patients with a median duration of treatment of more than 4.5 years. 
Methods: The study applied a Knowledge Engineering approach to interpret the 
complexities of RA management, in order to implement a knowledge-based CDSS. 
The study utilised Knowledge Acquisition processes to elicit and explicitly define the 
RA management rules underpinning the development of the CDSS; the processes were 
(1) conducting a comprehensive literature review of RA management, (2) observing 
clinic consultations and (3) consulting with local clinical experts/leaders. Bayes’ 
Theorem and Bayes Net were used to generate models for assessing contingent 
probabilities of unwanted events. A questionnaire based on 16 real patient cases was 
developed to test the concordance agreement between CDSS generated guidance in 
response to real-life clinical scenarios and decisions of rheumatologists in response to 
the scenarios. 
 
Results: (1) Complex RA management rules were established which included (a) 
Rules for Changes in Dose/Agent and (b) Drug Toxicity Monitoring Rules. (2) A 
computer interpretable dynamic model for implementing the complex clinical guidance   V
was found to be applicable. (3) A framework for a methotrexate (MTX) toxicity 
prediction model was developed, thereby allowing missing risk ratios (probabilities) to 
be identified. (4) Clinical decision-making processes and workflows were described. 
Finally, (5) a preliminary version of the CDSS which computed Rules for Changes in 
Dose/Agent and Drug Toxicity Monitoring Rules was implemented and tested. One 
hundred and twenty-eight decisions collected from the 8 participating rheumatologists 
established the ability of the CDSS to match decisions of clinicians accustomed to 
application of Rules for Changes in Dose/Agent; rheumatologists unfamiliar with the 
rules displayed lower concordance (0.7857 vs. 0.3929, P = 0.0027). Neither group of 
rheumatologists matched the performance of the CDSS in making decisions based on 
highly complex Drug Toxicity Monitoring Rules (0.3611 vs. 0.4167, P = 0.7215). 
Conclusion: The study has made important contributions to the development of a 
CDSS suitable for routine use in the eRA clinic setting. Knowledge Acquisition 
processes were used to elicit domain knowledge, and to refine, validate and articulate 
eRA management rules, that came to form the knowledge base of the CDSS. The 
development of computer interpretable guideline models underpinned the CDSS 
development. The alignment of CDSS guidance in response to clinical scenarios with 
questionnaire responses of rheumatologists familiar with and accepting of the 
management rules (and divergence with responses by rheumatologists not familiar 
with the rules) indicates that the CDSS can be used to guide toward evidence-based 
considered opinion. The poor correlation between CDSS generated guidance regarding 
out of range blood results and response of rheumatologists to questions regarding 
toxicity scenarios, underlines the value of computer aided guidance when decisions 
involve greater complexity. It also suggests the need for attention to rule development 
and considered opinion in this area. 
Discussion: Effective utilisation of extant knowledge is fundamental to knowledge-
based systems in healthcare. CDSSs development for chronic disease management is a 
complex undertaking which is tractable using Knowledge Engineering and Knowledge 
Acquisition approaches coupled with modelling into computer interpretable algorithms. 
Complexities of drug toxicity monitoring were addressed using Bayes’ Theorem and   VI
Bayes Net for making probability based decisions under conditions of uncertainty. 
While for logistic reasons the system could not be developed to full implementation, 
preliminary analyses support the utility of the approach, both for intensifying treatment 
on a response contingent basis and also for complex drug toxicity monitoring. CDSSs 
are inherently suited to iterative refinements based on new knowledge including that 
arising from analyses of the data they capture during their use. This study has achieved 
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1 Introduction 
Purpose of the Study 
Rheumatoid Arthritis (RA) is a chronic autoimmune disease. RA affects primarily the 
joints and in the absence of effective treatment, causes widespread systemic 
complications and progressive joint destruction that can lead to disability and/or 
premature death. Intensive therapy with Disease Modifying Anti-Rheumatic Drugs 
(DMARDs) has the benefits of reducing symptoms and slowing progression of RA. 
However, managing RA is a complex task by virtue of the need to consider and 
prioritise a multiplicity of potential treatments. In addition, DMARDs can be 
responsible for Adverse Drug Reactions (ADRs). Methotrexate (MTX) is one of the 
most widely used DMARDs. Adverse effects caused by the administration of drugs 
such as MTX can be serious or life threatening. Clinicians tailor treatments to 
accommodate many factors, such as disease activity, the number and location of joints 
affected, and possible toxic effects associated with drugs, which make decision-
making a complicated process intrinsically. Published Clinical Practice guidelines 
(CPGs) aim to improve clinical decision-making; however, due to factors such as high 
complexity and a lack of specificity, they have relatively limited immediate impact on 
clinical practice. Furthermore, implementation research has shown the difficulty 
rheumatologists’ experience in implementing guidelines into clinical practice, and 
better strategies for translating evidence into rheumatology practice are needed[1]. 
 
The early Rheumatoid Arthritis (eRA) Clinic of the Royal Adelaide Hospital (RAH)
has been organised to provide prompt assessment and treatment of patients with eRA. 
The objective is to apply effective treatment in order to achieve remission in RA as 
soon as is practical, thereby avoiding irreversible joint damage caused by unsuppressed 
RA. Good decision-making for RA entails a balance between the benefits of treatment 
and the potential and realised risks of toxic drug effects. The eRA clinic has 
established the Dose Modification Protocol to assist the clinicians to adjust drug 
dosages for patients according to the selected disease activity assessment indices and 
laboratory variables. However, there were considerable exceptions for the clinicians to   2
fully comply the protocol. I performed a secondary data analysis on the relevant data 
extracted from the eRA clinical database; the results showed that the clinicians of the 
eRA clinic integrated additional clinical expertise into their decision-making, which 
complemented the protocol according to individual patient’s particular clinical 
circumstance. For example, a clinician may breach the protocols because of his or her 
concern regarding a potential or realised drug toxicity risk or due to other issues 
including logistical factors and patient preference. Such considerations can also lead to 
inconsistent protocol compliance by individual clinicians, who may weigh multiple 
considerations differently at different times. 
 
In order to systematically incorporate up-to-date evidence into clinical decision-
making coherently, the eRA clinic aimed to establish a full-scale RA management 
rules, coexisting with the Dose Modification Protocol. The RA management rules will 
provide evidence-based recommendations, which aim to assist the clinicians in their 
decision-making with the intent of achieving a balance between the benefits that 
accrue from disease suppression and events arising from unwanted drug effects. 
However in spite of guidance from the use of a paper-based approach, developing a 
knowledge-based computer application such as CDSS, with the features of delivering 
complex CPGs will be valuable to assist clinical decision-making. The eRA clinic 
needs interventions such as CDSSs to facilitate the decision-making process by 
computerising the complex RA management rules, and to tailoring treatment advice 
for individual patients according to relevant clinical and laboratory data inputs, thereby 
supplying best evidence in the most apt way at the time of decision-making. CDSSs 
also provide the opportunity for violations of the rules to be recorded at the point of 
care allowing alter evaluation of the reasons for violations and possible improvements 
in decision-making which can then be incorporated into the CDSS. 
 
In addition, the study conducted a questionnaire to analyse the agreement between the 
CDSS recommendation and the rheumatologist’s decision. This analysis evaluated the 
guideline compliance. It provided the insights into the acceptance of the guidelines, 
hence the future practicability of the CDSS. This information is valuable for future 
refinement of the RA management rules and further improvement of the CDSS.   3
 
In summary, the establishment of comprehensive RA management rules and the 
development of CDSS can facilitate the practice of Evidence-based Medicine (EBM) 
by utilising up-to-date evidence and case-based data to deliver patient-centred care. 
When integrated into the eRA clinic workflow, the CDSS can assist clinicians to make 
consistent, evidence-based decisions in daily clinical practice and thereby achieve 
better management of RA. This work builds upon the current project to computerise 
patient data in the eRA clinic that is funded by a grant from the Australian Department 
of Health and Ageing and administered through the Royal Australasian College of 
Physicians. The project utilizes patient data from the Rheumatology Unit’s ongoing 
Early Arthritis study (REC Approval No: 981105a). These patients have given written 
consent for long-term follow-up as part of the study (981105a). This project used the 
follow-up data during the CDSS development and the questionnaire. The patient data 




Clinical decision-making is central to medical practice. Clinical decision-making is a 
process that clinicians use to determine a patient’s needs based on the interpretation of 
medical observations according to the patient’s particular clinical state [2]. Today’s 
ageing population combined with increasingly sophisticated medical technology, make 
clinical decision-making increasingly complex. This complexity arises from factors 
such as a high prevalence of chronic diseases, increasing therapeutic options and 
patients with multiple co-morbidities who are consequently on multiple medications. 
The growing complexity results in increased uncertainty surrounding many decisions 
in clinical practice. In response to decision-making under increased uncertainty, 
clinicians have adopted the practice of EBM. EBM is the conscientious, explicit and 
judicious use of best evidence sourced from relevant clinical research and clinical 
expertise in decision-making relevant to the care of individual patients [3]. Submission 
to the disciplines of EBM is motivated by a desire to make ‘good’ clinical decisions. A 
‘good’ decision is the identification of an option with the highest expected ‘utility’ 
over other alternatives. A ‘utility’ is a numerical measurement of preference assigned   4
to a state or an outcome. According to Bayesian Decision Theory, A decision network 
represents information about the agent’s current state, the agent’s possible actions, the 
state/outcome that will result from the agent's action, and the utility of that 
state/outcome. When the state or the outcome of the agent’s action is unknown, find 
the utility of each possible state/outcome (action-state pair), and take the action with 
the maximum expected utility [4]. Clinical decision-making reflects how a clinician 
values a state or an outcome compared with other alternatives regarding to a specific 
clinical scenario. 
 
Despite the general enthusiasm for adopting EBM in clinical decision-making, gaps do 
exist between optimal practice and actual practice [5, 6]. Barriers such as time 
constraints for collecting the most recent, relevant medical evidence, and professional 
inertia in behavioural change required for utilisation of the evidence in daily practice 
remain. Therefore, a considerable number of clinical decisions are ‘suboptimal’ 
because a clinician makes his or her judgment based on outdated evidence or 
incomplete information or fails to act on new information. There is an increasing 
interest in facilitating EBM by promoting the implementation of best evidence from 
research findings to assist optimal decision-making in clinical practice. It is necessary 
to use efficient and effective practitioner-directed interventions to ensure that changes 
occur in actual practice. Nevertheless, uncertainty in clinical decision-making remains 
a problem, which affects the outcomes of decisions that are made based on expected 
outcomes regardless of the process of decision-making. For any single decision, there 
is a chance of resulting in a bad outcome. Therefore, evaluating the decision-making 
process, instead of evaluating a decision by the clinical outcome that follows the 
decision, will give us the insight into whether an intervention to improve decision-
making is better than other competing processes. 
 
People often make errors when confronted with complex problems. Moreover, the 
combination of time constraints, workload and competing demands in the clinical 
environment means that errors can occur at any phase in the clinical decision-making 
process. Clinical errors refer to any mistake made by a healthcare provider in a clinical 
setting. These errors are often made under a set of conditions within the system in   5
which individual healthcare providers practice. Making clinical errors during decision-
making is a direct cause of poor clinical actions, which can result in unnecessary death 
or injury. Most clinical errors are preventable through the improvement of decision-
making processes before they result in harmful outcomes. 
Clinical Decision Support System Aided Decision-Making 
Publication of new evidence from clinical research occurs continually. However, new 
evidence cannot improve the quality of a clinical decision unless healthcare providers 
incorporate it into their decision-making processes. CPGs are systematically developed, 
evidence-based recommendations that assist clinicians in decision-making for specific 
clinical circumstances [7]. Over the past decade, adherence to CPGs has become the 
gold standard for ensuring quality in clinical practice; however, they have limited 
impact in clinical decision-making. Extensive evidence in literature and practical 
experience shows that passive dissemination of CPGs is not sufficient to improve 
guideline compliance [8-10]. Strategies for incorporating EBM into decision-making 
processes are needed [6, 11, 12]. Furthermore, there is additional best evidence that 
can be integrated into decision-making to complement CPGs, because CPGs provide 
generic recommendations, and are not expected to address all aspects of patient care. 
Therefore, establishing systematic approaches, which incorporate this additional best 
evidence into clinical decision-making processes, are also needed. 
 
Information technology has been introduced to assist healthcare practice for more than 
two decades [13]. Information systems enhance data storage, data retrieval, as well as 
the manipulation of data. Clinical Decision Support Systems (CDSSs) are information 
systems specifically designed to aid clinical decision-making [14]. There is clear 
evidence that CDSSs are able to assist clinicians in practicing EBM, prevent errors and 
detect adverse events by delivering useful information when needed [15-19]. CDSSs 
have benefits for healthcare, which is demonstrated through automated checks for 
unwanted interactions, reminders and alerts, and the delivery of CPGs [20-24]. Studies 
also show that computer-based CPG implementation systems improve guideline 
compliance [20, 25, 26]. However, there is consensus that CDSSs are little used in real   6
clinical settings despite their promising benefits. Numerous obstacles need to be 
overcome before realising an optimal CDSS. Issues such as adaptation of guidelines 
for electronic implementation and integration with clinical workflow make 
implementing CDSSs a challenging task [27]. Furthermore, the extent to which CDSSs 
will be effective and practical in a real clinical setting remains unclear. More research 
is needed into the issues regarding clinical effectiveness and acceptance of CDSSs [28]. 
Figure 1.1 illustrates that practising EBM with the aid of CDSSs plays a role to close 
the gap between the optimal practice and the actual practice. CDSSs can deliver CPGs’ 
recommendations, therefore reinforce the compliance of CPGs; CDSSs can present 
additional clinical evidence which has not been included into CPGs, CDSSs can also 
display relevant clinical information when needed.   7   8
2 Literature  Review 
2.1 Practising Evidence-based Medicine 
Over at least the last decade, EBM has been the guiding mantra of clinical practice. 
EBM integrates clinical expertise with current best evidence from clinical care 
research to manage the individual patient [3]. Evidence-based clinical practice 
represents an approach to decision-making, in which the clinician uses the best 
evidence available, in consultation with the patient, to decide upon the option that suits 
that patient best [29]. However, to incorporate new evidence and relevant research 
findings into daily clinical practice remains a challenge for clinicians. Research has 
revealed the difficulties in persuading health professionals to actually practice EBM in 
patient care [16]. 
 
CPGs have been widely promoted for more than two decades, CPGs are defined as 
‘systematically developed statements to assist practitioner and patient decisions about 
appropriate healthcare for specific clinical circumstances’ [30]. It is believed that 
CPGs have the potential to play an important role in narrowing the gap between 
evidence and practice in daily medical practice. Health professionals have been 
encouraged to develop and apply guidelines that assist in clinical decision-making in 
order to achieve better quality healthcare and patient outcomes. Nevertheless, Gaps 
have been identified between evidence and practice [5, 12, 31], CPGs have had limited 
impact on clinical practice or health outcomes [8]. A structured review of guidelines 
from medical literature shows that adherence is not as good as might be expected [9]. 
Barriers such as a lack of agreement with specific guidelines and a lack of self-efficacy 
have been identified as affecting clinicians’ adherence to guidelines [32, 33]. In 
addition, conventional narrative CPGs, which give general population-based 
recommendations, are not specific for the individual patient. Difficulties in accessing 
CPGs in real time during consultations add to these difficulties in applying them to 
specific patients [34]. Haynes identified special problems in applying evidence in 
clinical practice [31]; they are (1) the lack of agreement on evidence standards, which  
undermines the effectiveness of authoritative practice guidelines, (2) ineffective and   9
inefficient application of evidence and practice guidelines due to mismatches in 
evidence and usual practice circumstances, and (3) time constraints, which undermine 
the interpretation and application of evidence. 
 
Moreover, adhering to clinical guidelines depends on whether physicians are 
sufficiently influenced by the guidelines to change their behaviour. Farquhar et al. 
systematically reviewed 153 surveys of clinicians’ attitudes to CPGs. They found that 
clinicians’ attitudes to clinical guidelines were positive in most cases [8]. However, for 
individual clinicians, the barriers to making significant changes to their practices 
included the need for educational, organisational and structural changes in the 
healthcare system. 
 
Passive dissemination of information, such as CPGs or educational materials, are 
generally not effective [6]. Lomas et al. evaluated a series of published guidelines and 
found that it took an average of approximately five years for routine practice to follow 
these guidelines [35]. This indicates that the current practice of medicine significantly 
lags behind the standard of medical knowledge. Numerous studies have suggested that 
using specific and effective strategies to implement research-based best evidence 
ensures that practices change [6, 11, 12]. Bero et al. systematically reviewed rigorous 
studies from 1966 to 1995 regarding the effectiveness of different strategies for the 
dissemination and implementation of research findings. They concluded that 
computerised decision support systems are among the most effective interventions [6]. 
 
2.2 Electronic Health Record and Computer-based Patient Record 
Electronic Health Record (EHR) is a lifetime patient record in digital format that 
includes all information from all specialties and requires full interoperability [36]. The 
establishment of EHR enables sharing and exchange of patient clinical data between 
disparate systems. Implementing EHR offers remarkable opportunities for practicing 
EBM using Clinical Information Systems (CISs) and CDSSs to improve healthcare [15, 
16]. However, to implement EHR at a national level or even at an international level 
faces enormous political and social challenge.   10
 
Computer-based Patient Records (CPRs) are increasingly used in today’s clinical care, 
clinical research, and health system management [37]. However, as CPRs are 
relatively unsophisticated and lack standard nomenclature or vocabularies, the task of 
implementation is complex [38]. Translating free-text clinical notes into computer-
legible codes presents a challenge [39]. Coded data with a structured format can be 
restrictive when compared to the free text in paper-based charting systems [40]. 
Regardless, CPRs provide a solid foundation of information to be used during the care 
process and as a source of scientific data. 
 
There are many clinical benefits of CPRs [41]. First of all, they provide easy access to 
patients’ charts, in that data can be accessed simultaneously from many locations, and 
can be printed out using a variety of fonts, colours, and sizes that help draw the 
clinician's attention to the most important data. Parallel access to patient data from 
different locations enhances clinical workflow and improves work processes. Secondly, 
CPRs assist clinicians in decision-making as patient data are structured and coded in 
an unambiguous fashion by software programs or clinical decision support tools that 
continually check and filter data for errors, summarise and interpret data, and issue 
alerts and/or reminders for clinicians, as they monitor for unwanted events that may 
develop into organ-threatening or life-threatening complications. Thirdly, CPRs can be 
integrated with computerised CPGs to deliver patient-specific recommendations when 
and where needed. In addition, images can be combined with textual data to create a 
more complete ‘picture’ of the patient’s condition. The accuracy of data in CPRs is 
therefore of great importance [37] and should improve as the use of CPRs increases. 
 
2.3 Clinical Decision Support 
Clinical decision support is described as an aggregate of electronic information 
resources that enable practicing clinicians to quickly obtain bottom-line summary 
information on clinical topics to aid in decision-making at the point of care. CDSSs are 
software packages designed specifically to aid clinical decision-making. 
Recommendations tailored to individual patients can be presented to the clinician or   11
patient for decision-making from a computerised clinical knowledge base. CDSSs are 
especially important for the practice of EBM as they can close the gap between 
evidence and practice and thereby improve the quality of healthcare [15, 16]. 
 
Published studies show that CDSSs improve clinicians’ performance [14, 42, 43]. Hunt 
et al. systematically reviewed controlled clinical trials of patient care with a CDSS 
comparing with care without one from 1974 to 1998, and found a beneficial effect on 
physician performance in 43 of 65 studies (66%). Six out of fourteen studies assessing 
patient outcomes also found a benefit. 
 
CDSSs can benefit health care by preventing errors and adverse events, by facilitating 
a more rapid response to adverse events, and by tracking and providing feedback about 
adverse events [19, 44]. Research shows that a Computerised Physician Order Entry 
(CPOE) with embedded decision support features substantially decreased medication 
error rates [18]. A systematic review also showed that the use of CDSSs significantly 
decreased medication error rates [17]. 
 
Specific CDSSs, such as computerised reminders and alert systems, have increasingly 
demonstrated their effectiveness in modifying clinician behaviour in drug management 
and preventive care. Shea et al. performed a meta-analysis, which concluded that 
computer-based reminder systems improved prevention services [23]. Dexter et al. 
performed a randomised controlled study and found that computerised reminder 
systems increased the delivery of preventive care to hospitalised patients [22]. Bennett 
et al. systematically reviewed the benefits of computerised reminders based on 76 
randomised controlled trials of computer-generated medication reminders directed at 
clinicians or patients. Their results showed that computerised reminders can improve 
various behaviours related to drug management, and patient-directed reminders can 
improve medication adherence [21]. Raschke et al. developed and evaluated a 
computerised alert system to correct errors that might lead to Adverse Drug Events 
(ADEs) [24]. During the evaluation period, the alert system fired 1116 times and 53% 
of the alerts were true-positive alerts. Of the 596 true-positive alerts, 265 were not 
identified by the physician prior to alert notification (effective value of 44%). This   12
study indicates potential for physicians to be prompted to act in a more timely manner 
and thereby avoid possible patient harm associated with ADEs, and demonstrates that 
computerised alert systems can detect ADEs in a timely and cost-effective way to 
prevent patient harm. 
 
However, CDSSs do not always enhance clinical practice. The successful 
implementation of CDSSs needs carefully designed procedures for the delivery of 
information. Bennett et al. suggest that the most effective way of presenting 
information is to deliver it close to the time of decision-making [21]. Patterson et al. 
claim that human factors, such as arduous workloads, are a barrier in the use of 
computerised reminder. [45]. Kawamoto et al.’s systematic review identified features 
critical to success in improving clinical practice using CDSSs; multiple logistic 
regression analysis shows four independent predictors; they are (1) integrating into 
clinical workflow, (2) providing clinical recommendations rather than assessments, (3) 
providing decision support at the time and location of decision-making and (4) using 
computers to generate the decision support [46]. 
 
Nevertheless, CDSSs provide valuable assistance to clinicians by performing complex 
evaluations based on patient-specific information and presenting the results and 
recommendations in a timely fashion. In order to be widely accepted by practicing 
clinicians, CDSSs must be integrated into clinical workflows and be able to provide 
the right information at the right time without extra effort [16] [47]. More research is 
needed to reveal the factors pertaining to the successful implementation of CDSSs [17]. 
 
2.4 Computerised Clinical Practice Guideline 
CPGs are commonly delivered in a paper-based format to guide clinical decision-
making. However, clinicians have not incorporated paper-based clinical guidelines into 
their practices as expected [8, 9, 32, 33]. Recently published research has shown that 
information technology can provide valuable assistance to health professionals in 
adhering to CPGs, and consequently reduce harmful practice variations and improve 
patient outcomes [18, 19, 44]. Yet, simply placing CPGs on a computer network does   13
not necessarily increase guideline adherence [48]. Stolte et al. suggested that 
computerised CPGs should be integrated into the clinical decision-making process for 
better CPGs compliance. 
 
The implementation of computer-based guidelines promises to improve the acceptance 
of CPGs in the clinician’s daily practice. Lobach et al.’s research revealed that a 
computerised diabetes management protocol significantly improved clinicians’ 
compliance with guideline recommendations [25]. Sintchenko et al. also demonstrated 
that computer-based decision support with recommendations for prescribing antibiotics 
significantly improved the quality of decisions [20]. Shiffman et al. performed a 
systematic review, which concluded that guideline compliance improved in 14 out of 
18 computer-based guideline implementation systems [26]. 
 
However, obstacles remain regarding guideline adaptation for electronic 
implementation. Wang et al. reviewed literature on guideline representation models; 
they found that the representation of CPGs in a computer-interpretable format is a 
critical issue for guideline development and implementation [49]. Moreover, an 
understanding of clinical workflow is a critical step in the success of implementing 
computer-based CPGs [27, 50]. Workflow integration is a strong impediment in the 
successful implementation of a computer intervention. Eccles et al. [51] performed a 
trial study, which concluded that integrating systems into clinical environments 
remains a challenge even though the technical problems of producing such a system 
are solved. 
 
In conclusion, several issues relating to guideline-based CDSSs, such as guideline 
representation and workflow integration, need to be addressed more intensively. 
Substantial work remains to be done to realise the potential benefits of computerised 
CPGs. 
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2.5 Review of Managing Rheumatoid Arthritis 
2.5.1 Rheumatoid  Arthritis 
RA is a chronic disease that affects approximately 1% of the adult population 
worldwide [52]. RA is heterogeneous with natural fluctuations in clinical course. RA 
primarily affects joints and often causes progressive joint destruction, which leads to 
progressive disability. Non-articular complications, particularly those involving the 
cardio-vascular system can lead to premature death. RA develops predominantly in 
people aged between 20-50 years and once acquired is generally a lifelong affliction 
that reduces quality of life [53]. While recent advances in treatments have yielded 
better outcomes, for best results interventions need to be applied early and continuing 
treatments and continual optimisation of treatments as drug ‘resistance” or intolerance 
develop through the course of the disease, are generally required. 
 
2.5.2  Rheumatoid Arthritis Management Goal 
The principal goal of managing RA is to suppress the disease. This entails eliminating 
symptoms and signs of joint and systemic inflammation as soon as practicable and to 
thereby minimise joint damage. This approach when applied in a timely manner with 
sufficient intensity can often achieve remissions and prevent disability [54]. 
 
2.5.3  Modern Treatment of Rheumatoid Arthritis 
In recent years RA has been treated earlier and more intensively than previously [55-
59]. Detecting and treating RA at its earliest stages offers many patients the prospect of 
RA remission [57]. While non-steroidal, anti-inflammatory drugs (NSAIDs) can be 
used for symptomatic relief during the period of initial evaluation of RA, they are no 
longer considered adequate, even for milder RA, as they are associated with significant 
unwanted effect, have not been shown to favourably influence disease progression in 
RA and their widespread use may have contributed to the increased risk of 
cardiovascular events associated with RA [60]. This perspective contrasts with the now 
obsolete  ‘pyramidal’ approach to the management of RA which restricted use of 
longer acting DMARDs to patients whose symptoms were not reduced to tolerable   15
levels by NSAIDs [61] or who had already developed radiographic evidence of joint 
damage. In contrast to NSAIDs, DMARDs do not have a direct analgesic action but 
have been shown to reduce symptoms and signs of RA and to inhibit damage caused 
by synovial inflammatory tissue (pannus) to peri-articular bone (erosions) and to 
maintain physical function in the longer term [52, 62]. Recent studies indicate that 
DMARDs should be introduced as soon as a diagnosis of RA can be established and 
that doses should be adjusted and other DMARDs added in a timely fashion until the 
patient has achieved a low level of disease activity and preferably remission [63]. 
 
Rheumatology professional organizations have updated guidelines to adopt new 
approaches that have been shown to be superior to the traditional approach to 
management of RA. For example, the American College of Rheumatology has 
published updated guidelines for managing RA [52, 64]. The Scottish Intercollegiate 
Guidelines Network published a national clinical guideline for management of RA [65]. 
 
2.5.4  Toxicity of DMARDs Therapy 
In DMARDs therapy for RA, inefficacy and adverse drug effects are the two main 
limiting factors. When drug doses are increased due to lack of efficacy, potential and 
realised drug toxicity become an increasing concern. Therapy-related, severe drug 
toxicity can cause irreversible organ damage and lead to life threatening complications. 
Treatment-related adverse effects are the predominant reason for discontinuing an 
effective drug; thereby limiting potential benefits of the therapy. Ultimately 30% of 
RA patients have had experience with discontinuation of one or more drugs for toxicity 
reasons, irrespective of the drug used [66]. 
 
Clinical trials have clearly defined the toxicity profiles of the individual DMARDs 
[66-69]. However, when drugs are used in combination or in a “real-life” setting, 
therapy may disclose different toxicity manifestations [70]. Instances of increased 
toxicity have been reported when combined DMARDs therapy is introduced [71]. 
Therefore, it is important for clinicians to monitor patients during the treatment of RA 
over the longer term in order to prevent serious drug toxicity and thereby achieve drug 
use that is as safe as possible.   16
 
2.5.5  Balancing Risks and Benefits 
There is no stand alone wholly effective treatment for RA and no treatment that is free 
from safety concerns. While RA treatments are generally more effective when given in 
combinations, in practice, concerns regarding the potential for more frequent adverse 
events have limited the application of this approach. Thus clinicians face an ongoing 
challenge of making clinical decisions that balance benefits against perceived risks, 
while taking account of the patient’s prior experiences and concerns. There is also a 
need subsequently to make adjustments in light of responses and tolerance to 
interventions undertaken [53]. 
 
2.5.6  Guidelines in Rheumatoid Arthritis Management 
Clinical guidelines and algorithms are essential elements in guiding clinical decision-
making [72, 73]. There are numerous guidelines that have been published to manage 
RA [52, 64, 65, 74], as well as guidelines developed to monitor DMARDs therapy 
during the management of RA [75-77]. However, these guidelines give general 
recommendations; they define a range of acceptable practices or a range of 
management options rather than give specific detailed recommendations. Therefore, 
they have limited immediate impact on clinical practice. 
 
Research has illustrated the difficulty that rheumatologists have in implementing 
guidelines into clinical practice, and suggests that additional strategies that incorporate 
evidence into practice in rheumatology should be studied [1]. Ellrodt et al. [72] 
introduced the concept of developing and implementing a framework to aid in 
decision-making for managing patients with chronic musculoskeletal diseases. 
Cannella et al. [55] suggested rheumatologists should use a treatment algorithm as a 
guide in the treatment of RA. 
 
Collectively, a better understanding of how to utilise RA management options more 
effectively [56] and the development of more specific guidelines that deal with narrow 
clinical scenarios is needed [74].   17
 
2.5.7  Computer Aided Approach of Managing Rheumatoid Arthritis 
While managing RA is generally regarded as requiring multidisciplinary approach, in 
eRA prompt, systematic pharmacological interventions appear to yield the greatest 
impact on long-term outcomes However, in spite of a burgeoning trend toward eRA 
clinics, there is comparatively little data that compare outcomes achieved by different 
practices and practitioners [78]. 
 
The Swedish Society of Rheumatology introduced a national Swedish surveillance 
registry for patients with eRA in 1994. It collected data from all the rheumatology 
units nationally across Sweden. One of the major goals of the project was to construct 
a structured data registry that could be used in future software developments that 
would enable physicians to enter data directly, while providing graphical and historical 
information on the individual patient in the regular out-patient clinic. The registry led 
to a substantial change in drug prescription patterns in some units, and has played a 
role in the optimisation of treatment and new therapy evaluations for the future. Using 
the surveillance registry in the management of RA illustrates that computerised clinical 
tools can guide and improve daily clinical practice to achieve better patient outcomes. 
 
2.6 Review of Adverse Drug Reactions 
Adverse Drug Reactions (ADRs) can cause significant morbidity and mortality. The 
World Health Organization’s (WHO) definition of an ADR is ‘a response to a drug 
that is noxious and unintended and occurs at doses normally used in man for the 
prophylaxis, diagnosis or therapy of disease, or for modification of physiological 
function’. Most ADRs happen in patients who are prescribed treatment within the 
limits of accepted clinical practice [79]. 
 
ADRs are common in the Australian health system [80]. At least 80,000 medication-
related hospitalisations occur each year in Australia, with an estimated cost of $350 
million annually [81]. A review of medical records has indicated that up to 69% of 
these hospital admissions are considered preventable [80, 81].   18
 
There is a trend in contemporary healthcare of increasing ADRs. Recently, Burgess et 
al. completed a study, which analysed ADRs causing or extending hospital admissions 
in people aged 60 years or over in Western Australia. The figures showed that 
hospitalisations associated with ADRs in people of this age more than doubled 
between 1991 and 2002 [79], and had increased almost fivefold in between 1981 and 
2002, with the figures continuing to rise until the end of the study. The study also 
pointed out that the most common drugs involved were cytotoxic and anti-rheumatic 
agents. In 2002, a report from the Australian Council for Safety and Quality in Health 
Care showed that statistics of hospital related ADRs for South Australia in all age 
groups increased fourfold between 1988/89 and 2000/01, and correlated strongly with 
changes in medication use in the community [82]. 
 
These data underline the importance of investing in systems for prevention and 
management of ADRs. Revision of clinical guidelines, identification of populations at 
risk and improved patient monitoring are recognised methods for addressing the ADR 
issue [79, 80, 83]. While interaction checking is a well established application of 
decision support technology used by prescribers, clinical trials are needed to explore 
the potential benefits of more complex CDSSs in patient care. 
 
2.7 Review of Methotrexate in Rheumatoid Arthritis 
2.7.1  Methotrexate Combination Therapy 
Methotrexate (MTX) is the most widely used DMARD for the treatment of RA. 
Multiple randomised controlled trials have established the efficacy and tolerability of 
MTX [84-88]. 
 
During the past decade, treating RA patients with more intensive therapies that 
combine MTX with other DMARDs have shown superior clinical responses and 
patient benefits [53, 62, 89]. MTX, when used in combination with cyclosporine A, 
has been shown to improve disease control without a significant increase in toxicity 
[90, 91]. MTX plus hydroxychloroquine is one of the most effective and best tolerated   19
DMARD combinations [92, 93]. The combination of MTX and sulphasalazine also has 
a positive clinical effect [94-96]. Lehman et al. performed a randomised, double-blind 
controlled trial, which showed that the addition of weekly intramuscular (IM) 
myocrisin (Gold) caused significant clinical improvement in RA patients with a 
suboptimal response to MTX [97]. No clear advantage was seen with the addition of 
azathioprine to MTX [98-100]. 
 
More recently, a randomised, double-blind, placebo-controlled trial showed that 
addition of leflunomide yielded clinical benefit in RA patients taking MTX and was 
well tolerated [101]. The combination of sulfasalazine-hydroxychloroquine-
methotrexate, also known as ‘triple therapy’, is being used increasingly in RA [62] as 
multiple studies have shown that it is a very effective therapy and well tolerated in the 
majority of patients [102-105]. Collectively, it has become apparent that MTX 
combination therapies offer substantial clinical improvements in comparison to single 
drug therapies. The advantages of use with MTX extend to the newer biological agent 
therapies, such as tumour necrosis factor (TNF) blockers [106]. 
 
2.7.2  Drug Action Analysis for Methotrexate Toxicity  
Drug toxicity may occur through the over dosage of medication, an accumulation of 
the drug in the body over time, or the inability of a patient’s body to eliminate the drug. 
MTX is a potent folate antagonist that inhibits dihydrofolate reductase, which is an 
enzyme necessary for the formation of tetrahydrofolate, which is needed for 
thymidylate biosynthesis and purine biosynthesis. MTX inhibits DNA formation and 
thereby reduces cell replication. MTX is used to treat a wide variety of cancers, 
psoriasis and RA. These conditions all have in common abnormal rates of cell 
replication. 
 
In RA, MTX is used in doses substantially lower than those used in cancer 
chemotherapy. It is thought to act, at least in part, by suppressing replication of 
leucocytes and other immune cells that are needed to sustain the intensity of the 
unwanted inflammation that is the hallmark of this condition.  Due to the fact that 
MTX inhibits cell division by inhibiting DNA formation, MTX toxicity occurs mainly   20
in tissues that are involved in cell renewal, including bone marrow, gastrointestinal 
tract mucous, skin, etc., although the mechanism of MTX liver toxicity is not very well 
understood. It has been suggested that hypersensitivity is responsible for most MTX 
pulmonary toxicity [107, 108]. MTX is primarily excreted by the renal route. In 
patients with impaired renal function, MTX can accumulate to toxic levels with 
marrow suppression being a salient issue [109]. 
 
2.7.3  Methotrexate Toxic Effects Analysis 
As the therapeutic effect of MTX and its most frequent unwanted effects are both 
dose-related, MTX therapy is commonly limited by intolerance. Most often this takes 
the form of non-threatening post-dose nausea and upper gastro-intestinal symptoms 
[110-113]. More serious adverse events can occur, including lung [114, 115], liver 
[116, 117] and haematological toxicity [118, 119]. Fatal events have been reported. 
 
MTX toxic effects can affect individual people in different ways. Drug toxicity-related 
symptoms can be useful for predicting more progressive and severe life-threatening 
toxicity events. It is important when summarising MTX toxicity, to distinguish 
potential life threatening events from minor side effects [66]. Wilke et al. [109] has 
provided a classification schema of adverse effects associated with MTX, which makes 
this distinction. Alarçon et al. [110] advised temporary and permanent discontinuation 
of MTX in response to minor and major toxicity events respectively. I have outlined 
MTX common minor side effects and MTX major toxicity in RA (Table 2.1).   21
Table 2.1 Methotrexate Toxic Effects in RA 
Minor side 
effects 
Gastrointestinal: nausea, vomiting, abdominal pain, diarrhoea 
Haematological: mild/transient myelosuppression 
Hepatic: mild/transient elevations of hepatic enzymes 
Skin/Mucocutaneous: rash, stomatitis 
Neurologic: fatigue, headache, dizziness 




Bone Marrow Toxicity: 
Methotrexate may produce marked depression of bone marrow, such as 
anaemia, aplastic anaemia, macrocytic anaemia, leukopenia, neutropenia, 
thrombocytopenia and bleeding. 
Pancytopenia may occur and is potentially fatal. 
  Gastrointestinal Toxicity: 
Diarrhoea and ulcerative stomatitis are frequent toxic effects; 
haemorrhage enteritis and death from intestinal perforation may occur. 
  Hepatotoxicity: 
Methotrexate may be hepatotoxic, particularly at high dosage or with 
prolonged therapy.  
Liver atrophy, necrosis, cirrhosis, fatty changes and periportal fibrosis 
have been reported.  
Acute increases in transaminase and bilirubin concentrations are common 
with high doses. 
  Pulmonary Toxicity: 
Methotrexate-induced lung disease may occur acutely at any time during 
therapy. It is not always fully reversible.  
Reversible eosinophilic pneumonitis occurs most commonly.  
Pulmonary fibrosis is uncommon but may be fatal. 
 
 Impaired renal function can contribute to haematological toxicity and 
hepatotoxicity. 
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2.7.4  Literature Review of Risk Factors for Methotrexate 
Although the toxicity profile of MTX is well defined, defining risk factors for MTX 
toxicity in a clinical context is challenging because susceptibility to drug-related toxic 
effects may vary widely between individuals. MTX toxicity is affected by many 
factors, including advanced age, drug dosage, concomitant drugs, pre-existing 
complications and environmental effects [120]. 
 
There is a limited literature focusing on identifying risk factors for toxicity prediction 
in RA [71]. I performed a systematic review of medical literature for the risk factors 
associated with MTX in RA using the MEDLINE database provided by PubMed.
Bibliographies of papers and articles retrieved were cross-checked for further relevant 
articles. Search terms included the Medical Subject Headings (MeSH) of 
‘Methotrexate’, ‘Arthritis, Rheumatoid’, ‘Drug Toxicity’, ‘Risk Factors’, ‘Risk 
Management’, ‘Lung/drug effects’, ‘Liver Function Tests’, ‘Hepatitis, Chronic’, 
‘Blood Cell Count’, ‘Neutropenia’, ‘Pancytopenia’ and ‘toxicity’ [Subheading]. A 
review of relevant literature showed that risk factors for MTX toxicity can be 
identified from the patient’s medical history, as well as from patient symptoms and 
laboratory investigations. I have summarised the details of this literature review, such 
as reference title, study type and identified risk factors, in a separate table (Table of 
MTX Toxicity Risk Factors), which is listed in the appendices. 
 
Research into candidate genetic polymorphisms for MTX toxicity risk is in its infancy, 
although preliminary observations hold promise for improved prediction of therapeutic 
ratios [121]. 
 
2.7.4.1 Common Risk Factors for Methotrexate Toxicity 
The common known risk factors for MTX toxicity include advanced age [111, 113, 
122, 123] and impaired renal function [112, 123, 124], while more recently, a lack of 
folate supplementation has been shown to be a risk factor in MTX toxicity [125-129]. 
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McKendry et, al. [111] conducted a 13 year, retrospective study of 144 RA patients 
treated with MTX; they found advanced age was associated with increased 
discontinuation of treatment due to major toxicity. Buchbinder et, al. [113] analysed 
data from 587 RA patients treated with MTX therapy in Australia; results showed that 
higher rates of toxicity were associated with the older age group (>65) than the 
younger age group (<65). Wolfe et, al. [122] conducted a retrospective review; they 
found more gastrointestinal complaints and more pulmonary complaints in older age 
groups. Mielants et, al. [112] suggest that potentially dangerous side effects are more 
likely to occur in patients with impaired renal function. An analysis performed on data 
from 11 MTX clinical trials, including a total of 496 RA patients treated with MTX, 
showed patients with renal impairment had a higher overall rate of toxicity, and also a 
higher risk of severe pulmonary toxicity [124]. 
 
2.7.4.2 Risk Factors for Methotrexate Pulmonary Toxicity 
Methotrexate-related pneumonitis is one of the hazardous adverse effects of treatment 
for RA. Reports of MTX-related pneumonitis with low-dose MTX therapy emerged in 
the early 1980s [114, 115]. However, relatively little is known about associated risk 
factors and strategies for risk avoidance are not well developed. 
 
There are numerous studies which identify a history of smoking [130, 131], pre-
existing pulmonary disease [107, 130, 132, 133] and abnormalities in chest 
radiographs [134] as risk factors. In addition, because of the potential for fatal toxicity, 
recommendations have been made that development of pulmonary symptoms, such as 
shortness of breath, cough and fever, should be considered signs of possible lung 
toxicity while patients take MTX during RA treatment and that treatment should be 
withdrawn [135-137]. 
 
Searles et, al. [130] reported four cases and reviewed six published cases in the 
literature; they concluded that smoking and pre-existing pulmonary disease were risk 
factors for pulmonary toxicity and that patients developing suggestive clinical 
symptoms should be monitored closely. Golden et al. performed a case-review study   24
[132], which found a significant difference in occurrence of MTX pneumonitis during 
low dose MTX therapy for RA between groups of patients with and those without pre-
existing lung disease . Carroll et, al. conducted a case-control study [107], and 
concluded that hypersensitivity is probably responsible for most cases of pneumonitis 
associated with MTX, but pre-existing lung disease may confer increased risk.  The 
case-control study by Alarçon et, al. [131] found that MTX-related lung injury in RA 
is associated with age, smoking, rheumatoid pleuropulmonary involvement, previous 
use of antirheumatic drugs and low serum albumin. 
 
2.7.4.3 Risk Factors for Methotrexate Hepatic Toxicity 
Cirrhosis and fibrosis are the best recognised long-term unwanted hepatic effects of 
MTX treatment [116], and liver biopsy studies have shown that long-term MTX 
therapy for RA is associated with changes in liver morphology [138]. 
 
Alcohol abuse [139, 140], obesity [126, 139, 141-143], diabetes mellitus [141], MTX 
dose [139, 140, 144], treatment duration [139], elevated liver enzymes [139, 144], 
advanced age [139, 144] and hepatitis are the most consistent risk factors for hepatic 
fibrosis. 
 
In a retrospective study conducted by Shergy et al. [141], 210 liver biopsies were 
performed on RA patients treated with MTX from 1979 to 1988. The study concluded 
that the prevalence of MTX hepatotoxicity in patients with RA receiving long-term 
low dose MTX therapy is low, and diabetes mellitus and obesity might be potential 
risk factors of hepatic fibrosis. 
 
Kremer et al. [139] performed a prospective cohort study and found that long-term 
MTX therapy in RA was associated with a statistically significant worsening in hepatic 
histologic grade; a history of alcohol consumption, obesity, dosage, treatment duration 
and a total number of aspartate transaminase (AST) elevations were strongly 
associated with progression of liver histological grade. 
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Whiting-O’Keefe et al. [140] conducted a meta-analysis of 15 studies (a total of 636 
patients) that examined the relationship between long-term MTX therapy and liver 
fibrosis. They found that a total cumulative dose and a history of alcohol abuse 
increased the risk of advanced grades of histologic change on liver biopsies in RA 
patients undergoing long-term, low dose MTX treatment. 
 
Walker and co-workers [139] surveyed rheumatologists to identify cases of serious 
liver diseases (cirrhosis and liver failure) in patients taking low dose MTX for RA for 
5 years or more. They identified 24 cases and estimated that this complication occurred 
in about 1 in 1,000 cases treated for this duration. In comparisons between cases and 
case-controls (taking MTX for RA without liver disease) [144],  the strongest 
associations with liver failure and cirrhosis were the age at which patients first used 
MTX and the time since initiation of MTX therapy. Serum AST and albumin were the 
only measures of hepatic function that were more likely to be abnormal in cases 
relative to controls but were as often normal as abnormal in cases one year before the 
onset of liver failure. 
 
Two cases of reversible liver failure, one with idiopathic chronic hepatitis, in patients 
receiving low dose MTX for RA were reported by Clegg et al. [112] Kujala and co-
workers reported a further case of reversible liver failure in a patient taking MTX for 
RA [116, 117]. In each of these three cases, liver function improved after MTX was 
discontinued. Both authors suggest that careful monitoring of patients undergoing 
long-term, low dose MTX treatment is important. 
 
Obesity will cause fatty liver and raised triglycerides. More recently, Kent et, al. [143] 
reported that high body mass index, untreated hyperlipidemia and lack of folate 
supplementation correlated with elevation in serum of the liver enzyme aspartate 
aminotransferase  based on a retrospective cohort study. 
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2.7.4.4 Risk Factors for Methotrexate Haematological Toxicity 
Haematological toxicity of MTX includes leukopenia, thrombocytopenia, 
megaloblastic anaemia and pancytopenia. Pancytopenia secondary to low-dose MTX 
in RA patients has been reported [118, 119, 145]. Pancytopenia-related death has been 
reported due to myelosuppression, which led to sepsis or haemorrhage. 
 
Numerous studies have identified risk factors that contribute to haematotoxicity. These 
include impaired renal function [146-151], elevated mean corpuscular volume (MCV) 
[152, 153], hypoalbuminemia [143, 146-148, 151], and concomitant medication [146-
148, 151, 154, 155]. 
 
Weinblatt et al. compared six RA patients with MTX-associated haematological 
manifestations and compared them with 17 other RA patients receiving MTX and 
argued that raised MCV may be associated with haematotoxicity, perhaps though 
relative folate depletion [153]. Al-Awadhi et al. [152] conducted a case-control study 
to identify risk factors associated with pancytopenia occurring during low-dose MTX 
therapy within the decade 1981 to 1991 as ascertained by a survey of haematologists, 
dermatologists and rheumatologists in the Ottowa region. Relative to controls matched 
for duration of MTX therapy, the pancytopenia group was more advanced in age and 
more often displayed impaired renal function and elevated MCV The study also 
suggested that co-administration of trimethaprim-sulphamethoxisole, an antimicrobial 
combination that, like MTX, can interfere with folate metabolism, is also a risk factor. 
Maricic et al. reported the case of a 47 year old woman, who developed megaloblastic 
pancytopenia shortly after trimethoprim/sulfamethoxazole was added to her regimen. 
 
Gutierrez-Urena et, al. [156] reviewed 68 pancytopenia cases in the medical literature 
published between 1980 to 1995 and also described two cases from their own 
experiences. They estimated that pancytopenia occurs in 1 to 2% of patients receiving 
low-dose MTX therapy in RA. Many of the cases reported in their review had occurred 
before folate supplementation had become a recommended accompaniment of MTX 
therapy and their estimate of the incidence of pancytopenia may be an over-estimate 
relative to contemporary practice.   27
Notwithstanding, MTX haematoxicity is an important complication, which can be fatal 
and for which there are multiple risk factors that are suited to inexpensive computer-
aided safety monitoring (renal function, MCV, serum albumin and cell counts for early 
recognition of adverse trends, reminders regarding folate administration and drug 
interaction alerts [trimethaprim-sulfamethoxisole]. Unpublished observations from the 
eRA clinic indicate a strong association between disease suppression and moderate 
reductions in leucocyte and platelet counts and increased MCV [157]. Accordingly, a 
balance between moderate reductions in cell counts and disease control may yield best 
results, thereby making computer-aided safety monitoring for safety and dose 
adjustments especially important. 
 
2.7.4.5 Risk Factors for Methotrexate Gastrointestinal Toxicity 
Gastrointestinal (GI) toxicity is the most common side effect in RA patients receiving 
low-dose MTX [110, 158-160], while haemorrhage, enteritis and death from intestinal 
perforation are rare. Nausea, vomiting, diarrhoea and ulcerative stomatitis are common 
unwanted effects. Supplementation with folic (or folinic acid) can be used to reduce 
the unwanted mucosal effects of MTX [161], but possibly at the cost of some reduction 
in efficacy [162]. 
 
Furst et, al. [159] performed a long-term prospective trial of 45 RA patients receiving 
MTX. They found that GI adverse effects occurred in 93% of patients during the trial 
period of 176 weeks. Bologna et, al. [160] reported after a long-term retrospective 
observation study of 453 RA patients treated with MTX, that GI effects are the most 
common adverse event (19.7%), and also a major cause of drug termination (5.7%). 
Hoekstra et, al. [126] conducted a study that analysed data from a 48 week randomised 
clinical trial on 411 RA patients treated with MTX. They found GI adverse effects are 
related to prior GI events (OR 1.81, P=0.02).   28
2.8 Decision Theory for Managing Drug Toxicity in Rheumatoid 
Arthritis
During the management of RA, assessing patients for drug toxicity is fundamental in 
decision-making. Clinicians often face the decision of whether to modify or maintain a 
patient’s current treatment based on their assessment of the likely best outcome in 
terms of achieving desired effects while avoiding unwanted events. Decision theory 
can be used to explain this decision-making problem. 
 
2.8.1 Conditional  Probability 
The process of deciding on a treatment option is based on the estimated probability of 
drug toxicity for the given decision alternatives. Probability is expressed on a scale 
from 0 to 1; a rare event has a probability close to 0, a very common event has a 
probability close to 1 [163]. 
 
P[T]Mt = P(T | Mt) = probability that drug toxic effects occur for given patient under 
maintained treatment decision. 
P[T]Mf = P(T | Mf) = probability that drug toxic effects occur for given patient under 
modified treatment decision. 
 
2.8.2 Decision  Tree 
A decision tree is a method of representing and comparing the expected outcomes for 
each management alternative [163]. Constructing a decision tree helps the clinician to 
understand the decision problem and choose the management option most likely to 
benefit the patient. 
 
Following a patient’s assessment for drug toxicity, clinicians could either maintain the 
patient’s treatment or modify treatment according to the patient’s particular clinical 
state. Regardless of which option is chosen, the patient’s ultimate outcome is 
determined by a set of chance events. The clinician has to estimate the probability of 
the outcome for the patient based on his or her knowledge and personal expertise.   29
Finally, a utility (expected value) has to be calculated for every outcome event. Figure 
2.1 shows a decision tree for the decision-making process to decide whether to modify 
or maintain a patient’s current treatment. 
 
 Decision alternatives: 
a) maintaining treatment (AMt)
b) modifying treatment (AMf)
 Chance events: 
a) with toxic effects (P[T]) 
b) without toxic effects (1-P[T]) 
 Outcome estimations(Utility): 
a) with toxic effects (U(T+)) 
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Figure 2.1 A decision tree comparing the two treatment alternatives   31
2.8.3 Decision  Theory 
Decision Theory refers to theories about how we should make decisions among the 
alternatives if we want to maximise expected utility [163]. Here I use Decision Theory 
to explain how to make decisions on whether or not to modify a treatment. 
The decision theory = probability theory + utility theory (maximum expected utility) [4] 
 
a) Probability theory provides a description of how to estimate complex probabilities 
under uncertainty. 
b) Utility theory refers to how to make the decision choice by determining the 
maximum expected utility of the decision outcomes. 
When deciding whether to modify a patient’s current treatment or maintain a patient’s 
treatment, there are two mutually exclusive patient outcome events for both decision 
alternatives: either the patient has drug-related toxic effects or the patient does not 
have drug-related toxic effects. Theoretically, clinicians’ decision-making is affected 
by their perceptions of the probability of these events. Clinicians make a choice from 
the decision alternatives by estimating the probability that a particular event will occur. 
It is often a reasoned assessment based on their knowledge and expertise. The 
preference for whether to continue treatment or to modify the treatment depends on the 
outcome of the estimation. 
 
UMt = P[T]Mt*U(T+)Mt + (1-P[T]Mt)*U(T-)Mt
UMf = P[T]Mf*U(T+)Mf + (1-P[T]Mf)*U(T-)Mf
 
The above equations calculate the expected utilities of the decision alternatives. By 
calculating the expected utility of maintaining treatment and the expected utility of 
modifying treatment, clinicians would choose the alternative with the highest expected 
utility. 
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2.8.4 Decision  Threshold 
While applying the decision theory, clinicians have to estimate P(T | Mt) and P(T | Mf), 
and then choose the treatment options with the maximum expected utility based on the 
calculation of UMt and UMf. If the expected utility for maintaining treatment is higher 
than for modifying treatment, clinicians will choose to maintain the treatment. On the 
other hand, if the expected utility for modifying treatment is higher than for 
maintaining treatment, clinicians will choose to modify the treatment. However, if the 
expected utility for maintaining treatment is the same as for modifying treatment, this 
means decision-making reaches a decision threshold. In other words, under P(T | Mt) 
and P(T | Mf), the expected utilities for maintaining treatment and modifying treatment 
are no different. Clinicians will have no preference between the two decision 
alternatives. Figure 2.2 shows that under one set of conditions, with the probability of 
drug toxicity under the modified treatment option being P[T]Mf and the probability of 
drug toxicity under the maintaining treatment option being P[T]Mt, as depicted, the 
expected utility UMf is greater than UMt; therefore, theoretically, other factors being 
equal, modifying treatment is the better option to take. Under another set of conditions, 
with the probability of drug toxicity under the modified treatment option being P[T]Mf’ 
and the probability of drug toxicity under the maintaining treatment option being 
P[T]Mt’, the expected utility UMf’ is the same as UMt’; therefore, decision-making 
reaches decision threshold, and the values of the P[T]Mf’ and P[T]Mt’ are called 
threshold probabilities.   33   34
3  Study Objects and Hypotheses 
EBM promotes the use of high quality evidence in clinical decision-making processes. 
For example, CPGs aim to improve the quality of clinical decision-making by 
synthesising best evidence into management plans. However, gaps exist between 
optimal practice and actual practice. Firstly, clinicians often have difficulty in adopting 
complex CPGs in practice because recourse to reference material impedes workflows 
that rely on direct action using clinician recall. Secondly, standard CPGs cannot 
address all aspects of patient care. They are largely limited to generic 
recommendations, which cannot address the myriad of contingencies encountered in 
practice. Thirdly, time constraints in accessing the latest information, and the 
habituation and inertia of professional behaviour militate against the incorporation of 
new evidence into routine practices. 
 
CDSSs can assist clinical decision-making through the delivery of CPGs at the point of 
care, through the provision of appropriate recommendations, reminders and alerts in 
response to entry of clinical and laboratory inputs and chronological assessment. 
Despite strong evidence that CDSSs can improve compliance with best practice and 
patient safety, they are used little in routine clinical settings. Obstacles to the wider use 
of CDSSs include the challenges of development and adaptation of guidelines for 
electronic implementation, and the efficient integration of CDSSs into clinical 
workflows. Finally, the extent to which CDSSs will impact positively in various 
clinical settings is yet to be established. This research is designed to explore the 
application of CDSSs in a clinical setting, where a relatively ordered approach to the 




1. To assess and understand the complexity of RA management 
2. To outline the business requirement of the CDSS for assisting clinical decision-
making   35
3. To establish comprehensive RA management rules by incorporating relevant 
evidence from the literature and expertise from domain experts 
4. To define a computer interpretable model of the RA management rules 
5. To create a MTX toxicity prediction model utilising the best evidence from 
relevant literature and clinical expertise 
6. To identify the opportunities for incorporating the CDSS into the clinic workflow 
7. To conduct a questionnaire to evaluate the compliance of the RA management 




1. The conscientious use of best evidence in clinical decision-making can be achieved 
through application of Knowledge Acquisition processes, in order to facilitate the 
development of CPGs 
2. A computer interpretable model can be established for highly complex CPGs 
3. The CDSS guidance concurs with interpretation of the RA management rules for 
dosage adjustment by clinicians experienced in their application and accepting of 
the rules 
4. More complex CPGs are associated with low compliance using manual approaches 
regardless of high guideline acceptance   36
4  Developing a Knowledge-based CDSS 
Understanding the domain problem and then acquiring and representing the knowledge 
to solve the problem are fundamental processes in developing an intelligent 
knowledge-based system. Hence, developing a CDSS to assist clinical decision-
making depends on an understanding of the clinical decision-making, which requires 
elicitation of extensive clinical knowledge. 
 
During the RA management, clinical decision-making necessarily draws on extensive 
domain knowledge and up-to-date medical evidence. Developing a knowledge-based 
CDSS, with the features of delivering complex RA management rules, involves 
multiple complex processes. This study employed Knowledge Engineering as a 
technique underpinning the CDSS development for the eRA clinic. Knowledge 
engineering is the technique of building intelligent knowledge-based systems such as 
CDSS [164]. It includes three main processes, which are (1) problem assessment, (2) 
data and Knowledge Acquisition, and (3) system implementation (Figure 4.1). 
Facilitating these processes during the development of CDSSs contributes to the 
ultimate effectiveness of the system.   37   38
Knowledge Acquisition is fundamental to Knowledge Engineering and is generally the 
rate limiting step in building a knowledge-base system. This process is comparable to 
the combination of requirements analysis phase and conceptualisation phase of the 
Software Development Life Cycle (SDLC). It is the process to gain the understanding 
of the problem for which the software system is to solve. Knowledge within a 
particular domain can be acquired through consulting human experts within the 
domain, and understanding their business processes and associated rules. Using 
graphical flow charts is a natural way to represent knowledge. Flow charts can be 
easily understood by humans; therefore they can be verified by the human experts. 
 
Knowledge acquired from human experts and relevant literature provides the substrate 
for constructing a conceptual model which represents knowledge. A conceptual model 
is a formal structure for describing knowledge using symbols. Symbols represent the 
concepts of knowledge and the implicit and explicit relationships between them. A 
conceptual model can be established by characterising the data of interest, context, key 
words, rules and relationships. Constructing a conceptual model is one of the crucial 
phases in the SDLC. Figure 4.2 schematically illustrates the major steps in building a 
knowledge-based CDSS. 
 
One of the key focuses of this study is Knowledge Acquisition. The objective of 
applying knowledge Acquisition in this study is (a) to identify the domain knowledge 
(clinical evidence, clinical expertise, etc.), (b) to develop and explicitly represent the 
clinical rules for decision-making, (c) to establish the knowledge models, (d) to outline 
the clinical decision-making processes and (e) to analyse the clinical workflows. 
 
At the early phase of the study, I outlined five key steps for the development of the 
knowledge-based CDSS. These five steps are (1) problem assessment, (2) Knowledge 
Acquisition, (3) evidence/knowledge establishment, (4) conceptual model development, 
and (5) CDSS implementation and evaluation. I also specified the key objectives for 
each step. The five steps and their objectives are listed as below: 
 
1. Problem assessment   39
To identify problems/questions which the clinicians are trying to solve/answer during 
RA management 
 
2. Knowledge Acquisition 
To understand the underlying rationale of the clinical decision-making in RA 
management; to analyse the decision-making processes and the clinical workflow 
 
3. Evidence/knowledge establishment 
To define a knowledge-based CDSS with the functions of guiding eRA management 
decisions in response to defined contingencies, both with regard to disease suppression, 
toxicity and unwanted events monitoring (it includes explicitly establishing RA 
management rules and identifying risk factors in developing MTX toxicity and side 
effects in RA) 
 
4. Conceptual model development 
To establish a computer interpretable model for the complex RA management rules; to 
set up a drug toxicity prediction model for MTX within the regimen; to map the 
computer interpretable model and the drug toxicity prediction model into the clinical 
decision-making process 
 
5. CDSS implementation and evaluation 
To implement the CDSS; to evaluate the CDSS; therefore to determine which features 
have been effective or ineffective in solving identified problems   40   41
5  Knowledge Engineering the Management of 
Rheumatoid Arthritis in the eRA Clinic 
Managing RA is a complex task because of the need to use combinations of DMARDs 
early for optimal disease control and long-term outcomes. MTX is one of the most 
widely used DMARDs. However it can cause potentially irreversible or even fatal 
ADRs. Best practice requires adjustment of dosages of medications and substitutions 
of medications according to a patient’s response and tolerance. These factors demand 
the close monitoring of disease activity and of certain blood investigations that are 
used for safety monitoring, as well as consistently applied responses to abnormal 
findings. Therefore, a knowledge-based CDSS is needed to assist clinicians in 
managing RA better. 
 
The study engaged Knowledge Engineering as a technique to gain understanding of 
knowledge within the RA management process, and then to elicit the knowledge 
underpinning the establishment of evidence-based CPGs, finally to develop a 
knowledge-based CDSS to assist clinical decision-making. This chapter details the 
Knowledge Engineering processes I applied during the study. It outlines the 
complexity of the RA management; analyses decision-making processes; explains the 
underlying rationale of decision-making in the domain; demonstrates the processes of 
establishing the evidence-based RA management rules; and finally describes the 
development of the knowledge models.   42
5.1 Problem Assessment 
During the first 6 months of the Project, study focused on the Problem Assessment. In 
order to understand the complexity of RA management, and how the eRA clinic has 
been approaching management complexity during its practice, I started to perform 
comprehensive review of literature for current best evidence in managing RA patients, 
in conjunction with consulting the local clinicians for their expertise in decision-
making. 
 
Conducting a comprehensive literature review is one of the key components of the 
Knowledge Acquisition. By reviewing literature, evidence can be identified and 
categorised. I conducted an exhaustive literature searching using Medline provided by 
PubMed; Search terms included the Medical Subject Headings (MeSH) of 
‘Methotrexate’, ‘Arthritis, Rheumatoid’, ‘Drug Toxicity’, ‘Risk Factors’, ‘Risk 
Management’ etc. 
 
In the meantime, I observed the clinic consultations on a weekly basis. I consulted the 
local clinicians and clinic experts on a regular basis. The observations and 
consultations helped me to understand the underlying rationale of clinical decision-
making in the domain. I also investigated the eRA clinic database to become familiar 
with the usage of clinical variables and data formats. In summary, I gained a basic 
understanding of RA management complexity and contingency during the Problem 
Assessment period. 
 
5.1.1 Triple  Therapy 
Prompt treatment of RA is a key to minimising joint and tissue damage, and enhancing 
a patient’s quality of life. The current RA management paradigm uses an intensive 
treatment combination that combines various DMARDs and biological agents to 
achieve remission. The eRA clinic incorporates this paradigm into its practice. Patients 
commence RA treatment with Triple Therapy (Table 5.1). 
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Theoretically, optimal treatment decisions in the management of a disease such as RA, 
yield maximum benefits to the patient with minimal drug toxic effects. In order to 
enhance the quality of decision-making, the eRA clinic practices EBM by 
incorporating current best evidence into its decision-making process. Clinicians who 
better manage risks for possible drug toxic effects while delivering acknowledged 
benefits of treatment can reduce the incidence of drug discontinuation; thereby, 
maintaining DMARDs at whatever dose is necessary to achieve clinical improvement 
with fewer drug toxic effects. 
 
Table 5.1 Triple Therapy 
1  methotrexate (MTX) 10 mg/week (with folic acid 0.5 mg/d) 
2  sulfasalazine (SSA) (0.5 g/day then increase by 500 mg/d at weekly intervals to 
1 g bd) 
3  hydroxychloroquine (HCQ) (200 mg bd)   44
5.1.2  Dose Modification Protocol 
The eRA clinic developed a Dose Modification Protocol (Table 5.2). This protocol is 
supported by clinical expertise and best evidence [165]. The intensity of treatment 
beyond the doses specified in the starting Triple Therapy regimen is increased when 
predetermined RA disease suppression criteria are not met (as defined in Table 5.2). 
Clinicians thus decide whether to adjust drug dosage or add additional agents 
according to the patient’s response to the treatment. 
 
The eRA clinic has incorporated the Dose Modification Protocol (Table 5.2) into its 
practice through a paper-based approach. Clinicians apply this protocol during the 
decision-making process to adjust therapy in order to achieve the treatment’s desired 
effects. According to the protocol, if a patient’s treatment is insufficiently effective as 
determined by a formal disease activity assessment; pre-determined dose adjustments 
will be made. If the patient has a satisfactory response to the therapy, then the patient’s 
current therapy is maintained. 
 
Table 5.2 Dose Modification Protocol 
A. Early Morning Stiffness   30 minutes 
B. Fatigue  30 mm 
C. Joint pain   30 mm 
D. Joint tenderness or pain on movement   2 
E. Soft tissue swelling (joints or tendon)  2 
F. Acute phase response (at least 1 of the following 2): 
1. Erythrocyte sedimentation rate (ESR)   28 mm/hour, 
2. C-reactive protein (CRP)   10 mg/L) 
 
If there is a positive response to E & F OR positive response to E or F and 2 of A – D, 
drug dosage will be modified as defined in the treatment algorithm (refer to Figure 5.6)   45
5.1.3  Patient Assessment Process Analysis 
After twelve weeks of observing the eRA clinic consultations plus interviews with 
local clinicians, I gained a working knowledge of the patient assessment process in the 
eRA clinic. The overall assessment process involves not only an assessment of the 
effectiveness of the treatment, but also an assessment of toxic effects associated with 
the drugs. The result of the patient assessment process leads to a decision-making of 
adjusting the patient’s treatment. 
 
The process of assessing a patient includes two components which are an assessment 
of disease activity and an assessment of drug tolerance. During a clinical consultation, 
the clinician assesses the patient’s disease activity for treatment efficacy and any signs 
of drug toxicity to protect the patient’s safety under its current drug regimen. Disease 
activity assessment involves reviewing relevant laboratory test results and checking 
disease activity associated symptoms. Drug tolerance assessment involves reviewing 
drug toxicity monitoring tests and enquiring regarding symptomatic adverse events. 
The clinician applies the paper-based clinical rules and acts by protocol accordingly to 
the results of the two assessments. The paper-based clinical rules and protocols are 
here referred to as Triple Therapy and Dose Modification Protocol. According to 
these rules, the clinician could adjust the patient’s treatment with a revised drug 
regimen. For instance, if the patient can tolerate the therapy, clinicians may increase 
the drug dosage to achieve targeted treatment effects. If the patient’s current drug 
therapy has been maximised but is insufficiently effective, the clinician can add 
additional DMARDs or biological agents into the drug regimen. On the other hand, if 
patient cannot tolerate the therapy (shows the sign of drug toxicity), the clinician can 
reduce or hold the suspected toxicity causing DMARDs or biological agents. 
 
Based on my understanding of the process, I drafted a patient assessment process flow 
chart. Then, I submitted the flow chart to the eRA clinic experts for verification. Some 
minor changes were made by the experts. Figure 5.1 is the verified version of the RA 
patient assessment process. On the flow chart, paper-based rules and protocols refer to 
the Triple Therapy and the Dose Modification Protocol.   46   47
5.1.4  Balance Disease Activity against Drug Tolerance 
Figure 5.1 illustrates the process of assessing a patient in the eRA clinic. The 
assessment process seems being relatively straight forward. It is about how to make 
clinical decision on adjusting a treatment that balances the potential risks associated 
with therapy with its known benefits. However, the assessment process actually aims 
to maximise treatment efficacy and minimise drug-related toxicity (optimise the 
‘Utility’). 
 
A revised drug regimen with potentially increased ‘Utility’ is a desired treatment 
decision. The “Utility” hanging at the end of the patient assessment process represents 
the estimated outcome (patient benefits) which decides the final decision-making on 
drug regimen. In other words, the decision-making on how to revise the drug regimen 
depends on the estimated “Utility”; a better decision-making in revised drug regimen 
can increase patient benefits (Utility) measured by the combination of improved 
patient disease activity and the absence of drug toxic effects. 
 
I found that the process has two important factors which drive the decision-making for 
revised drug regimen. Firstly, I found that the clinicians make treatment decisions by 
following the paper-based rules and protocols (refer to Triple Therapy and Dose 
Modification Protocol). However these rules give standard recommendations to assist 
clinical decision-making. Secondly, at the time of making decision in revised drug 
regimen, the clinicians often compromise the standard recommendations with their 
acquired personal preferences while estimating the ‘Utility’. Therefore, paper-based 
rules and protocols might not be followed strictly during the decision-making of 
revised drug regimen. This could result in inconsistency in complying the standard 
rules and protocols.   48
5.1.5  Dose Modification Protocol Compliance Analysis 
In order to further examine the degree of inconsistency in decision-making on revised 
drug regimen in the eRA clinic, I started to investigate the compliance rate of the Dose 
Modification Protocol at the early stage of the project while observing the clinical 
consultations. The eRA clinic had established a database that contains a broad range of 
patient data, including patient visit data, laboratory data, clinical data and patient 
treatment information. This database is a valuable source from which to perform 
secondary data analyses. 
 
5.1.5.1 Protocol Compliance Rate
There were clinical data and laboratory data relating to 469 patient visits in the 
database at the time of analysis (September 2004). I performed a secondary data 
analysis to analyse compliance rate for the Dose Modification Protocol. I developed a 
computer program using C# programming language. The program automatically 
retrieves relevant data from the database, implements the Dose Modification Protocol 
and calculates the protocol compliance rate. As regards the results, there were a total of 
101 patient visits in which the decision-making for revised drug regimen violated 
protocol recommendations. The protocol compliance rate was 78.5% and the protocol 
violation rate was 21.5%. 
 
5.1.5.2 Protocol Violation Categorisation 
The secondary data analysis showed the protocol compliance rate was 78.5%, which is 
mild to moderate degree of inconsistency in protocol compliance. Variation in 
compliance verified that the eRA clinicians employed additional personal expertise or 
preferences to complement the protocol according to the patient’s particular clinical 
circumstances. 
 
Base on the protocol violating cases, I further examined the case notes to explore the
reasons for violating the Dose Modification Protocol. As regards the results, I 
identified the main causes as being related to drug-related toxicity or patients being   49
perceived to be at risk of drug toxicity. I then categorised the causes of protocol 
violation (Table 5.3) and counted the frequency of the each causes. Based on the 
analysis, I found that drug toxicity, drug side effects and drug toxicity risks were the 
top three reasons for protocol violation by the clinicians. 
 
At the time the clinical decisions under analysis had taken place, drug toxicity rules 
had not been formulated which may explain the high rate of protocol violation. This 
deficiency was not appreciated until the CDSS project was undertaken and highlighted 
the need for detailed clinical guidelines to be formulated. 
 
Table 5.3 Categorisation of protocol violation causes (Dose Modification Protocol) 
Rank  Category Detail
1  Drug  toxic  effects  abnormality detected in liver function test (LFT), 
complete blood examination (CBE), eye test for 
colour discrimination, etc. 
2  Drug  side  effects  Symptoms such as nausea, hair loss, headache, 
irritability, etc. 
3  Drug  toxicity  risks  pneumonia, urinary tract infection (UTI), upper 
respiratory tract infection (URTI), etc. 
4  Special conditions  Undergoing antibiotic treatment, pregnant, etc 
5  Patient reasons  Refused to comply, patient mistakes, etc. 
6  Protocol exemptions   Patient in the early stage of the treatment (less than 
6 weeks) 
7  Special cases I  Dose modification criteria not fulfilled; but clinical 
evidence showed the disease was progressing 
8  Special cases II  Symptoms were not RA related: joint tenderness and 
patient pain were due to Osteoarthritis or other 
medical conditions 
9  Missing  data  Laboratory results such as ESR and CRP were 
missing when applying protocol   50
5.1.6   Problem Assessment Outcomes 
After spending 6 month on literature review of RA management, eRA clinic 
observation, and database investigation, I had gained a basic understanding of the 
fundamental decision-making and the ultimate goal of the RA management. The goal 
of the RA management is to balance patient disease activity against drug tolerance, 
therefore to make optimised treatment decision towards increased patient 
benefits. In order to achieve this goal, the eRA has established paper-based rules and 
protocols to standardise the decision-making on revised drug regimen. However my 
secondary data analysis found that the facts such as drug toxic effects, drug side effects 
and patient drug toxicity risks can lead clinicians to violate the standard 
recommendations, thereby leading to the inconsistency in clinical decision-making. 
Having gained insight into these issues, Knowledge Acquisition became the next step 
for incorporation of clinical evidence into the decision-making more completely, in 
order to improve the consistency and the quality of the decision-making.   51
5.2 Knowledge Acquisition 
I started to apply Knowledge Acquisition processes as soon as the eRA management 
goal had been recognised. Since I had identified that the drug toxicity related issues 
caused the inconsistency in decision-making on revised drug regimen, I immediately 
began to perform a comprehensive literature review of drug toxicity in RA 
management. Meanwhile, I continued working closely with the clinicians and the 
clinic experts of the eRA clinic to clarify the knowledge within the decision-making 
processes. 
 
During the management of RA, therapy-related toxic effects often cause treatments to 
be withheld and drugs to be discontinued or withdrawn, thereby, limiting the potential 
benefits of therapy. Identifying drug toxicity related symptoms and estimating the drug 
toxicity risk factors efficiently can prevent patients from suffering serious drug toxicity 
events. Clinicians therefore can revise patients’ therapy based on these estimations. It 
is important that these decisions be orderly and based on best evidence if dosage 
adjustments are to yield consistently the best balance between efficacy and reduced 
risk for unacceptable and dangerous unwanted events. Also distinctions need to be 
made between uncomfortable, non-threatening nuisance effects which impose little 
risk to long-term health and serious, potentially irreversible or even fatal organ-
threatening or life-threatening events. 
 
5.2.1  Categorise Evidence - Risk Factors for Methotrexate Toxicity 
Defining risk factors can be useful for quantitatively predicting the likelihood of 
developing drug toxicity in RA [70, 71]. Identifying risk factors helps planning for 
prevention of toxicities and gives clinicians the opportunity to apply appropriate 
medical interventions in time to avoid serious toxicity. Some studies have suggested 
that early recognition of risk factors for drug dosage adjustments or drug withdrawal 
may avoid serious and even fatal outcomes [70, 89]. 
 
I systematically reviewed a total of 23 studies from 1987 to 2004 for the risk factors 
associated with MTX in RA (refer to chapter 2.7.4 for details). I constructed a table of   52
risk factors that have been suggested as being associated with MTX toxicity. It 
summarises the reviewed studies (refer to appendix: tables of MTX toxicity risk 
factors) by detailing types of studies, analytical methods and identified risk factors, etc. 
Based on this table, I adopted the evidence grading methodology defined by Shekelle 
et al [166]. The categorisation is defined according to classification schemes based on 
the potential for bias that may influence the results (Table 5.4). As such the highest 
category evidence (Ia) is represented by meta-analyses of randomised control trials. 
And it provides support for the highest strength of recommendation (A). By contrast, 
evidence from expert committee reports or opinions or clinical experience of respected 
authorities falls in the weakest category evidence (IV). 
 
According to their defined categories of evidence, I classified and graded risk factors 
associated with MTX toxicity in RA from my literature review. Table 5.5-1 
summarises the common risk factors for MTX toxicity and their associated evidence 
category. The common risk factors include advanced age, impaired renal function and 
lack of folate supplementations. These common risk factors are dose related or affected 
by impaired drug clearance suggested a direct pharmacological effect on susceptible 
patients. 
 
Table 5.5-2 summarises the risk factors for MTX pulmonary toxicity and their 
associated evidence category. Table 5.5-3 summarises the risk factors for MTX hepatic 
toxicity and their associated evidence category. Table 5.5-4 summarises the risk factors 
for MTX gastrointestinal toxicity and their associated evidence category. Table 5.5-5 
summarises the risk factors for MTX haematological toxicity and their associated 
evidence category. These risk factors include not only direct drug effect related risk 
factors, but also risk factors related to aggregation of pre-existing diseases or 
conditioned by underlying organ specific diseases. 
 
According to the above categorisation, there is strong evidence that risk factors such as 
lack of folate supplementation, impaired renal function, prior gastrointestinal events, 
alcohol abuse and increased dosage are associated with MTX toxicity in RA. 
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The pie chart (Figure 5.2) gives an overview of the evidence category distribution of 
the studies on MTX risk factors. From the 23 studies which had identified the risk 
factors for MTX toxicity in RA, six studies (25% of the studies) recommended the risk 
factors with strong evidence (category II or plus). The remaining 17 studies (75% of 
the studies) had relatively weak evidence to support their recommended risk factors for 
MTX toxicity in RA.   54
Table 5.4 Categories of evidence and strength of recommendation 
Category of evidence: 
Ia – evidence for meta-analysis of randomised controlled trials 
Ib – evidence from at least one randomised controlled trial 
IIa – evidence from at least one controlled study without randomisation 
IIb – evidence from at least one other type of quasi-experimental study 
III – evidence from non-experimental descriptive studies, such as comparative studies, 
correlation studies and case-control studies 
IV – evidence from expert committee reports or opinions or clinical experience of 
respected authorities, or both  
Strength of recommendation: 
A -  directly based on category I evidence 
B – directly based on category II evidence or extrapolated recommendation from 
category I evidence 
C -  directly based on category II evidence or extrapolated recommendation from 
category I or  II evidence 
D – directly based on category IV evidence or extrapolated recommendation from 






Figure 5.2. The evidence category distribution of the studies 
on MTX toxicity risk factors 
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Table 5.5-1 Common risk factors for MTX toxicity with associated evidence categories 
Author(s) Study Design  Common Risk Factor for 
MTX Toxicity 
Evidence Category 
McKendry, R.J. et al., 
1993 
Retrospective survey of 144 
RA patients for 13 years 
Advanced age  III 
Buchbinder, R., et al., 
1993 
Retrospective review of 587 
patients up to 1986  
Advanced age  III 
Wolfe, F. et al., 1991  Retrospective review of 235 
RA patients from 1976 
to1990 
Advanced age  III 
Rheumatoid Arthritis 
Clinical Trial Archive 
Group, 1995 
A meta-analysis of 496 
patients from 11 placebo 
controlled and comparative 
MTX clinical trials 
Impaired renal function  Ia 
Mielants, H., et al., 1991  Open prospective study of 
92 RA patients 
Impaired renal function  III 
Morgan, S.L., et al., 
1990 
A 24 weeks, placebo-
controlled, double-blind, 
trial of 32 patients 
Lack of folate 
supplementation 
IIa 
Ortiz, Z., et al., 1998  A systematic review of 7 
trails (147 patients) 
Lack of folate 
supplementation 
Ia 
van Ede, A.E., et al., 
2001 
A 48 weeks randomized, 
double-blind, placebo-
controlled trial of 434 RA 
patients  
Lack of folate 
supplementation 
Ib   56 
Table 5.5-2 Risk factors for MTX pulmonary toxicity with associated evidence categories 
A Au ut th ho or r( (s s) ) Study Design  Risk Factor for MTX 
Pulmonary Toxicity 
Evidence Category 





Golden, M.R., et al., 
1995 
case-review study of 125 





Carroll, G.J., et al., 
1994 
case-control study of 12 
patients 
pre-existing lung disease  III 
Alarcon, G.S., et al., 
1997 
case-control study of 29 
patients from 1981 to 1993 




Kremer, J.M., et al., 
1997 
Retrospective combined 
cohort review and 
abstraction form the English 
medical literature 
Clinical features including 
shortness of breath, cough 
etc. 
IV   57 
Table 5.5-3 Risk factors for MTX hepatic toxicity with associated evidence categories 
Author(s)  Study Design  Risk Factor for MTX 
Hepatic Toxicity 
Evidence Category 
Shergy, W.J., et al., 
1988 
Retrospective study of 538 
patients from 1979 to 1988 
Diabetes, obesity  III 
Kremer, J.M. et al., 
1989 
A prospective study with 
baseline and sequential 
biopsy samples of 29 
patients 
Alcohol, obesity, dose, 




et al., 1991 
A meta-analysis of 334 RA 
patients from 15 studies 
Alcohol, dose  Ia 
Walker, A.M., et al., 
1993 
Case-control study of 24 
cases 
Age, dose and duration, 
elevated liver enzyme, 
hypoalbuminemia 
III 
Kent, P.D. et al., 2004  Retrospective cohort study 
of 481 RA patients 




Hoekstra, M., et al., 
2003 
A randomise clinical trial of 
411 RA patients for 48 
weeks 
Lack of folate, high BMI  Ib 
 
Table 5.5-4 Risk factors for MTX gastrointestinal toxicity with associated evidence categories 
Author(s)  Study Design  Risk Factor for MTX 
Gastrointestinal Toxicity 
Evidence Category 
Hoekstra, M., et al., 
2003 
A randomise clinical trial of 
411 RA patients for 48 
weeks 
Prior gastrointestinal events  Ib 
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Table 5.5-5 Risk factors for MTX haematological toxicity with associated evidence categories 




al-Awadhi, A. et al., 
1993 
Case-control study of 15 
cases for 10 years 
Impaired renal function, MCV, 
increased age 
III 
Weinblatt, M.E. et al., 
1989 
Retrospective analysis of 23 
RA patients 
Elevated MCV  III 
Gutierrez-Urena, S., et 
al., 1996 
Literature review + 2 cases 








Maricic, M. et al., 1986  1 Case report   Co-administration of 
trimethaprim-sulphamethoxisole 
IV   59
5.2.2  Categorise Evidence - Methotrexate Toxic Effect 
Identifying MTX toxic effects can be useful for preventing life threatening adverse 
drug reactions for RA patients on MTX treatment, thereby refining RA management 
for better patient outcomes. Identifying early signs of the toxic effects helps planning 
strategies for preventing toxicity and gives clinicians the opportunity to apply 
appropriate medical interventions in time in order to avoid serious toxicity. Some 
studies have suggested that understanding the prognostic factors of the drug-related 
toxic effects can influence the probability of maintaining a patient’s on MTX treatment 
for a long period of time [110, 111]. 
 
I systematically reviewed a total of 23 studies from 1983 to 2000 for the MTX 
associated adverse events in RA treatment (refer to chapter 2.7.3 and chapter 2.7.4 for 
details). Based on my literature review, I constructed a table of MTX associated toxic 
effects in RA by specifying study titles, study designs and identified toxic effects, etc.; 
Table 5.6-1 outlines MTX pulmonary toxic effects; Table 5.6-2 outlines MTX hepatic 
toxic effects; Table 5.6-3 outlines MTX gastrointestinal toxic effects; table 5.6-4 
outlines MTX haematological toxic effects. I once again applied the evidence grading 
methodology defined by Shekelle et al [166] to classify and grade these identified drug 
toxic effects with their associated evidence categories. According to this categorisation, 
there is strong evidence that folic acid and folinic acid reduce MTX gastrointestinal 
toxicity in RA. In addition, relatively strong evidence links MTX spoliated histological 
hepatic abnormalities with a subsequent hepatic fibrosis. 
 
The pie chart (Figure 5.3) gives an overview of the evidence category distribution of 
the studies on MTX toxic effects. From the 23 studies which had identified the MTX 
toxic effects in RA, only 2 studies (9% of the studies) recommended the MTX toxic 
effects with strong evidence (category II or plus). The remaining 21 studies (91% of 
the studies) had relatively weak evidence to support their recommended MTX toxic 
effects in RA. This finding suggested that more high quality clinical trials are needed 
to investigate MTX toxic effects in RA. Thereby, strong evidence can be incorporated 
into clinical decision-making processes for better RA management.   60 
 
Figure 5.3. The evidence category distribution of the studies 
on MTX toxic effects   61 
 
Table 5.6-1 MTX pulmonary toxicity with associated evidence categories 




Grant W. Cannon et 
al., 1983 
Acute lung disease associated with low-dose pulse 
Methotrexate therapy in patients with Rheumatoid 
Arthritis 
Case report  Pulmonary 
disease 
IV 
Jame A. Engelbrecht, 
et al., 1983 
Methotrexate pneumonitis after low-dose therapy for 
Rheumatoid Arthritis  
Case report  Methotrexate 
Pneumonitis 
IV 
Pilar Barrera, et al., 
1994 





Gordon Searles, and 
Robert J.R. 
Mckendry, 1987 
Methotrexate Pneumonitis in Rheumatoid Arthritis: 
Potential risk factors. Four case reports and a review of 
the literature 






Matthew R. Golden, 
et al., 1995 
The relationship of pre-existing lung disease to the 
development of Methotrexate pneumonitis in patients 





III   62 
Table 5.6-2 MTX hepatic toxicity with associated evidence categories 




Ahern M.J. et al., 
1998 
Methotrexate hepatotoxicity: What is the evidence  Commentary  Fibrosis  IV 
Jenny Heathcote, 
1996 
The significance of AST changes in patients with 
Rheumatoid Arthritis treated with Methotrexate 
Editorial Elevated  AST IV 
James H. Lewis, 1997  Monitoring for Methotrexate Hepatotoxicity in Patients 
with Rheumatoid Arthritis: Another hepatologist’s 
perspective 
Editorial Elevated  AST, 
ALT 
IV 
Stanley L. Bridges, 
Jr. et al., 1989 
Methotrexate-Induced liver abnormalities in 
Rheumatoid Arthritis 
Editorial Hepatic  fibrosis    IV 
Michael E. Weinblatt 
et al., 2000 
Serious Liver disease I a patient receiving Methotrexate 
and Leflunomide 
Case report  Early cirrhosis  IV 
William J. Shergy, et 
al., 1988 
Methotrexate-Associated Hepatotoxicity: Retrospective 




Joel M. Kremer et 
al.,1989 
Liver Histology in Rheumatoid Arthritis patients 
receiving long-term Methotrexate therapy 
Prospective 
study 
Mild fibrosis  III 
Quinn E. Whiting-
O’Keefe et al., 1991 
Methotrexate and histologic Hepatic Abnormalities: A 
meta-analysis 
Meta-analysis Hepatic  fibrosis  IIb 
Alexander M. Walker 
et al., 1993 
Determinants of serious liver disease among patients 







Christine A. Phillips 
et al., 1992 
Clinical Liver Disease in Patient with Rheumatoid 
Arthritis taking Methotrexate 
Case report  Hepatic 
fibrosis/cirrhosis 
IV 
Daniel O. Clegg et 
al., 1989 
Acute, reversible hepatic failure associated with 
Methotrexate treatment of Rheumatoid Arthritis 
Case report  MTX related 
chronic hepatitis 
IV 
Kujala, G.A., et al., 
1990 
Hepatitis with bridging fibrosis and reversible hepatic 
insufficiency in a woman with RA taking Methotrexate 
Case report  chronic 
hepatitis/fibrosis 
IV   63 
Table 5.6-3 MTX gastrointestinal toxicity with associated evidence categories 





Zulma Ortiz et al., 
1998 
The efficacy of Folic Acid and Folinic Acid in reducing 
Methotrexate gastrointestinal toxicity in Rheumatoid 
Arthritis. A meta analysis of randomised controlled 
trials 
Systematic 
review of RCTs 




Table 5.6-4 MTX haematological toxicity with associated evidence categories 





Adel Al-Awadhi et 
al., 1993 
Pancytopenia associated with low dose methotrexate 





Urena, et al., 1996 
Pancytopenia secondary to Methotrexate therapy in 
Rheumatoid Arthritis 




Bernhard Lang et al., 
1991 
Low dose Methotrexate therapy for Rheumatoid 
Arthritis complicated by Pancytopenia and 
Pneumocystis carinii Pneumonia 
Case report  Pancytopenia  IV 
Kevat S.G. et al., 
1988 
Pancytopenia induced by low-dose Methotrexate for 
Rheumatoid Arthritis 
Case report  Pancytopenia  IV 
Barrie Mayall et al., 
1991 
Neutropenia due to low-dose methotrexate therapy for 




Neutropenia III   64
5.2.3  Evidence-based Drug Toxicity Management in the eRA Clinic 
In the eRA clinic, the patient’s disease activity assessment evaluates the treatment 
benefits, while the patient’s drug-related toxic effects assessment considers the 
treatment risks. During the RA assessment process, there are multiple variables 
involved in the evaluation of both the treatment efficacy and the drug-related toxicity 
that can contribute to a decision on whether to adjust a specific treatment. Variables 
include standardised assessment indices, such as disease activity score (DAS) and 
other clinical and laboratory variables. In the eRA clinic where treatment is designed 
to abrogate periarticular erosions and other radiographic signs of RA related joint 
damage, radiological findings are not a formal aspect of the assessments upon which 
treatment decisions are made as there may be lag time of several months before erosive 
damage is evident radio-graphically by which time the damage is often well-advanced. 
 
5.2.3.1 Disease Activity Related Clinical Variables 
The clinicians assess RA patients at standardised intervals (starting from every three 
weeks; extending to every six weeks after the third visit and every three months once 
remission has been achieved). The clinicians carry out regular clinical assessments of 
swollen and tender joints counts, patient assessed pain, well-being and fatigue (on 
100mm visual analogue scores), duration of morning stiffness (minutes) and function 
(modified Health Assessment Questionnaire (mHAQ)) [167]. Laboratory 
investigations to evaluate the efficacy of treatment assess the acute phase response in 
the serum to inflammation with erythrocyte sedimentation rates (ESR) and C-reactive 
protein (CRP) as indices of disease activity. Assessments of the longer-term disease 
outcomes include radiographs of the hands and feet, bone densitometry at hip, spine 
and hands and quality of life (SF36, RAQoL). 
 
5.2.3.2 Drug Toxicity Related Clinical Variables 
Patients on DMARDs therapy are closely monitored for symptoms that may suggest 
drug toxicity. Regular blood tests are performed to detect the more serious toxic effects 
of DMARDs at an early stage (starting at every three weeks for 26 weeks; every six   65
weeks thereafter). At each clinic visit, the clinicians routinely require complete blood 
examinations (CBE) and liver function tests (LFT), which are used to assess 
haematological toxicity and hepatic toxicity of the treatments. Table 5.7 lists the major 
variables used for evaluating patient disease activity, drug-related toxic effects and 
longer-term effects of RA on skeletal structures. 
 
Table 5.7 Variables for disease activity assessment, drug toxicity assessment and 
longer-term disease outcomes 
Disease 
Activity 
1. Morning stiffness (EMS) 
2. Fatigue 
3. Joint pain 
4. Joint tenderness or pain on movement 
5. Soft tissue swelling (joints or tendon) 
6. Acute phase response  
Erythrocyte sedimentation rate (ESR) >= 28 mm/hour 
C-reactive protein (CRP) >= 10 mg/L 
7. Disease Activity Score (DAS) 
8. Physician assessment of disease activity 




1. Complete blood exam (CBE) 
2. Liver function tests (LFT) 
3. Urinalysis is performed as part of the monitoring intramuscular 
myocrisin (IM gold). 
4. Serum creatinine is required as a baseline for methotrexate therapy for 
monitoring cyclosporine A nephrotoxicity 
5. Pulmonary function test and Chest X-ray (CXR) are performed in 
smokers prior to treatment with methotrexate (MTX) 
6. Annual assessment of retinal function using peripheral field and colour 





1. X-rays of hands and feet (annually) 
2. Bone Densitometry (6 monthly)   66
5.2.3.3 Clinical Routine Surveillance for Drug Toxicity 
The eRA clinic applies Triple Therapy [methotrexate (MTX), sulfasalazine (SSA) and 
hydroxychloroquine (HCQ)] to RA patients from the time of diagnosis. Drug toxicity 
and nuisance side effects associated with, Triple Therapy or its components include 
effects on the lungs, blood cells, liver, gastrointestinal tract and retina. Identifying drug 
toxicity risk at an early stage and incorporating the risk into clinical decision-making is 
an important aspect of safety management. 
 
The eRA clinic has been establishing and maintaining its surveillance list for drug 
toxicity related symptoms and abnormal laboratory findings. This information elicited 
through consulting the clinicians, which is sought routinely by pro forma at the eRA 
clinic and is relevant to Triple Therapy and its components, is summarised in Table 5.8. 
According to these listed nuisance events and toxicity, I found that the MTX related 
toxicity events align well with the identified MTX risk factors and toxicity events from 
my comprehensive literature review (Table 5.5-1 –Table 5.5-5). It suggests that the 
eRA clinic has been aiming to incorporate evidence-based risk factors and events for 
MTX toxicity into its daily practice. Apart from the evidence-based risk factors, most 
parameters listed it Table 5.8 are nuisance side effects but these, if left untreated, may 
evolve into symptoms of more serious toxicity so in themselves represent risk factors 
for serious toxicity.   67
Table 5.8 Routine surveillance for nuisance events and toxicity associated with 
components of Triple Therapy in the eRA clinic 
Methotrexate  Sulfasalazine  Hydroxychloroquine
fever fever fever 
weight loss (more than 
4kg) 
weight loss (more than 
4kg) 
 
feeling unwell  feeling unwell  feeling unwell 
headache headache headache 
unusual fatigue  unusual fatigue  unusual fatigue 
swollen glands     
loss of appetite  loss of appetite   
skin rash  skin rash  skin rash 
loss of hair     
unusual bleeding  unusual bleeding  unusual bleeding 
stuffy nose / sinusitis     
sores in the mouth  sores in the mouth   
cough / phlegm     
shortness of breath  shortness of breath   
wheeze    
heartburn / acid reflux  heartburn/ acid reflux  heartburn/ acid reflux 
stomach pain or cramps  stomach pain or cramps  stomach pain or cramps 
nausea nausea nausea 
vomiting vomiting vomiting 
diarrhoea diarrhoea diarrhoea 
dark stools (bowel 
movement) 
  
blood in stool     
problems with urination  problems with urination   
abnormal vaginal bleeding     
dizziness   dizziness 
any new health problem  any new health problem  any new health problem   68
Methotrexate  Sulfasalazine  Hydroxychloroquine
any new drug prescription  any new drug prescription  any new drug prescription 
any discontinued drug  any discontinued drug  any discontinued drug 
more than 2 alcoholic 
drinks / day 
  
problems with thinking     
problems with memory     
  depression - feeling blue   
  anxiety - feeling nervous   
  abdominal bloating  abdominal bloating 
  problems with smell   
  problems with taste   
  problems with hearing  problems with hearing 
  other  skin  problems 
  other  eye  problems 
  ringing  in  the  ears 
  sensitivity to sulphur-
containing compounds 
 
a history of alcohol abuse     
impaired renal function     
impaired liver function  impaired liver function   





thrombocytopenia   69
5.3 Establish the Evidence-based RA Management Rules 
Practising the principles of EBM relies on the rules of evidence and research. The eRA 
clinic promotes systematic and consistent treatment for each RA patient. Practice has 
been made more orderly and evidence-based by applying knowledge gained from 
clinical trials to patient care to develop clinical protocols and rules for patient 
management. 
 
The eRA clinic has been establishing RA management guidelines aimed at improving 
and standardising clinical decision-making. Clinicians apply paper-based rules and 
protocols (Triple Therapy and Dose Modification Protocol) during an assessment of 
the patient before determining a recommended drug regimen. There are recognised 
limitations of paper-based rules and protocols, namely that they reflect general 
population standards for treatment and monitoring and may need to be tailored to the 
circumstances of an individual patient. For example, for the individual patient, some 
recommendations might seem too intensive, while others might be too conservative. 
While applying guidelines, a physician will often incorporate his or her expertise, extra 
knowledge, preferences and prejudices into the decision-making process, 
complementing standard rules and protocols according to the individual patient’s 
medical condition. These modifications are not necessarily well-grounded and are an 
important source of variability in practice. 
 
The eRA clinic has had an eight year experience with the implementation of Triple
Therapy and Dose Modification Protocol for disease control and has established the 
general utility of its therapeutic algorithm [168]. By contrast, prior to the present study, 
formal rules for modification of treatment because of out-of-range blood results had 
not been articulated. A discretionary decision to violate eRA guidelines often depends 
on an estimate of the patient’s toxicity risks based on laboratory data. It was therefore 
considered important to address this source of variability. 
 
The identified clinical evidence from the literature review and the elicited clinical 
expertise from the eRA clinic forms a solid foundation to further establish and   70
maintain pertinent evidence-based CPGs, and consequently to incorporate the CPGs 
into daily clinical practice. With my assistance, the establishment of RA management 
rules was undertaken to assist clinicians in consistent, sound decision-making, 
therefore to formalise the decision-making process. 
 
During the Knowledge Acquisition in the eRA clinic, the clinic consultations were 
observed. Interviewing/consulting the clinicians facilitated the process and benefited 
the thorough understanding of the domain knowledge. The eRA clinic experts used 
think-aloud strategy to verbalise their judging processes for a specific patient case. 
During the interviews, I used the transcripts to record the reasoning behind their 
decisions. I also pinpointed various types of knowledge surrounding the decision-
making, such as rule sets, attributes, and relationships. As regards results, the clinical 
decision-making processes and underlying rationale of clinical decision-making were 
elicited. Based on the transcripts, I undertook further analysis to determine what 
clinical data were applicable to decision-making. 
 
I created numerous draft versions of flow charts recording the clinical decision-making 
process. I also drafted flow charts for the RA management rules. The clinical experts 
from the eRA clinic were also engaged in the process during this period, especially 
during the period of verifying sketches of the flow charts. As regards results, the study 
has established two sets of evidence-based RA management rules; they are (a) Rules
for Changes in Dose/Agent, and (b) Drug Toxicity Monitoring rules. 
 
The development of these RA management rules reinforces standardised practice with 
consistent treatment. The eRA management rules incorporate both the best available 
evidence from the literature and the clinical expertise and experience within the eRA 
clinic. Participating clinicians can use them to make clinical decisions in adjusting 
therapy to achieve pre-defined levels of treatment response and with due regard to the 
tolerance of the patient to component medications in the treatment regimen.   71
5.3.1  Drug Toxicity Monitoring Rules 
Developing Drug Toxicity Monitoring Rules can standardise patient monitoring of 
drug-related toxicity. It can also formalise clinical decision-making by incorporating 
the best evidence from relevant literature and clinical expertise. Therefore to prevent 
drug-related toxicity effectively and also reduce practice variation. The establishment 
of the Drug Toxicity Monitoring Rules started from mid 2005. The development 
consisted of methods such as identifying the evidence from the literature review and 
consulting the local clinical experts in the eRA clinic. 
 
According to the literature review, risk factors such as lack of folate supplementation, 
impaired renal function, prior gastrointestinal events, alcohol abuse and increased 
dosage are associated with MTX toxicity in RA. Furthermore, according to the 
evidence categorisation, there is also strong evidence showing that MTX is associated 
with histological hepatic abnormalities such as hepatic fibrosis (refer to chapter 5.2.2). 
In addition, according to the secondary data analysis, concern regarding drug-related 
toxic effects such as abnormality detected in liver function test (LFT) and complete 
blood examination (CBE) was the major cause of protocol violation. Based on these 
facts, I began to engage the eRA clinicians to formalise the clinical decision-making 
rules on RA management for medication changes by incorporating best evidence, 
including not only that regarding identified risk factors and drug-related toxic effects, 
but also the relevant laboratory tests for drug toxicity monitoring. 
 
An evidence-based expert consensus process was also used to create Drug toxicity 
Monitoring Rules. Rule scribbles written by the experts were collected and recorded 
(Figure 5.4). After I looked through the recorded rule scribbles, I found that Drug 
Toxicity Monitoring Rules are highly complex. They feature loops, complex state 
transition and time dependency. I therefore suggested the use of a flowchart to 
represent these rules. This was designed to allow clinicians to communicate more 
easily thereby facilitating refinements through exchange of opinions based b clearer 
concepts.   72
 
Figure 5.4 The recorded rule scribbles 
 
I choose flowcharts as a form of graphical language to represent complex clinical rules 
such as the Drug Toxicity Monitoring Rules (Figure 5.5). Flowcharts allow clinical 
rules to be represented on a natural language-like pseudocode. As such, I believed that 
the complex rules are much better described in the form of flowchart. The relationships 
and flows between the corresponding rules are more clearly expressed in the diagram, 
and therefore the rule structure can be more easily understood. 
 
The flowchart of the Drug Toxicity Monitoring Rules illustrates complexity and 
contingencies within the rule algorithm. It integrates neutrophil count which is a test 
within the CBE. It also integrated AST (aspartate transaminase) and ALT (alanine 
transferase) which are the tests within the LFT (liver function tests). 
 
The eRA clinic had agreed on the decision of classifying the laboratory tests results 
(LFT and neutrophil count) into five ranks; they are normal, mild, moderate, severe 
and very severe toxicity (Table 5.9). Within the Drug Toxicity Monitoring Rules, mild   73
ranking and moderate ranking were combined together; therefore the Drug Toxicity 
Monitoring Rules included four sets of sub-rules (refer to Figure 5.5). 
 
Table 5.9 The ranking of the laboratory test results in the eRA clinic 

































UNL: Upper Normal Limit 
 
The development of the Drug Toxicity Monitoring Rules was designed to assist the 
clinician in making optimal decisions. The rules provide more specific 
recommendations regarding patients in the events of drug toxicity. By classifying the 
ranking of the laboratory test results, the drug regimen can thus be modified 
consistently if the patient is likely to suffer drug toxicity. The agents that appear to 
cause significant unwanted effects can be revised or withdrawn.   74   75
5.3.2  Rules for Changes in Dose/Agent 
Rules for Changes in Dose/Agent were designed as a standardised set of 
recommendations for the introduction of Triple Therapy and for increasing the 
intensity of treatment through increases in doses and addition of further DMARDs if 
disease suppression criteria are not met. They are based on the premise that early 
remission-inducing interventions restore health and avoid or reduce long-term joint 
damage and disability. This protocol is in accordance with emerging worldwide 
treatment practices and extends existing trends through the application of more orderly 
and rigorous dose modification procedures.
 
Rules for Changes in Dose/Agent are contingent on the criteria for intensifying 
Treatment. These criteria reflect persistence of disease as evidenced by one or more 
swollen joints and increased acute phase reactants, or one of these plus two of: 
increased joint paint, stiffness, fatigue and more than 1 tender joint. According to the 
algorithm, clinicians could either increase the dosage of the drug agent or add an 
additional DMARD into the drug regimen depending on the patient’s tolerance or 
point of progression through the algorithm. 
 
Rules for Changes in Dose/Agent introduce drug agents into the drug regimen in a 
specified order (Table 5.10). As one of the agents in the Triple Therapy, MTX is 
always the first choice of the eRA clinic. In the initial period of the eRA clinic practice, 
myocrysin had preceded leflunomide in the order of application. With further 
experience with leflunomide, and in particular its more prompt therapeutic response 
rate relative to myocrysin, the order was reversed.   76
Table 5.10 Order of agents in the drug regimen of the Rules for Changes in 
Dose/Agent 
Order  Agents 
1 methotrexate  (MTX) 
2  sulfasalazine EC (Salazopyrin EN, SSA) 
3 hydroxychloroquine  (HCQ) 
4 leflunomide  (Arava) 
5  intramuscular myocrisin (Gold) 
6  cyclosporine A (Neoral) 
7 TNF  Blocker 
8 azathioprine  (AZA) 
 
An evidence-based expert consensus process was also used to create Rules for 
Changes in Dose/Agent. Rule scribbles were collected and recorded during the group 
discussions with clinical experts from the eRA clinic. Then, I developed a flowchart 
for the Rules for Changes in Dose/Agent (Figure 5.6). 
 
Rules for Changes in Dose/Agent integrated the identified drug toxicity risk factors 
and drug-related toxic effects from the literature review and evidence categorisation I 
performed earlier. Risk factors for MTX toxicity such as impaired renal function 
(measured by decreased creatinine clearance), increased age and increased dosage was 
incorporated into the rules. Rules for Changes in Dose/Agent also formalised the use 
of folic acid within the drug regimen. It supported the evidence from the meta-analysis 
of randomised controlled trials which showed the efficacy of folic acid in reducing 
MTX gastrointestinal toxicity in RA [128]. In additional MTX toxic effects such as GI 
side effects was included into the rules.   77   78
5.4 Knowledge Engineering Outcomes 
From the literature, there were limited RA management rules for managing drug 
toxicity during RA management pathway, as well as introducing the sequence of 
different drug agents to control RA progression effectively and efficiently. Hence 
developing a comprehensive evidence-based RA management rules was drastic needed. 
 
Knowledge Engineering had successfully identified the goal of the RA management, 
which is to balance patient disease activity against drug tolerance, therefore to make 
optimised treatment decision towards increased patient benefits. Through the 
Knowledge Acquisition processes, I established and categorised MTX toxicity risk 
facts and MTX toxic effects based on the literature review I performed earlier. 
Consequently, I engaged the eRA clinic; with my assistance, the eRA clinic developed 
the comprehensive RA management rules which integrated the best evidence and the 
local clinic expertise. The establishment of Drug Toxicity Monitoring Rules and Rules 
for Changes in Dose/Agent standardised the decision-making on revised drug regimen 
in the eRA clinic. Drug Toxicity Monitoring Rules gave specific recommendations 
regarding patients in the events of drug toxicity; and Rules for Changes in Dose/Agent 
focused on the specified order of introducing drug agents into the drug regimen. 
 
The eRA-CDSS which was designed to implement the RA management rules can 
assist the eRA clinicians to comply with the rules. The eRA-CDSS has the potential to 
record the compliance data for audit. Thereby a more complete rules set with 
consequent elimination of variability in management can be established which allows 
outcomes from the eRA approach to contribute more meaningfully to knowledge about 
management, thereby creating a basis for refinement in management of RA.   79
6 Clinical  Guideline  Modelling 
CDSSs can automate complex CPGs at point of care and deliver timely 
recommendations to clinicians thereby assisting clinical decision-making. Adopting 
CDSSs can reinforce guideline compliance hence practise of EBM. However, in order 
to deliver computerised clinical guidelines, human readable guidelines have to be 
represented into a format that can be interpreted by computers [49, 169]. 
 
The establishment of CPGs is fundamental to the development of guideline conceptual 
models that underpin CDSS implementation. This chapter explains the process of 
establishing conceptual models for the RA management rules including Drug Toxicity 
Management Rules and Rules for Changes in Dose/Agent. Based on the conceptual 
models, I further developed computer algorithms required for the CDSS application. 
 
The exhaustive literature review on MTX toxicity had identified a complete list of risk 
factors for MTX toxicity and MTX toxic effects in RA. In addition, Bayes’ Theorem 
and Bayes Net was studied in order to maximise expected utility while making 
decisions under uncertainty. Utilising Bayes’ Theorem and Bayes Net to construct a 
drug toxicity prediction model allow unknown probabilities to be computed from 
known ones. This study has applied Bayes’ Theorem and Bayes Net to establish drug 
toxicity prediction models for managing MTX toxicity in RA. 
 
Furthermore, in order to achieve clinical efficiencies and wide clinical acceptance, 
CDSSs must not impact negatively on workflows. Thus, integration of CDSS into 
workflows is essential for the utility of CDSS in clinical decision-making. In this study 
a clinical workflow analysis was therefore performed to identify opportunities for the 
CDSS to be incorporated seamlessly into clinical management of RA.   80
6.1 Dynamic Characteristic of the RA Management Rules 
Using flowcharts to represent the complex RA management rules, I have illustrated 
Drug Toxicity Monitoring Rules and Rules for Changes in Dose/Agent into sequential 
flows of decisions that match scenario with action (Figure 5.5, 5.6). However, due to 
the characteristics of RA management, the comprehensive RA management rules are 
highly complex; they feature loops, time dependency, state dependency and state 
transition. The state here stands for a patent’s clinical condition at a specific point of 
time. 
 
Using the Drug Toxicity Monitoring Rules as an example, this rule set features more 
complex rule structure. It consists of dynamic state transitions. The ancestor state 
within the rule set has multiple descendant states. As such it features state transition 
loops. This dynamic characteristic makes the rule set more complex to clarify. 
Therefore, conceptual models needed to be established for the RA management rules 
before implementing into the CDSS. 
 
I drafted a sample dynamic model (Figure 6.1) to show a complete set of potential 
transitions between the normal state and the three toxicity states (previously defined in 
Table 5.9; mild toxicity and moderate toxicity were combined). Oval represents a 
patient state defined using LFT or neutrophils test results; and the colour coded lines 
linking the ovals represent the potential transitions from one state to another. Every 
state within the sample model has three ancestor states and three descendant states. As 
illustrated, there are total of 12 unique state transitions within the model. 
 
A number of methods to support the computerisation of guidelines have been or are 
being developed by the Health Informatics community [170]. Tu et, al. [169] 
recommended a standard computer interpretable guideline structure. It used Decision 
Maps to represent static recommendations and ‘guideline processes’ to link the 
individual static recommendations together as a computational model. They had 
evaluated the proposed guideline structure by mapping GLIF, EON, PRODIGY3, and 
Medical Logic Modules into the proposed structures.   81
 
However, due to the dynamic characteristics (dynamic state transitions and transition 
loops) of the RA management rules, it remained challenging to work out the potential 
state transitions and transition loops of the RA management rules exhaustively. The 
pathways of the RA management rules are erratic when it progresses. Therefore 
Decision Tables cannot be linked by a simple ‘guideline processes’. Further analysis to 
determine a complete set of pathways for the RA management rules is needed. 
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6.2 RA Management Rules Break Down 
In order to clarify the Drug Toxicity monitoring Rules (Figure 5.5), I categorised the 
previously defined ranking of the laboratory test results into three toxicity events. They 
were mild-moderate event, severe event and very severe event. According to the three 
toxicity events, I then broke down the Drug Toxicity Monitoring Rules further into 
three sets of sub-rules. 
 
The three sets of sub-rules started with the laboratory tests for drug toxicity (LFT and 
neutrophils). Three flowcharts for these sub-rules were illustrated (Figure 6.2-6.4). 
Figure 6.2 represented the sub-rule in the event of mild or moderate toxicity; Figure 
6.3 represented the sub-rule in the event of severe toxicity; Figure 6.4 represented the 
sub-rule in the event of very severe toxicity. 
 
The rule flowchart of the Rules for Changes in Dose/Agent I developed earlier featured 
combined sub-rules (Figure 5.6). I then separated the combine sub-rules and updated 
the flowchart. Figure 6.5 is the updated flowchart which illustrated the complete rule 
branches of the Rules for Changes in Dose/Agent. 
 
The rectangle boxes from the flowcharts represented decisions or actions under a 
recognisable patient state; while the arrows indicated the sequence/flow of the clinical 
rules. The numbers on corners of the rectangle boxes labelled the sequence of the 
states within the rule set.   83
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6.3 Exhaustive Search of State Transition Combinations in the 
Severe Toxicity sub-Rule 
In order to manage a chronic disease such as RA, clinicians provide treatment to RA 
patients on a regular basis. Treatment adjustment is dependent on the decisions made 
and actions taken during a patient’s previous and current visit. Clinicians can modify 
therapies over time depending on a patient’s response to, and tolerance of the treatment. 
 
Having created the flowchart for the severe toxicity sub-rule set, I illustrated the loops, 
time dependency and state transition in the event of severe drug toxicity. However, the 
transition loops brought the difficulties to work out the state transitions elementary. In 
order to demonstrate every potential state transition combination along the rule 
pathway exhaustively, I performed a “stress test” by walking through every possible 
rule branches manually; and then created a diagram demonstrating a complete set of 
state transition combinations (Figure 6.6). According to the thorough search, this 
diagram represented a complete set of state transition pathway within the severe 
toxicity sub-rule set. 
 
Then I further analysed the diagram of the exhaustive state transition pathway. I 
identified a total of 19 alternative state transition combinations with 20 unique states in 
the severe toxicity rule set. A state was defined as ‘unique’ because the combination of 
its ancestor states and descendant states along the state transition pathway was 
exclusive. On the diagram, I used different colour code to represent each unique state 
if it had a special ancestor states and descendant states combination. However, if two 
states shared same descendant states but not the ancestor states, I applied same colour 
code but added an extra number to differentiate one from another. 
 
Performing a “stress test” by walking through every possible rule branches manually 
gave an alternative way to demonstrate complexity and contingency of the RA 
management rules. It helped tremendously in understanding the state transition 
alternatives along the rule pathway, therefore establishing an algorithm to computerise 
the complex clinical rules.   88 
 
Figure 6.6 Exhaustive state flow combinations in the event of severe toxicity  89
6.4 Establishing Dynamic Model and Algorithm for the RA 
Management Rules 
In order to translate the complex RA management rules into computer interpretable 
formats as a precursor to implementation utilising CDSS approach was to establish a 
dynamic model to represent the Drug Toxicity Monitoring Rules and the Rules for 
Changes in Dose/Agent. The dynamic model consisted of Decision Tables and Node 
Tables. A Decision Table contained static recommendations relating to specific patient 
clinical conditions (states). A node Table represents the dynamic relationships between 
these states. 
 
According to the established rule flowcharts, two types of knowledge had been 
identified which were declarative knowledge and procedural knowledge. Declarative 
knowledge refers to specific clinical judgment such as scenarios and actions. For 
example, the first declarative knowledge within the severe toxicity rule set is ‘if severe, 
hold MTX for 2 doses, repeat tests after 2
nd missed dose’. Procedural knowledge 
includes sequences of the clinical judgments and transitions between the judgments. 
For example, the procedural knowledge relating to the first clinical judgment is either 
‘Normal/Mild’ transition, or ‘Moderate’ transition, or staying at ‘Severe’ without a 
transition. 
 
I transformed the flowcharts of the Drug Toxicity Monitoring Rules (mild or moderate 
toxicity rule set, severe toxicity rule set and very severe toxicity rule set) , and the 
Rules for Changes in Dose/Agent (Figure 6.2-6.5) into dynamic models (Figures 6.7-
6.10) respectively. Each clinical scenario and associated actions within the boxes of 
the flowcharts was represented as a corresponding node of the dynamic model. 
Procedural knowledge was represented by a link with arrow connecting two nodes. 
 
For each dynamic model, I further modelled procedural knowledge and declarative 
knowledge separately into a node table and a decision table. Firstly, I set up the node 
tables (Table 6.1, Table 6.3, Table 6.5, and Table 6.7) to specify the transitions and 
sequences of the clinical scenarios (procedural knowledge) for the dynamic models of   90
the Drug Toxicity Monitoring Rules (mild or moderate toxicity rule set, severe toxicity 
rule set and very severe toxicity rule set), and the Rules for Changes in Dose/Agent. 
Each node table included a complete set of nodes within its related dynamic model. All 
the corresponding descendant nodes were also listed. The ‘Parent Node number’ 
within the first column matched the numbers stated on its related dynamic model. 
Secondly, I created decision tables (Table 6.2, Table 6.4, Table 6.6 and Table 6.8) to 
sum up the declarative knowledge for the dynamic models. The decision tables 
illustrated the clinical scenarios and related actions for each node within the dynamic 
models. 
 
Supplementing the dynamic models with the node tables and the decision tables 
captures knowledge encompassed within the RA management rules; CDSS application 
can be developed to access these decision tables. Both the node tables and the decision 
tables served as a knowledge base of the CDSS. Computer algorithms can be 
established according to the node tables for selecting required rules stored in the 
decision tables for execution.   91
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Table 6.1 Node table of the Drug Toxicity Monitoring Rules 
in the event of mild or moderate toxicity 
Parent Node#  Child Node# 
Normal  Mild  Moderate 
1 -  -  - 
2 1  3  4 
3 -  -  - 
4 -  -  5 
5 1  3  5 
 
 
Table 6.2 Decision table of the Drug Toxicity Monitoring Rules 
in the event of mild or moderate toxicity 
Node #  Scenarios  Action/Plan 
1  If normal  Repeat tests every 3/52 for 6/12, then every 6/52, 
continue Protocol 
2  If mild or moderate  Repeat tests within 1w 
3  If  mild  Continue treatment, repeat tests every 3/52 for 
6/12, then every 6/52, continue Protocol 
4  If moderate  Repeat test within 1w
5  If remains moderate  Reduce MTX dose by 5mg/w, repeat tests every 
3/52, continue Protocol   93  94
Table 6.3 Node table of the Drug Toxicity Monitoring Rules 
in the event of severe toxicity 
Parent Node#  Child Node# 
Normal/Mild  Moderate  Severe 
1 2  3  4 
2 5  3  4 
3 2  6  6 
4/1 7  4  4 
4/2 7  9  9 
5 -  -  - 
6/1 8  6  6 
6/2 8  9  9 
7 10  6  6 
8 13  -  - 
9 -  -  - 
10 13  11  11 
11 12  11  11 
12 13  14  14 
13 13  15  15 
14 17  14  14 
15 16  15  15 
16 -  -  - 
17 -  -  -   95
Table 6.4 Decision table of the Drug Toxicity Monitoring Rules 
in the event of severe toxicity 
Node
#
Scenarios  Action/Plan 
1  If severe  Hold MTX for 2 doses, repeat tests after 2
nd missed dose 
2  If  normal/mild  Resume MTX at 50% previous dose, repeat tests 
every1/52 for 3/52, then every 3/52 for 6/12, then every 
6/52, continue protocol 
3  If moderate  Continue to hold MTX & reduce SSA by ½, repeat test 
every 1/52 for 3/52 
4  If severe  Continue to hold MTX & also hold SSA, repeat tests 
every 1/52 until normal 
5  If normal/mild  Repeat tests every1/52 for 3/52, then every 3/52 for 6/12, 
then every 6/52, continue protocol 
6 If  remains 
moderate/severe 
Continue to hold MTX & stop SSA, repeat tests every 
1/52 
7  If normal/mild  Continue to hold MTX & resume SSA at 50% previous 
dose (round down), repeat test every 1/52 for 3/52 
8 If  remains 
normal/mild 
Restart MTX at 50% of last dose used, do not resume 
SSA, repeat test every 1/52 for 3/52, then every 3/52 for 
6/12, then every 6/52, continue protocol 
9 If  still 
moderate/severe 
After 3w or if febrile, continue to hold MTX & 
haematology opinion or gastroenterology 
10 If  remains 
normal/mild 
Restart MTX at 50% of last dose used, repeat test every 




Stop MTX, repeat test every 1/52 until normal/ mild 
12  If normal/mild  Resume MTX 2.5mg/w, repeat tests after 2
nd dose 
13  If normal/mild  Increase 2.5mg every 2/52, repeat tests every 2/52 until 
maximum tolerated dose achieved up to dose dictated by   96
Node
#
Scenarios  Action/Plan 
disease activity 
14  If normal/mild  Stop MTX, repeat tests every 1/52 until normal 
15  If  normal/mild  Reduce to last OK dose, repeat tests every 2/52 until 
stable tolerated dose achieved 
16    After stable dose achieved, resume protocol based on 
this as maximum MTX dose, repeat tests every 3/52 for 
6/12, then every 6/52 
17  If normal/mild  Resume protocol without MTX   97  98
Table 6.5 Node table of the Drug Toxicity Monitoring Rules 
in the event of very severe toxicity 
Parent Node#  Child Node# 
Normal/Mild  Moderate  Severe 
1 3  2  2 
2 4  5  5 
3      
4 4  6  6 
5 -  -  - 
6 7  6  6 
7 -  -  - 
 
Table 6.6 Decision table of the Drug Toxicity Monitoring Rules 
in the event very severe toxicity 
Node
#
Scenarios  Action/Plan 
1  If very severe  Hold MTX and SSA, repeat tests every week until normal 
2  If normal  Resume MTX 2.5mg/w, repeat tests after 2
nd dose 
3 If  still 
moderate/severe 
After 3w or if febrile, haematology opinion or 
gastroenterology 
4  If normal  Increase 2.5mg every 2/52, repeat tests every 2/52 until 
maximum tolerated dose achieved as dictated by disease 
activity, may restart SSA 1/2 dose if patient still has 
active disease activity 
5  If not normal  Stop MTX, repeat tests every 1/52 until normal, resume 
protocol without MTX 
6  If not normal  Reduce to last OK dose of MTX and SSA, repeat tests 
every 2/52, until stable tolerated dose achieved 
7    After stable dose achieved, repeat tests every 3/52 for 
6/12, then every 6/52, resume protocol based on this as 
maximum MTX dose   99
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Unconditional Condition  Satisfied  Not 
satisfied 
1 2  -     
2 3  -     
3  -  If CREAT CL<30 ml/min 4  5 
4 10  -    
5 6  -     
6  -  If weight <50 and/or 
CREAT CL >30 but <60 
ml/min 
7 8 
7 10  -    
8 9       
9 10      
10 11       
11 -  PBS  criteria  fulfilled  12  13 
12 -  -    
13  -  If satisfactory response 
after 6 month 
14 15 
14 -  -    
15  -  If weight <50 kg and/or  
age >70 years 
16 17 
16 18  -     
17 18  -     
18 19  -     
19 -  PBS  criteria  fulfilled  12  20 
20 21  -     
21 -  -      101
Table 6.8 Decision table of the Rules for Changes in Dose/Agent 
Node
#
Scenarios  Action/Plan 
1    MTX 10mg/w (with folic acid 0.5mg/d) (MTX 
parenteral if GI side effects), SSA 0.5g/d, HCQ 
200mg bd 
2    MTX 10mg/w (with folic acid 0.5mg/d) (MTX 
parenteral if GI side effects), SSA increase by 
0.5g/d at weekly intervals to 1g bd, HCQ 200mg bd 
3    Increase SSA to 1.5g bd 
4  If CREAT CL <30 
ml/min 
Increase MTX to 15mg/wk (Max dose) (MTX 
parenteral if GI side effects) 
5  If CREAT CL >30 
ml/min 
Increase MTX to 15mg/wk (MTX parenteral if GI 
side effects) 
6    Increase MTX to 20mg/wk (MTX parenteral if GI 
side effects) 
7 If  weight<50kg 
and/or CREAT 
CL >30 but <60 
ml/min 
MTX 20mg/wk oral –>parenteral 
8  If weight > 50kg and 
CREAT CL > 60 
ml/min 
Increase MTX to 25mg/wk (oral) (MTX parenteral 
if GI side effects) 
9    MTX 25mg/wk parenteral 
10    Add leflunomide 10mg/day 
11    If leflunomide tolerated increase to 20mg/day 
12    TNF Inhibitor can be added, if PBS criteria are 
fulfilled 
13    Add intramuscular Gold 50mg i.m./wk after a test 
dose of 10mg i.m 
14    If a satisfactory response is seen after 6 months,   102
Node
#
Scenarios  Action/Plan 
continue weekly injection for another 6 month, then 
reduce the frequency of injections to fortnightly 
15    If an inadequate response has occurred after 6 
month, Gold will be ceased 
16    If weight<50kg and/or age >70, add cyclosporine A 
1.5mg/kg 
17    If weight>50kg and age <70, add cyclosporine A  
2.5mg/kg 
18    Neoral will be increased to 3mg/kg 
19    Neoral will be increased to 4mg/kg 
20    AZA 1mg/kg-2mg/kg can be added, after a TPMT 
activity test 
21    If an inadequate response has occurred after 3 
months, deem a treatment failure and withdraw 
from the protocol   103
6.5 Drug Toxicity Prediction Model 
The risk of developing drug toxicity varies between individuals and may hinder the 
achievement of optimal doses of DMARDs. Yet, the Dose Modification Protocol of 
the eRA clinic provides standard treatment recommendations that were not designed to 
accommodate out-of-range laboratory results or other factors that can contribute to an 
individual patient’s risk for developing significant toxic effects from agents within the 
combination therapy regimen. It has therefore been incumbent on clinicians to utilise 
additional knowledge to estimate the risk of drug toxic effects developing in individual 
patients and to adjust treatment accordingly. To monitor risk, clinicians examine 
factors such as prevailing clinical symptoms, out-of-range laboratory results and the 
patient’s co-morbidities and past medical history. Failure to develop a set of rules for 
responding to out-of-range laboratory results was a source of avoidable practice 
variability that came to light during the eRA-CDSS project. 
 
The eRA clinic has been aiming to apply routine surveillance for drug toxicity and 
nuisance side effects associated with the Triple Therapy or its components, including 
effects on the lungs, blood cells, liver, gastrointestinal tract and retina (refer to chapter 
5.2.3). However in order to systematically integrate these drug toxicity risks into the 
clinical decision-making process and to complement the eRA clinical guidelines, drug 
toxicity prediction models needed to be established to tailor guidelines better to 
individual patient management. In this undertaking, I use Bayes’ Theorem and Bayes 
Net to explain the establishment of the drug toxicity prediction model. 
 
6.5.1 Bayes’  Theorem 
In many situations, estimates of the probability of outcome events can be revised as 
further information becomes available. During decision-making of RA treatment for a 
given patient under a given drug regimen, the clinician can estimate the probability of 
a patient developing drug-related toxic effects. However, should the clinician notice a 
patient has an elevated serum liver enzyme result, the probability of having developing 
significant drug-related liver toxicity will increase. This is the conditional probability   104
of drug toxic effects under the drug regimen given that the patient has an elevated liver 
enzyme result. 
P(A | B) denotes the probability that event A will occur given that event B has 
occurred already. Conditional probabilities can also be denoted as causal relationship, 
which is P(Effect | Cause). 
 
Bayes’ Theorem provides a method of manipulating conditional probabilities. It allows 
new information to be used to update the conditional probability of an event [4]. These 
appear frequently when making medical diagnoses. It has proven to be very useful, and 
is used in programming to help diagnose diseases. 
P(Effect | Cause)=(P(Cause | Effect)*P(Effect))/P(Cause) 
Bayes’ Theorem can be used for reversing a conditional probability and combining 
evidence for decision-making. 
 
6.5.2 Bayes  Net 
A Bayes Net is a model that reflects the states of some part of a world, and it describes 
how those states are related by probabilities. Bayes Nets are directed acyclic graphs 
where each node represents a random variable. Bayes Nets naturally represent causal 
chains, that is, the links represent cause-effect relationships between parent and child 
nodes. Each node corresponds to some condition of the patient. The influences are 
measured by conditional probabilities. Figure 6.11 is a graphical representation of a 
sample casual independence model using Bayes Nets.   105
 
 
Because Bayes Nets describe how these parent-child nodes are related by probabilities; 
they can be used to make predictions in the context of clinical decision-making. Bayes 
Nets can project the most likely outcomes by supplying the best available evidence. 
Bayes Nets express the probable conditional independence, allowing a compact 
representation of the joint distribution. They only recount nodes that are 
probabilistically related by some sort of causal dependency, resulting in an enormous 
saving of computation. 
 
P(D | A, B, C) = P(D |B ,C) 
 
From the illustrated sample casual model (Figure 6.11), in order to generate the 
probability of the drug toxicity presence, we need to know the information regarding to: 
 
1. the probability of drug toxicity presence under the condition of high drug dosage 
was true and impaired the renal function was true   106
2. the probability of drug toxicity presence under the condition of high drug dosage 
was false and impaired the renal function was true 
3. the probability of drug toxicity presence under the condition of high drug dosage 
was true and impaired the renal function was false 
4. the probability of drug toxicity presence under the condition of high drug dosage 
was false and impaired the renal function was false 
 
In other words, we needed to know the probability values of the data A to D within the 
Table 6.9. Since the Bayes Nets model uses these values to formulate prediction rules, 
and then the model can compile the probability we were looking for, that was the 
probability of drug toxicity presence (refer to Figure 6.11). 
 
When the Bayes Nets model is implemented into a CDSS, the CDSS can further help 
to collect utility data from clinicians before implementing the decision tree model 
(refer to chapter 2.8.2). 
 
 
Table 6.9 Drug toxicity causal probability table 
Causal dependency nodes  Drug toxicity (probability %) 
High drug dosage  Impaired renal function  Present  Absent 
True True  A  100-A 
True False  B  100-B 
False True  C  100-C 
False False  D  100-D 
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6.5.3  Establish Methotrexate Toxicity Prediction Model 
Prior to establishing a drug toxicity prediction model for MTX, I performed a 
comprehensive review of the literature on risk factors of MTX toxicity in RA (refer to 
chapter 2.7.4), As a result of this review; I identified a broad range of evidence-based 
toxicity risk factors for developing MTX toxicity. I categorised the risk factors into 
five major categories (refer to chapter 5.2.1); they are (1) common risk factors for 
MTX toxicity, (2) MTX pulmonary toxicity risk factors, (3) MTX hepatic toxicity risk 
factors, (4) MTX haematological toxicity risk factors, and (5) MTX gastrointestinal 
toxicity risk factors. In addition, I classified the major MTX toxic effects into four 
groups (refer to chapter 5.2.2); they are (1) MTX pulmonary toxic effects, (2) MTX 
hepatic toxic effects, (3) MTX haematological toxic effects, and (4) MTX 
gastrointestinal toxic effects. 
 
I employed a Bayes Net causal model to set up the MTX toxicity prediction model. I 
applied the categorised risk factors as evidence nodes on the causal chains. The 
corresponding MTX toxicity (e.g. MTX hepatotoxicity), was represented as a query 
node. The model demonstrated cause-effect relationships between the risk factors and 
the toxicity consequences. In addition to the risk factors, the drug toxicity prediction 
model included secondary evidence nodes (MTX toxic effects) on the causal chains, 
such as relevant out-of-range laboratory results and relevant clinical symptoms. These 
secondary evidence nodes are the consequences of the query node. 
 
The establishment of the drug toxicity prediction model applied Probability Theory 
and Bayes Theorem. Each consequence node corresponds to some condition of the risk 
factor nodes. The influences are measured by conditional probabilities. Therefore, by 
supplying patient risk factors, relevant laboratory test results and drug toxicity related 
symptoms, this model can predict the probability of developing MTX toxicity in an 
individual patient. However, for every causal relationship on the causal chain, the 
causal probability table must be available for the model to generate the query 
probability. 
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In order to maximise expected utility while making decision under uncertainty, the 
establishment of the drug toxicity prediction models can provide assistance to 
clinicians in estimating the probability of developing drug toxicity. The estimated 
probability of developing drug toxicity can help clinicians make treatment decisions 
tailored to the specific situation of individual patients. 
 
The MTX toxicity prediction model can be computerised and the probability of 
developing drug toxicity can be predicted and presented to the clinician. Incorporating 
this automated evidence-based MTX toxicity prediction model into the decision-
making process promises to reduce the incidence of clinically significant MTX toxicity 
by adjusting a therapy before toxic effects occur. Alternatively, the computed risk 
assessment may prevent clinicians over-reacting and withdrawing treatment when not 
warranted by the extent of risk. The MTX toxicity prediction model may thereby help 
maintain patients on MTX on longer on effective doses thereby realising greater 
therapeutic benefits. 
 
Figures 6.12-15 shows the Bayes Nets models for MTX Hepatotoxicity Prediction, 
MTX Haematological Toxicity Prediction, MTX Pulmonary Toxicity Prediction and 
MTX Gastrointestinal Toxicity Prediction respectively. These models incorporated the 
evidence-based MTX toxicity risk factors and the MTX toxic effects which I 
summarised in chapter 5.2. 
 
Theoretically, the drug toxicity model can estimate probabilities for the occurrence of 
toxicity provided a completed causal probability table is available. However, the 
literature review failed to pin down probability data quantifies the rate of MTX toxicity 
occurrence in the presence of realised risk factors, or the rate of MTX toxic effect 
occurrence in the presence of MTX toxicity. As such, these conditional probabilities 
along causal chains of the model were not available to generate the probability of the 
query node. While these deficiencies are barriers to model implementation, they have 
identified questions for research that could lead to better management. 
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I used the MTX pulmonary toxicity prediction model (refer to Figure 6.14) as an 
example to give more detailed explanation. The query node of this model was MTX 
pulmonary toxicity. In order to generate the probability for presence of MTX 
pulmonary toxicity, the model needs three causal probability tables (Table 6.10 – 6.12) 
to be filled with the required probability data. However the required conditional 
probabilities data A to H were not available from the literature. These data quantifies 
the rate of MTX pulmonary toxicity occurrence in the presence of smoking or pre-
existent pulmonary diseases, or the rate of toxicity related symptoms and abnormal 
laboratory test results occurrences in the presence of MTX pulmonary toxicity. As 
such, the model cannot be implemented to generate the query probability. 
 
The study failed to implement the MTX toxicity prediction models due to lack of 
availability of conditional probabilities in the literature for estimating risk for MTX 
toxicity. Consequently, the study cannot utilise computerised MTX pulmonary toxicity 
prediction model for further collecting utility data, therefore the decision tree model 
was unable to be implemented during the study. Nevertheless, the establishment of the 
architecture for the model had set the framework for future continuous model 
development and implementation.   110
Table 6.10 MTX pulmonary toxicity causal probability table I 
Causal dependency nodes  Pulmonary toxicity (probability %) 
Smoking Pre-existent  pulmonary 
disease 
Present Absent 
True True  A  100-A 
True False  B  100-B 
False True  C  100-C 
False False  D  100-D 
 
Table 6.11 MTX pulmonary toxicity causal probability table II 
Causal dependency nodes  Related Symptom (probability %) 
Pulmonary toxicity  Present  Absent 
True E  100-E 
False F  100-F 
 
Table 6.12 MTX pulmonary toxicity causal probability table III 
Causal dependency nodes  Related Lab result (probability %) 
Pulmonary toxicity  Normal  Abnormal 
True G  100-G 
False H  100-H 
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6.6 Integrate the RA Management Rules into the eRA Practice 
For efficiency, decision support must be seamlessly integrated into clinicians’ 
decision-making procedures. Therefore, clinical guidelines and supporting evidence 
that are used by clinicians in their decision-making need to be delivered to each 
decision-making point. 
 
Base on the clinical consultants I observed, I performed an analysis of when clinicians 
apply clinical guidelines and expertise and of the procedures for applying clinical 
guidelines and expertise. With an understanding of how the clinicians integrate the 
clinical guidelines and their expertise into their practice, I mapped the RA management 
rules against the appropriate decision-making points. 
 
6.6.1  Map the RA Management Rules into the eRA Patient 
Assessment Process 
In the eRA clinic, previous analysis of the patient assessment process showed that the 
clinical decision-making integrates the eRA guidelines and additional knowledge to 
estimate drug toxicity risk. The latter and contingent responses were not systematised 
and were therefore a source of avoidable practice variability. 
 
After the eRA clinic established the comprehensive RA management rules, the 
clinicians applied two sets of rules during the decision-making process in order to 
adjust a treatment. They were the Dose Modification Protocol and the Rules for 
Changes in Dose/Agent. Drug Toxicity Monitoring Rules were developed in this
project to complement former rules including the Triple Therapy and the Dose 
Modification Protocol. 
 
During the RA patient assessment process, if a patient’s laboratory results are out-of-
range, clinicians can now apply the Drug Toxicity Monitoring Rules to tailor a drug 
regimen and dosage recommendation to accommodate risks for clinically significant 
toxicity displayed by the patient. If the patient has normal laboratory results, clinicians 
apply the Dose Modification Protocol. If a change in dosage is required by the protocol,   116
the clinicians apply the Rules for Changes in Dose/Agent to gain a drug regimen and 
dosage recommendation. If out-of-range blood results occur, the Drug Toxicity 
Monitoring Rules take priority. The drug toxicity prediction model can be applied to 
generate the probability of drug toxicity developing in the individual patient and may 
be used to revise guidelines to adjust these risks or intensify adverse effects monitoring. 
 
With clinicians combining the guideline recommendations and the drug toxicity 
prediction outcome, management may be refined. I have mapped the eRA clinical 
guidelines and the drug toxicity prediction model into the patient assessment process 
(Figure 6.16).   117   118
6.6.2  Analyse the Decision-Making Procedure in the eRA Clinic 
To deliver timely clinical decision support, CDSS should understand clinical decision-
making procedures. In the eRA clinic, clinicians applied the clinical rules, protocols 
and the newly established RA management rules in a particular order to reach a final 
decision on adjusting a treatment. 
 
I analysed the decision-making process of the eRA clinic. Based on an understanding 
of the type of clinical knowledge/evidence and when the clinical knowledge/evidence 
should be incorporated by clinicians into the decision-making process, I established a 
graphical representation of the decision-making porcedure of assessing an RA patient 
in the eRA clinic. It maps the eRA Dose Modification Protocol, RA management 
Rules, and the drug toxicity prediction to the decision-making points. 
 
Figure 6.17 illustrated the sequential process of clinical decision-making in the eRA 
clinic. The process started from retrieving patient clinical data and laboratory data. The 
diamond boxes stood for decision-making points. The rounded rectangle boxes 
represented predicting risk of developing drug toxicity. The grey rectangle boxes 
denoted the final decisions on patient treatment. 
 
I also translated this sequential process into an UML Activity Diagram (Figure 6.18). 
The UML diagram can be easily understood by software developers. By establishing 
the decision-making procedure, a foundation is provided for the application design and 
implementation. Based on this procedure, computer algorithms can be set up and 
patient data can be determined for CDSS implementation.   119   120  121
7 The eRA-CDSS 
In managing RA, best practice requires the adjustment of medication dosages and the 
substitution of medications according to a patient’s response and tolerance. These 
factors demand close monitoring of disease activity and of certain blood investigations 
that are used to monitor safety, as well as consistent considered responses to abnormal 
findings. 
 
In the eRA clinic, practising EBM requires clinicians to comply with CPGs while 
making clinical decisions. However, Drug Toxicity Monitoring Rules and Rules for 
Changes in Dose/Agent are complex. It is difficult for clinicians to manually apply 
such complex rules during busy consultations. The complexity of the eRA guidelines 
contrasts with that of usual therapeutic guidelines which are designed as general 
statements intended to guide practice for populations of patients, with the expectation 
that individual clinicians will apply considerable discretion in their application in 
practice according to the many contingent circumstances about which the guidelines 
are silent. The eRA guidelines differ in attempting to anticipate contingent events in 
order to provide more specific guidance that reduces practice variability. The eRA 
guidelines are thus more prescriptive than usual guidelines and thus substantially more 
complex. This complexity is problematic for administration of paper-based guidelines 
and more suited to delivery in a point of care using CDSSs. 
 
In order to (1) facilitate the compliance of complex eRA guidelines and reinforce the 
integration of extra knowledge into decision-making processes in a systematic fashion, 
and (2) assist clinicians in making better clinic decisions when adjusting therapy 
according to treatment response and drug tolerance, the study developed a CDSS 
specific to the eRA clinic (eRA-CDSS), in which a relatively orderly approach to 
managing RA had already been established. 
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7.1 Rule-based Expert System 
A rule-based expert system is a knowledge-based program that provides ‘expert 
quality’ solutions to problems in a specific domain. Its knowledge is extracted from 
human experts in the domain and it attempts to emulate their methodology and 
performance [171]. The eRA-CDSS is such a rule-based expert system. Having 
adopted Knowledge Acquisition, the eRA clinic established the comprehensive RA 
management rules which form a knowledge base. Automation of highly complex 
clinical rules is the core functionality of the eRA-CDSS. Figure 7.1 illustrates the basic 
architecture of an expert system. 
 
1. Knowledge Base 
Knowledge base contains the domain knowledge used for problem solving. 
Knowledge is represented as rules having the IF (condition) THEN (action) 
structure. 
2. Database 
Database includes facts used to match against the IF part of the rules stored in the 
knowledge base. 
3. Inference Engine 
Inference Engine provides a solution by reasoning, linking the rules with the facts. 
4. Explanation Facility 
Explanation Facility explains how a particular conclusion is reached and why a 
specific fact is needed. 
5. User Interface 
User Interface enables communication between a user seeking a solution to a 
problem, and an expert system. 
6. Developer Interface 
Developer interface enables a knowledge-base editor to insert and modify rules. It 
has debugging capabilities in order to trace and examine the rules and data. An 
input/output facility such as runtime Knowledge Acquisition enables the running 
expert system to ask for required information whenever this information is not 
available in the database.   123
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7.2 Use Case 
The eRA-CDSS was designed to computerise the comprehensive eRA guidelines that 
include Dose Modification Protocol, Rules for Changes in Dose/Agent and Drug 
Toxicity Monitoring Rules. It was also designed to provide drug toxicity predictions 
and alerts. The established Bayes Nets model for toxicity prediction can be realised if 
the causal probabilities are available and an individual patient’s risk factors, laboratory 
results and clinical symptoms are known. Outcomes of the guidelines-based, situation-
contingent recommendations and drug toxicity predictions are presented to clinicians 
to guide decision-making of managing RA. 
 
7.2.1  Use Case Diagram 
I used an UML (Unified Modelling Language) use case diagram (Figure 7.2) to show 
the functional requirements of the eRA-CDSS. 
 
 Clinician: The individual clinician providing care to an individual patient. 
 eEA data system: The clinic data system used by the clinician to support patient 
care. This system should support functions of the eRA-CDSS. 
 Use case: 
1. Apply eRA guidelines 
A Request is placed by a clinician within the eRA data system. It requires 
corresponding patient data to be transferred to the eRA-CDSS. Then, eRA clinic 
rules are triggered to generate recommendations displayed to the clinician. 
2. Predict drug toxicity risk 
Subsequently, the drug toxicity prediction model is populated to generate alerts or 








eRA data system Clinician eRA data system
«extend»
 
Figure 7.2 The eRA-CDSS use case   126
 Scenario and Example 
1. Scenario 
At the eRA clinic consultation, Dr S preformed a routine check-up for Mrs 
Jones. Then Dr S entered the patient’s reported duration of early morning 
stiffness, fatigue score on a 100 mm visual analogue scale (VAS), joint pain 
score by VAS, tender joint count and count of swollen joints or tendons into 
the eRA data system. The eRA data system generates a request for applying the 
eRA guidelines. The patient’s clinical information (entered by Dr S) together 
with the patient’s current medication information (e.g. drug dosage) and recent 
laboratory data such as LFT, CBE, ESR and CRP are sent to the eRA-CDSS 
for execution of the eRA clinical rules. Finally the eRA-CDSS presents the rule 
recommendations to the clinician for decision-making. 
 

















Patient clinical data  Early Morning Stiffness  15 minutes 
Fatigue 30  mm 
Joint pain  60 mm 
Joint tenderness (or pain on movement) 
count 
3 





MTX   15mg/week 
Patient laboratory 
data 
LFT (AST)  Normal 











Increase MTX to 20mg/week, repeat laboratory test every 3 weeks   127
7.2.2 Activity  Diagram 
In addition to the use case diagram, I used UML activity diagram (Figure 7.3) to show 
how the eRA data system and the eRA-CDSS worked together to accomplish the 
interactions. This diagram illustrated the sequence of messages between the systems 
during an interaction. 
 
class activity
eRA CDSS eRA data system
input patient clinical data
gather required 
data for eRA 
rules 
gather required 









Figure 7.3 The UML activity diagram   128
7.3 Workflow 
Understanding the clinical decision-making process, clinical workflow and dataflow is 
fundamental to the development of a CDSS that can be successfully integrated into 
clinical practice and accepted by clinicians. In order to design a CDSS that is sensitive 
to clinical workflow, I explored opportunities for improvements to current clinical 
practices that could be provided by a CDSS. Possible negative effects of the CDSS on 
work flows were also considered. 
 
7.3.1  The eRA Clinic Workflow Analysis 
The eRA clinic operates on every Wednesday mornings from 9am until early afternoon, 
with an average 20 RA patients attending. On each clinic day, one clinic nurse and 3 
senior consultants (or one registrar and 2 senior consultants) work in the clinic. 
 
The clinical workflow analysis is a collaborative process that includes people who are 
currently involved in the clinic and the CDSS intervention that will be integrated into 
the clinical workflow. Performing a clinical workflow analysis helped to identify 
opportunities for the intervention to provide the most immediate and quantifiable 
effects for the clinic. At the beginning of this study while observing the eRA clinic 
consultation, I analysed the workflow and dataflow of the clinic. Having identified the 
integration opportunity, I therefore incorporated the proposed CDSS into the clinic 
workflow. The following diagram (Figure 7.4) shows that the eRA-CDSS can be 
incorporated into the eRA clinic workflow seamlessly. The eRA-CDSS co-exists, and 
closely interacts with the eRA data system. 
 
At the time of consultation, nurse and rheumatologist inputs the patient clinical data 
into the eRA data system. The eRA-CDSS would access patient data before executing 
the clinical rules. Then the eRA-CDSS would display the guideline recommendations 
on the computer screen to assist clinicians’ decision-making when needed at the time 
of the consultation. Finally, computer would automatically print the patient data 
records along with the eRA guideline recommendations for clinicians to keep as hard 
copy documents.   129   130
The detailed descriptions for the corresponding numbers on Figure 7.4 were listed 
below: 
 
1. Nurse collects the Vital Activities and Lifestyle Index form from the patient 
2. Nurse examines the patient 
3. eRA data system queries the patient laboratory results from the Lab System 
4. Nurse queries data from the eRA data system 
5. Nurse inputs patient data to the eRA data system 
6. Doctor queries data from the eRA data system 
7. Doctor examines the patient 
8. Doctor inputs the patient’s clinical data into the eRA data system 
9. CDSS queries data from the eRA data system 
10. CDSS generates guideline recommendations   131
7.3.2  The eRA Clinic Stakeholder Analysis 
Groups of people or institutions that may significantly influence the success of an 
activity or project; therefore, a stakeholder analysis is a technique that can be used to 
identify and assess the benefits and costs of key people. I performed a stakeholder 
analysis for the clinicians to analyse the potential impact of incorporating the eRA-
CDSS into the practice. The benefits and costs of the eRA-CDSS were identified for 
each stakeholder, the details of which were listed in the following table (Table 7.2). 
 
The major cost of adopting CDSS into the current practice is the time spent on data 
entry using computers. However, it can be offset by the saved time spent on filling 
paper forms. As such, CDSS will not cost clinicians any additional effort.   132
Table 7.2 Stakeholder analysis of the eRA clinic 




Mitigation for research 
Nurse  Clinical decision 
support 
 Easy data access 
 Adherence to 
clinical guidelines 
 Data entry 
time 
 Enter data via 
computers rather than 
filling paper forms 
Physician   Clinical decision 
support 
 Easy data access 
 Adherence to 
clinical guidelines 




 Enter data via 
computers rather than 
filling paper forms 





 More structured 
practice environment 
Patient  Reinforced patient 
monitoring 
 Improved care 
Nil Nil   133
7.4 The eRA-CDSS Architecture 
7.4.1 Conceptual  View 
The core component of the eRA-CDSS is the inference engine. It executes the rules of 
the eRA clinical guidelines and implements the established drug toxicity prediction 
models. The corresponding rule can be triggered automatically by retrieving patient 
data from the CPR (e.g. the Lab System), or by receiving patient data entered by the 
clinician. If the rule conditions are satisfied, it is executed. Finally, the CDSS delivers 
the guidelines-based recommendations and the probabilities of developing drug 
toxicity to the clinicians for decision-making. Figure 7.5 shows a conceptual view of 
the eRA-CDSS architecture. 
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7.4.2 Logical  View 
The design of the eRA-CDSS was based on a multi-tiered Service Oriented 
Architecture (SOA). The front-end user interface and the back-end services are loosely 
coupled. A loosely coupled architecture allows you to replace components, or change 
components, without having to make reflective changes to other components in the 
architecture/systems. The CDSS back-end services are exposed as a set of web services 
via the Internet. This model provides great flexibility for clinicians in accessing the 
CDSS services when the CDSS front-end is connected to the Internet. Figure 7.6 
showed a logical view of the eRA-CDSS architecture. 
 
The CDSS front-end Graphic User Interface (GUI) is implemented as a Windows 
desktop application. It retrieves patient data from CPR, such as the eRA Data System 
or the Lab System, and submits these data to the CDSS back-end service via the 
Internet. The CDSS back-end web service defines the interface between the front-end 
and back-end such as formats for exchanging data. The inference engine applies a 
predefined rule set to the supplied data and executes the rules. The data access logic 
performs database operations. It retrieves a nominated rule set from the back-end 
database and passes it to the inference engine. The Service Framework contains shared 
services to support all the back-end components including auditing, exception 
management, security and reporting.   135
   136
7.4.3  The eRA Data System with Inbuilt CDSS GUI Snapshot 
The eRA-CDSS co-exist with the eRA Data System. The eRA Data System with 
inbuilt CDSS will have five key business functions. They are (1) real-time patient data 
entry, (2) graphical presentation of data trends, (3) generation of reports of patient data, 
(4) delivery of guideline recommendations, and (5) prediction of probabilities of 
developing drug toxicity. 
 
I have included some sample Graphic User Interfaces (GUI) snapshots (Figures 7.7-7.9) 
to provide a general overview of the developed System. These GUIs were designed to 
assist clinicians to interact with the system in a user-friendly manner, therefore to 
minimise cost of time. 
 
Figure 7.7 demonstrates a real-time data entry screen for joint scores. Clinicians can 
record tender joints and swollen joints (required by Dose Modification Protocol) by 
simply clicking the corresponding joints illustrated on the screen. The system 
automatically calculated tender joint count and swollen joint count for the clinician. It 
then displayed the results on the screen. It also passed the data to the eRA-CDSS for 
rule execution. DAS can be calculated for clinicians if its required data had been 
provided to the system. 
 
Figure 7.8 shows the key patient clinical indexes (e.g. DAS) and the laboratory data 
(e.g. CRP). These data are displayed in graphical trends. The patient’s clinical indices 
and laboratory data from the antecedent period were plotted on the graph. These visual 
graphic trends can help clinicians foresee the future clinical status of a patient. In 
addition, the six laboratory variables including CRP, ESR, neutrophils, ALT, AST and 
creatinine are needed by the eRA guidelines; therefore, they are to be passed to the 
eRA-CDSS for rule execution. 
 
Figure 7.9 displays a screen of CDSS recommendations. The eRA-CDSS executed the 
eRA clinical rules upon receiving the required patient data. Then it passed the 
guideline recommendations to the eRA Data System for demonstration. As shown in 
the Figure 7.9, the scheduled routine visits, scheduled blood tests and   137
recommendations on medication changes were generated by the eRA-CDSS. However, 
clinicians have the options to accept or ignore the CDSS recommendations by 
checking ‘Agree’ or ‘Disagree’ checkboxes. The eRA Data System has the potential to 
record clinicians’ responses to the CDSS recommendations. These data can be audited 
or analysed in the future for guideline compliance analysis or guideline evaluation.   138   139   140   141
8 Guideline  Verification 
Adherence to CPGs can improve the quality of clinical decision-making. Compliance 
with guidelines in the eRA clinic, for which eRA clinicians incorporate Drug Toxicity 
Monitoring Rules and Rules for Changes in Dose/Agent into their practice, has 
never been studied. The level of guideline compliance addresses the issues in guideline 
acceptance, which is fundamental for developing a clinically accepted CDSS. 
 
In order to test the benefits of the guideline automation system in a real clinical setting 
and to ensure wide applicability for the future use of the CDSS in the eRA clinic or 
other clinical settings, I conducted a questionnaire to test the acceptance of the newly 
established RA management rules. The questionnaire provided valuable information 
not only for future guideline refinement and development, but also for future CDSS 
improvement. 
8.1 Method - Questionnaire 
The concordance between clinicians’ decisions and CDSS recommendations can be 
used to gauge the acceptance of computerised guidelines by clinicians in making 
clinical decisions. In early 2007, I conducted a questionnaire-based assessment to 
assess the acceptance of the guidelines amongst two groups of rheumatologists (an 
eRA clinic group and a non-eRA clinic group). The questionnaire was designed to test 
the acceptance of the guideline recommendations generated by CDSS, to locate the 
gaps between guidelines and practice, and to provide information that may be used for 
the development of the CDSS tool with regard to broader clinical acceptability. 
 
I designed 16 questions based on 16 real patient case scenarios extracted from eRA 
clinical records. I ran these 16 cases through the CDSS and retrieved the CDSS 
recommendations. The objective of the questionnaire was to collect the treatment 
decisions from the rheumatologists for the 16 patient case scenarios in order to 
measure the differences between the doctors’ decisions and computerised guideline 
recommendations, and to analyse the results.   142
 
8.2 Participant & Sample Size 
 Characteristics of participants 
A total of eight rheumatologists (n=8) participated in this questionnaire study, 
including 7 senior consultants and 1 rheumatology advanced trainee. Four 
rheumatologists working in the eRA clinic were grouped in the eRA group (D1-D4); 
the other four rheumatologists who do not work in the eRA clinic were grouped in the 
non-eRA group (D5-D8). The non-eRA group received no pre-test training regarding 
the CDSS rules. Comprehension of the eRA guidelines in the eRA group is better 
compared with the non-eRA group because the rheumatologists are more familiar with 
the eRA rules and protocol. 
 
 Characteristics of the patient cases 
Patients over the age of 18 diagnosed with RA according to the 1987 revised American 
College of Rheumatology (ACR) criteria, who are receiving treatment with triple 
therapy (MTX, SSA and HCQ) for early RA. 
 
8.3 Cases Selection 
The questionnaire was designed to test compliance with eRA guidelines in a simulated 
clinical setting using selected patient cases. From late 2006, I started to read through 
eRA clinic correspondence to referring doctors for the period from early 2002 until 
October 2006. There were total of 923 RA patient visits to the eRA clinic during the 
period. I carefully selected 16 real patient cases based on the fact that these cases have 
scenarios that can trigger the rules included in Drug Toxicity Monitoring Rules or in 
Rules for Changes in Dose/Agent. Among the 16 cases, 7 cases triggered the rules in 
Rules for Changes in Dose/Agent (from here on I shall call them ‘triple therapy cases’), 
and 9 cases triggered the rules in Drug Toxicity Monitoring Rules (from here on I shall 
call them ‘toxicity cases’). 
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8.4 Questionnaire Design 
I designed the questionnaire to include the 16 selected patient case scenarios. I 
manually retrieved case associated clinical data and laboratory data from the eRA 
clinic database. In the questionnaire, each case is represented as a real case abstract, 
including the patient’s clinical, laboratory and therapy information. 
 
The questionnaire asked the rheumatologists to use the provided information to make a 
decision on whether treatment should be changed, and if so, how. Each case abstract 
had two copies; one copy included the minimum clinical variables required by the RA 
management rules (CDSS input), the other copy provided patient clinical information 
(e.g. symptoms regarding drug side effects other than GI symptoms and laboratory 
tests) in addition to the minimum clinical variables required by the RA management 
rules. The rheumatologists were asked to respond to both copies in each case. Their 
decisions on the copy with the minimum CDSS input were compared to the CDSS 
outputs, and the differences were analysed. Whether the decision made by clinicians 
changed between the two questionnaire copies was also analysed. The questionnaire 
samples are shown in the Appendices (questionnaire1 includes the minimum CDSS 
input; questionnaire2 provides extra patient clinical information). 
 
8.5 Intervention  
A preliminary version of the CDSS that automates comprehensive eRA guidelines has 
been implemented. The eRA-CDSS computerises Dose Modification Protocol, Rules 
for Changes in Dose/Agent and Drug Toxicity Monitoring Rules. It was used to 
generate drug regimen recommendations, drug dosage and patient monitoring plans for 
the 16 patient cases. I compared these CDSS generated recommendations with the 
decisions from the questionnaire.   144
8.6 Evaluation
For the purpose of evaluating and analysing the results, I defined a rule for grouping 
the data. I defined five decision categories, which were (1) stop/hold, (2) decrease, (3) 
no changes made, (4) increase/restart, and (5) add. The questionnaire results and CDSS 
outputs were grouped into these categories. I further arranged these five categories into 
a predefined decision sequence, which ranges from a cautious or conservative decision 
to an assertive decision. I also assigned a distinct value to each decision category 
(Figure 8.1). 
 
C o n s e r v a t i v e         A s s e r t i v e  
 
Stop/hold Decrease  No  changes 
made 
Increase/restart Add 
-2 -1 0  1  2 
 
Figure 8.1 Predefined decision categories with distinctive assigned values 
 
By assigning a distinct value to each decision category, I was able to compare and 
measure the metric distance between the rheumatologists’ decisions and CDSS 
recommendations. I defined a Distance Calculating Formula* to calculate the metric 
distance as follows: 
 
*Distance = Doctor-CDSS 
 
Comparing the gaps in decision-making by grouping the data into predefined decision 
categories does not distinguish between differences such as dosage and various drug 
differences within a particular category. In order to analyse the dosage and various 
drug differences within the decision categories, between rheumatologists and CDSS, I 
calculated two sets of compliance rates; the first set of compliance rates considers both 
dosage difference and various drug differences; the second set of compliance rates 
considers various drug differences, but not the dosage difference.   145
 
8.7 Statistical Analysis 
I applied Kappa statistics to analyse the agreement between each rheumatologist’s 
decision and CDSS output for the 16 patient cases. Kappa is an index of observer 
agreement, which indicates the degree of agreement over and above that which would 
be expected by chance alone (Table 8.1). 
 
Table 8.1 Agreement of categorical measurements 






0.81-1.00 Almost  perfect 
 
I calculated the compliance rate for each individual rheumatologist by comparing the 
rheumatologist’s decision with the recommendations generated by the CDSS. I applied 
two sample mean comparison tests to compare the mean compliance rate between the 
two groups of rheumatologists. 
 
This study used Stata 8 software (State Corp., College State, TX, USA) to analyse the 
data. Binary variables for five different drug treatment strategies (stop/hold, decrease, 
no changes made, increase/restart and add) were used to calculate Kappa.   146
8.8 Results
A total of eight rheumatologists from the two groups completed the questionnaire. I 
collected the rheumatologists’ decisions on the 16 patient cases, and retrieved the 
CDSS output for the same 16 cases. I measured the metric distance by comparing the 
rheumatologists’ decisions with the CDSS recommendations according to the 
predefined decision categories and Distance Calculating Formula. I also calculated the 
compliance rate for the combined 16 cases; 7 triple therapy cases and 9 toxicity cases 
respectively. 
 
1. Metric distance 
The Distance Calculating Formula was applied to measure the distance between the 
decisions made by rheumatologists and CDSS recommendations. One sample t-test 
shows that there was no statistical difference between the eRA group and the 
CDSS (mean distance=0.0313, P=0.7879); but results for the non-eRA group were 
significantly different when compared with the CDSS (mean distance=-0.4219, 
P=0.0009). In addition, the mean distance between the eRA group and the CDSS is 
statistically different, compared to the distance between the non-eRA group and the 
CDSS (P = 0.0079) (Figure 8.2). 
 
Figure 8.3 shows the metric distance between decisions made by the two groups of 
rheumatologists and the recommendations generated by the CDSS. The columns 
represent the metric distance calculated by the Distance Calculating Formula (1-7 
are triple therapy cases, 8-16 are toxicity cases). In order to show the dosage and 
various drug differences between the rheumatologists and the CDSS, I added 
arrows to represent the differences. 
 
Interestingly, Figure 8.3 shows all the rheumatologists responded conservatively 
on case 12. I reviewed the clinical scenario of case 12 which stated the patient had 
two consecutive mild toxicity events (mild elevated ALT 87 and 62); the patient’s 
disease activity was not well controlled according to the eRA Dose Modification 
Protocol (Tender joint 7, swollen joint 2, Fatigue 33); the patient was on MTX 25   147
mg. According to the RA management rules, a new drug leflunomide (Arava) 
should be added to the drug regimen. However, the decisions made by the 
rheumatologists were to either keep the treatment unchanged, or reduce the dosage 
of MTX, or hold MTX. 
 
This is an interesting scenario in which the conservative approach is to ignore the 
imperatives for better disease control in favour of avoiding possible aggravation of 
the out of range blood results. As addition of leflunomide would be subject to close 
monitoring of liver enzymes (three weekly or potentially more often) and the drug 
could be cleared promptly with Questran if needed due to unwanted effects 
(including rise in LFTs), addition of leflunomide 10mg daily would have been 
reasonable. It is possible that the patient was subjected to greater risk from disease 
when short-term risks for toxicity were acceptably low, testable and by no means 
inevitable. It is perhaps an example of how considered opinion regarding risks and 
strategy (testing of drug subject to potential modification of drug dose and timing 
of review) can benefit from prior considered opinion based on scenario analysis.   148   149  150
2. Kappa statistics analysis 
I applied Kappa statistics to analyse the overall agreement between the 8 
rheumatologists and the CDSS on the 16 cases. Table 8.2 shows the Kappa 
analysis results. 
 
Three rheumatologists from the eRA group have substantial agreement (kappa 
statistics 0.6000 and 0.6098; one has moderate agreement (kappa statistics 0.4217). 
No rheumatologist from the non-eRA group has substantial kappa values; three 
rheumatologists from the non-eRA group have moderate agreement (kappa 
statistics 0.4947, 0.4839 and 0.4286); one has slight agreement (kappa statistics 
0.2727). 
 
Table 8.2 Kappa analysis results for the agreement 
      Agreement  Kappa  Standard error 
eRA group  D1 75.00%  0.6000  0.1521 
D2 75.00%  0.6098  0.1568 
D3 62.50%  0.4217  0.1510 
D4 75.00%  0.6098  0.1370 
non-eRA group  D5 62.50%  0.4839  0.1402 
D6 50.00%  0.2727  0.1477 
D7 62.50%  0.4947  0.1261 
D8 56.25%  0.4286  0.1230   151
3. Compliance rate analysis 
I calculated the compliance rate by comparing whether the decisions made by the 
rheumatologists fell into the same decision categories as the CDSS generated 
recommendations, as well as by comparing the drug dosage and various drug 
differences between the rheumatologists and the CDSS. Table 8.3 shows the 
compliance rate of the eight individual rheumatologists for combined cases, triple 
therapy cases and toxicity cases respectively. Table 8.4 and Figure 8.4 show the 
mean compliance rate comparison between the two groups for combined cases, 
triple therapy cases and toxicity cases respectively. 
 
Table 8.3 Mean of compliance with CDSS for individual rheumatologists 
         Combined 




number of cases     16  7  9 
compliance rate  D1  56.25%  71.43%  44.44% 
     D2  75.00%  85.71%  66.67% 
     D3  43.75%  85.71%  11.11% 
     D4  43.75%  71.43%  22.22% 
     D5  43.75%  57.14%  33.33% 
     D6  25.00%  28.57%  22.22% 
     D7  43.75%  28.57%  55.56% 
      D8  50.00%  42.86%  55.56% 
 
Table 8.4 Mean of compliance with CDSS for eRA group and non-eRA group 
    eRA group  non-eRA group  P value 
combined  0.5469 0.4063  0.17550 
triple therapy  0.7857 0.3929  0.00270 
toxicity  0.3611 0.4167  0.72150   152   153
a) Inner group comparison 
In the eRA group, the compliance rate for the triple therapy rule is statistically 
higher than the compliance rate for toxicity rule (0.7857 vs. 0.3611, P = 0.0171). In 
the non-eRA group, no difference was found between the compliance rates for 
triple therapy rule and toxicity rule (0.3929 vs. 0.4167, P = 0.8324). 
 
b) Inter group comparison 
There is no statistical difference in mean compliance rates between the eRA group 
and the non-eRA group in combined cases (0.5469 vs. 0.4063, P = 0.1755). The 
mean compliance rate of the eRA group for triple therapy is significantly higher 
than the mean compliance rate of the non-eRA group (0.7857 vs. 0.3929, P = 
0.0027). There is no statistical difference between the eRA group and the non-eRA 
group for toxicity rule (0.3611 vs. 0.4167, P = 0.7215). 
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4. I calculated the compliance rate again by assessing whether the decisions made by 
the rheumatologists fell into the same decision categories as the CDSS generated 
recommendations by comparing the direction change in drug dosage if any while 
tolerating dosage difference between rheumatologists and the CDSS. Table 8.5 
shows the compliance rate for the eight individual rheumatologists in combined 
cases, triple therapy cases and toxicity cases respectively. Table 8.6 and Figure 8.5 
show a comparison of the groups’ mean compliance rates in combined, triple 
therapy and toxicity cases respectively. 
 
Table 8.5 Mean of compliance with CDSS by decision category (dose-tolerant) 
for individual rheumatologists 
         Overall  Triple therapy  Toxicity 
number of cases     16  7  9 
compliance rate  D1  75.00%  100.00%  55.56% 
     D2  75.00%  85.71%  66.67% 
     D3  56.25%  85.71%  33.33% 
     D4  75.00%  100.00%  55.56% 
     D5  43.75%  57.14%  44.44% 
     D6  43.75%  42.86%  44.44% 
     D7  56.25%  28.57%  77.78% 
      D8  56.25%  42.86%  66.67% 
 
Table 8.6 Mean of compliance with CDSS by decision category (dose-tolerant) 






combined  0.7031 0.5000  0.01390 
triple therapy  0.9286 0.4286  0.00040 
toxicity   0.5278 0.5833  0.62800   155   156
a) Inner group comparison for dosage tolerated compliance 
In the eRA group, the compliance rate for triple therapy rule is statistically higher 
than the compliance rate for toxicity rule (0.9286 vs. 0.5278, P = 0.0117). In the 
non-eRA group, no difference was found between the compliance rates for triple 
therapy rule and toxicity rule (0.4286 vs. 0.5833, P = 0.3355). 
 
b) Inter group comparison 
The eRA group has a statistically higher mean compliance rate in comparison to 
the non-eRA group in combined cases (0.7031 vs. 0.5, P = 0.0139). The mean 
compliance rate of the eRA group for triple therapy is significantly higher than the 
mean compliance rate of the non-eRA group (0.9286 vs. 0.4286, P = 0.0004). 
There is no statistical difference between the eRA group and the non-eRA group 
for toxicity rule (0.5278 vs. 0.5833. P = 0.6280). 
   157
5. By calculating the complete compliance rate (drug compliance and dosage 
compliance) and dose-tolerant compliance rate (drug compliance but tolerating 
dosage difference ) for the two groups in 16 combined cases; 7 toxicity cases and 9 
triple therapy cases, the results reveal a higher dose-tolerant compliance rate than a 
complete compliance rate (Figure 8.6). The statistical analysis shows that the mean 
dose-tolerated compliance rate of the eRA group is significantly higher than the 
complete compliance rate for triple therapy cases. (0.9286 vs. 0.7857, P value = 
0.0498). However, there is no statistical difference found in toxicity cases and 
combined cases. 
 
6. In the second copy of the questionnaire extra information, such as patient 
additional drug toxicity related symptoms other than GI side effects and extra 
laboratory test results, was provided, which influenced clinicians to change their 
decisions on some cases. Among the 128 decisions made by 8 rheumatologists on 
16 patient cases, a total of 24 decisions had been changed upon the questionnaire 
provided extra information, twelve in the eRA group and 12 in the non-eRA group. 
The rate was 19% for both groups. However, the changes were spread out among 
the cases and also varied between the two groups. It underlines more patient cases 
are needed for further investigation. The yellow person like symbol in Figure 8.7 
represents the change on the corresponding cases.   158   159   160
From the statistical analysis, it was concluded that: 
 Rheumatologists from the non-eRA group were more conservative in their 
practice relative to CDSS recommendations and eRA rheumatologists 
 The eRA group had better agreement with CDSS recommendations compared 
to the non-eRA group 
 The eRA group had a higher mean compliance rate in the triple therapy cases 
than the toxicity cases; whereas, in the non-eRA group, the mean compliance 
rate for the triple therapy cases was not statistically different from the mean 
compliance rate for the toxicity cases 
 The eRA group had a higher mean compliance rate in triple therapy cases 
compared to non-eRA group, but there was no difference between the two 
groups in the mean compliance rate for toxicity cases 
 In both groups, analysis of dose-tolerant on drug dosage yielded higher 
compliance between decisions made by the rheumatologists and CDSS 
generated recommendations 
 In both groups, providing additional patient information caused changes in 
decision 
 
Based on the statistical analysis results, I found that the rheumatologists from the non-
eRA group practiced more conservatively compared with the rheumatologists from the 
eRA clinic (P value = 0.0079). In addition, the eRA group had a higher mean 
compliance rate in triple therapy cases compared to the non-eRA group. The combined 
results verify that CDSS guidance concurs with interpretation of eRA management 
rules for dosage adjustment by clinicians familiar with their application, and well 
accepting the rules. Compliance with guidelines leads to more consistent, evidenced 
based clinical decision-making in the eRA clinic. 
 
Results from the statistical analysis also indicate that the rheumatologists from the 
eRA group did not comply as well with Drug Toxicity Monitoring Rules as they did 
with Rules for Changes in Dose/Agent. Moreover, the results show that the eRA group 
had a significantly poor compliance rate with the recommendations based on Drug 
Toxicity Monitoring Rules as that seen in the non-eRA group. The findings also may   161
be explained by the extensive eRA clinic experience with Rules for Changes in 
Dose/Agent and the Dose Modification Protocol, whereas the formulation of 
prescriptive Drug Toxicity Monitoring Rules had been overlooked and were 
formulated during the present project and little clinical experience with these latter 
rules had accrued. The discrepancy between the considered evidence-based and expert 
consensus-based Drug Toxicity Monitoring Rules and the variable ad hoc responses of 
rheumatologists to the toxicity scenarios underlines the need for further clinical 
validation of the rules. The observed low concordance with Drug Toxicity Monitoring 
Rules was not unexpected as this product of Knowledge Engineering and guideline 
development proved to be remarkably complex to an extent likely to defy consistent 
unaided real-time manual application. The analysis identified that both groups had 
19% decision revision against the eRA guidelines due to providing additional patient 
information. In addition, the analysis revealed a variation in applying the drug dosage 
between the RA management rules and actual practice. These findings further 
highlight the need of clinical evaluation for the development of CPGs.   162
9  Summary and Conclusions 
The decision-making involved in adjusting treatments for the management of RA is a 
complicated task for clinicians due to the complexities of response-driven combination 
DMARD therapy and the need to balance imperatives of adequacy of clinical response 
with safety considerations in relation to possible drug toxicity. A CDSS has been 
proposed to integrated up-to-date evidence and therefore to assist clinicians in making 
better decisions in terms of complying clinical guidelines and mitigating drug toxicity 
in RA management. 
 
The primary objective of the study was to establish and articulate explicitly the RA 
management rules in the eRA clinic, as a basis for implementing a knowledge-based 
CDSS for improved guideline compliance and better RA management. The study 
hypotheses are (1) the conscientious use of best evidence in clinical decision-making 
can be achieved through application of Knowledge Acquisition processes in order to 
facilitate the generation of CPGs, (2) a computer interpretable model can be 
established for highly complex CPGs, (3) the CDSS guidance concurs with 
interpretation of the RA management rules for dosage adjustment by clinicians 
experienced in their application and accepting of the rules, and (4) more complex 
CPGs are associated with low compliance using manual approach regardless of high 
guideline acceptance. 
 
During this project, I applied Knowledge Engineering as a technique for the 
development of the eRA-CDSS. The data and Knowledge Acquisition achieved is a 
fundamental aspect of this project. During the early stage of the Knowledge 
Acquisition, I reviewed literature, observed the eRA clinic consultations, consulted the 
local clinicians and clinic experts, and investigated the eRA clinic database. Studying 
the clinic database revealed that inconsistency existed in complying the eRA Dose 
Modification Protocol during the clinic practice, particularly under the circumstances 
of managing individualised patient toxicity risks. As a result of my insight, the eRA 
clinic became committed to establishment of more comprehensive RA management 
rules that addressed this unwanted variability in application.   163
 
In order to develop evidence-based clinical guidelines, clinical evidence has to be 
identified and characterised. Reviewing literature, observing clinic consultations and 
consulting clinicians played a central role during the development and articulation of 
the evidence-based RA management rules. These processes helped to synthesize the 
clinical evidence from the relevant literature and the clinical experts. 
 
During the processes of Knowledge Acquisition, I preformed a comprehensive 
literature review of MTX toxicity management in RA. I identified the risk factors for 
MTX toxicity in RA. I also characterised the MTX toxic effects, such as symptoms 
and abnormal laboratory results. Furthermore, I categorised the identified evidence 
into evidence categories using the evidence grading methodology defined by Shekelle 
et al [166]. The categorisation helped to identify high grade evidence, with which to 
underpin clinical guideline development using the best available evidence. In addition, 
conditional probability, Bayes’ theorem and Bayes Net were studied in order to 
represent the dependence between risk factors, toxicities and toxic effects. 
 
With my assistance, the eRA clinic established the comprehensive RA management 
rules including Drug Toxicity Monitoring Rules and Rules for Changes in Dose/Agent. 
The RA management rules have incorporated higher grade evidence identified from 
the literature. I have also established the framework for MTX toxicity prediction 
models of hepatic toxicity, haematological toxicity, pulmonary toxicity and 
gastrointestinal toxicity. I applied Bayes Net for model formation. The models 
incorporate identified risk factors for MTX toxicity in RA, and clinical effects of MTX 
toxicity such as symptoms of toxicity and abnormal laboratory results. The 
development of MTX toxicity prediction models aimed to provide extra decision-
making assistance to clinicians in estimating the patient’s risks for developing MTX 
toxicity according to the patient’s present risk factors, symptoms, and abnormal 
laboratory results. 
 
Due to the characteristics of management of a chronic disease such as RA, it is 
necessary to embrace management rules that feature dynamic state transitions over   164
time. As a result the RA management rules proved to be highly complex, especially the 
Drug Toxicity Monitoring Rules. For this reason, computer interpretable models are 
needed before implementing them into the CDSS. A number of guideline 
representation models have been developed by the Health Informatics community 
[170]. Tu et, al. [169] have recommended using Decision Maps to represent static 
recommendations and using guideline processes to link the individual static 
recommendations together as a computational model. However, because of the 
dynamic characteristic of the RA management rules, the transitions between states are 
unpredictable and there are no straight forward “guideline processes” that can link the 
static recommendations. The study developed a novel guideline representation model - 
a dynamic model. The dynamic model describes the dynamic state transitions as a 
parent-child relationship. The dynamic model includes a node table; each row contains 
a complete set of children states in relation to each parent state. The dynamic model 
also includes a decision table which contains the static recommendations of each state. 
Based on the parent-child relationships, an algorithm was established for 
computerisation of the rules. The dynamic model ultimately realised electronic 
implementation of the complex RA management rules. 
 
During the study, I analysed the workflow and data flow of the eRA clinic. I 
investigated the clinical decision-making process and patient assessment process in 
detail. I integrated the knowledge models into the above processes. In order to assess 
the potential impact of incorporating the eRA-CDSS, I also performed the stakeholder 
analysis. 
 
The preliminary version of the eRA-CDSS was implemented. This prototype captured 
and implemented the eRA Dose Modification Protocol, Rules for Changes in 
Dose/Agent, and Drug Toxicity Monitoring Rules. I then conducted a questionnaire-
based study in order to test the acceptance of the computerised guideline 
recommendations by practising rheumatologists; to discern the gaps between the 
guidelines and practice; and to collect valuable information for developing the CDSS 
tool with regard to broader clinical acceptability. The questionnaire tested and   165
analysed the distance and direction between decisions made by clinicians and guideline 
recommendations generated by the eRA-CDSS. 
 
Statistical analysis showed that (1) the eRA group of rheumatologists had better 
agreement with the CDSS recommendations compared to the non-eRA group of 
rheumatologists; (2) rheumatologists in the non-eRA group practised more 
conservatively compared with the rheumatologists in the eRA clinic (P value = 0.0079); 
(3) the eRA group had a significantly higher mean compliance rate in scenarios 
designed to test for adjustment of triple therapy without complicating unwanted effects 
than the non-eRA group (0.7857 vs. 0.3929, P = 0.0027); (4) both groups had low to 
moderate compliance rates in scenarios chosen to test responses to out-of-range 
laboratory results and there was no significant difference in mean compliance rates 
between the two groups (0.3611 vs. 0.4167, P = 0.7215). This poor concordance 
underlines the value of computer aided guidance when decisions involve greater 
complexity; and (5) for both groups, 19% of the decisions relative to the both rules 
were revised when additional patient information was provided. 
 
The questionnaire validated the hypothesis, which is that the CDSS guidance concurs 
with interpretation of the RA management rules for dosage adjustment by clinicians 
familiar with their application, and well accepting the rules. By contrast, the Drug 
Toxicity Monitoring Rules, which were developed as a considered best practice 
approach, achieved low compliance rates and no higher concordance by eRA 
rheumatologists than by those not involved in the eRA clinic. This discrepancy 
verified the hypothesis, which is that the complexity of the Toxicity Monitoring Rule 
makes it difficult to apply consistently using manual approach. Hence the delivery of 
clinical guidelines by CDSS is needed to assist clinical decision-making when the 
CPGs are well accepted by clinicians, and the complexity of CPGs is high. 
 
Both groups thus had low compliance rates for Drug Toxicity Monitoring Rules, and 
19% decision revision when supplied with additional information suggesting that (1) 
the complexity of the rules reduces compliance, in which case, the CDSS tool can   166
facilitate this process; and (2) further studies should be carried out to validate the 
evidence behind the rules and to assess their implementation further. 
 
The overall eRA experience of more than 160 patients, treated according to the Dose 
Modification Protocol and Rules for Changes in Dose/Agent has not been associated 
with any serious drug-related toxic events to date. Along with demonstrably more 
conservative responses of non-eRA rheumatologists, this experience suggests that the 
rules deliver better disease control without an important increase in serious unwanted 
events than routine or standard care. The more conservative approach is likely to arise 
from concerns regarding drug toxicity which may not be well grounded in terms of 
actual risk. Systematic implementation of the Drug Toxicity Monitoring Rules 
developed in this project and implementation of a drug toxicity risk assessment tool to 
identify sub-groups in which a more conservative approach may indeed be appropriate 
or in whom more intensive toxicity monitoring may be required, should deliver 
refinements that increase confidence in more intensive application of treatment where 
appropriate, while managing risk better. 
 
The study has formulated a framework for predicting MTX toxicity. This model holds 
promise for presenting additional clinical evidence to the clinicians, thereby supporting 
clinical decisions more completely. However, based on the comprehensive literature 
review performed during the study, the probability data that quantify the MTX 
toxicities based on its risk factors or its associated toxic effects were not available. 
Accordingly neither the Bayes Net model, nor the decision tree model was realised 
during this project. Nevertheless, the conceptual framework established offers a new 
mechanism for managing patient risks of drug toxicity; it thereby provides the 
foundation for future model enhancement and implementation. 
 
In summary, Knowledge Acquisition methodology proved effective in the 
development and the implementation of a clinically sophisticated CDSS for the 
management of a serious and highly prevalent rheumatic disease. Complex clinical 
guidelines were computerised in order to assist clinicians make better decisions for the 
management of RA. In future risk factors for drug toxicity can be established, and drug   167
toxicity prediction models can be created using Bayes Net. I believe that the 
implementation of drug toxicity prediction models can complement the clinical 
guidelines, thus optimising clinical decision-making for customised patient care. 
 
This study outlines the process of building a knowledge-based CDSS, and addresses 
questions regarding computerising complex CPGs. The study also acknowledges that 
an understanding of the issues regarding CPG acceptance is important for effective 
implementation of a CDSS in a real clinical setting. I am optimistic about the potential 
impact of the eRA-CDSS on clinical decision-making. Furthermore, because new 
evidence continually emerges from research and accumulated clinical experience, this 
CDSS can be updated when and where necessary through knowledge management to 
incorporate new and compelling evidence as it becomes available.   168
10 Discussion and Future Directions 
In today’s healthcare environment, new evidence is continually being published. The 
availability of updated knowledge is desirable for patients and clinicians. However, 
determining how to best utilise new knowledge, and thereby improve decision-making 
in the care of patients is a daunting challenge. In the management of RA, the decision-
making involved in adjusting treatment to achieve best outcomes with due regard to 
benefits and risks is a complex task. Busy clinicians have difficulty incorporating the 
extensive knowledge and evidence available into the decision-making process, which 
results in gaps between evidence and practice. 
 
CDSS tools with automatically generated guidelines can positively influence clinicians 
to comply with guidelines. CDSSs can be integrated into clinical workflow, delivering 
the right information at the right time in order to assist in clinical decision-making. 
However, in order to realise an effective and therefore widely accepted CDSS by 
clinicians, clinical sophistication, workflow integration and guideline validation must 
all be addressed as these a critical determinants of success. 
 
Gaps between practice and evidence 
The use of CPGs has been widely promoted to assist clinicians in making decisions 
about appropriate management of specific clinical circumstances. CPGs are based on 
best available evidence and play a role in closing gaps between practice and evidence. 
However, it has proven difficult to convince clinicians to utilise clinical guidelines in 
practice as evidenced by the limited impact of guidelines in changing the ways that 
clinicians practice. Moreover, CPGs are not designed to address every aspect of patient 
care. They provide generic recommendations that do not take into account variations in 
individual patients that are needed to address complex clinical scenarios. To provide 
personalised treatment, clinicians need to incorporate extra knowledge into their 
decision-making processes. This study established a drug toxicity prediction model to 
complement standard CPGs. Although the model has not been implemented during 
project, it provides an alternative way of synthetically integrating clinical evidence into 
clinical decision-making.   169
 
Guideline development 
Knowledge acquisition is a critical process during the development of CPGs. An 
exhaustive systematic review of relevant literature is needed to capture durable and up-
to-date evidence. Categorisation of levels of evidence underpins the strength of the 
recommendations. Clinical expertise can be elicited through consulting/interviewing 
clinicians. Think-aloud strategies that verbalise their briefs, judgements and decision-
making are useful adjuncts to formulation of guidelines. This study reviewed over 150 
relevant papers, and intensively engaged the eRA clinicians. These processes led to 
more comprehensive RA management rules and identified deficiencies in the literature 
that could be addressed in order to develop management rules further. 
 
Guideline validation 
A lack of guideline acceptance is one barrier to applying guidelines in patient care. 
This study included a questionnaire designed to evaluate congruence between 
guideline performances as implemented by the CDSS and simulated ad hoc clinical 
decision-making. By conducting the questionnaire, I identified the gaps between the 
guidelines and the actual practice, which suggested the causes for guideline violation 
with complexities of decision-making emerging as a candidate factor. The 
questionnaire identified opportunities for the CDSS to complement CPGs by 
incorporating extra knowledge to assist clinical decision-making, particularly in the 
management of out-of-range laboratory safety monitoring data. The study also 
provided valuable information for future guideline developers to refine, enhance, and 
develop guidelines. 
 
Work flow integration 
Performing a clinical workflow analysis helped to identify opportunities for integration 
with current clinical practice in order to provide the most direct beneficial effects of a 
CDSS in the clinic. Understanding clinical decision-making processes was crucial for 
this integration into the clinical workflow. Mapping knowledge and decision-making 
points underpins the seamless integration into clinicians’ decision-making procedures, 
which is needed for a clinically acceptable and effective CDSS.   170
 
Computer interpretable model development 
Over the past decade, adherence to CPGs has become the gold standard for ensuring 
quality in clinical practice. Researchers and developers have been developing software 
applications that computerise these guidelines and protocols in order to provide 
decision support at points of care. However, the complexity of clinical guidelines 
brings the challenges to implementation. A chronic disease such as RA involves 
patient state transitions over time. The established RA management rules specify 
patient conditions and corresponding clinical recommendations for the conditions that 
take place over time. Furthermore the descendant states of each ancestor state during a 
state transition are dynamic, and these involve considerable understanding. 
 
This study detailed the construction of a dynamic model with which to interpret 
complex clinical guideline. Utilising parent-child relationships to represent the 
dynamic state transitions makes the model distinct from other guideline modelling 
methodologies. The dynamic model includes a node table; each row contains a 
complete set of children states in relating to each parent state. The dynamic model also 
includes a decision table which contains the static recommendations relative to each 
patient state. A preliminary version of the CDSS has successfully automated the 
established RA management rules. This established dynamic model can be adopted for 
modelling clinical guidelines which feature dynamic state transitions, thereby 
underpinning the electronic implementation of complex CPGs. 
 
A CDSS development processes 
A clinically efficient CDSS requires a sophisticated knowledge base. Acquiring the 
required knowledge for clinical decision-making and representing the knowledge are 
challenging tasks. I have summarised the processes that I applied in this study as 
follows: 
 
1. Knowledge acquisition from clinical expertise and best available evidence from 
relevant literature and research findings   171
2. Understanding of clinical decision-making processes, and mapping knowledge to 
the decision-making points in order to integrate knowledge with decision-making 
processes 
3. Establishment of a computer interpretable model for CPGs. The model can address 
many contingencies of a complex CPG, thereby enhancing compliance with 
guidelines 
4. Identification of fields of Extra knowledge needed to complement the guidelines 
because the CPGs have limited customisation potential for individuals (atypical 
patients). An extra knowledge model could be set up to provide evidence-based 
recommendations in addition to CPGs 
5. Exploration of decision theory approaches to assist clinical decision-making, e.g., 
establishing a Bayes Net model of drug toxicity prediction, which uses known risk 
factors and toxic effects to project probabilities for occurrence of drug toxicity 
 
Further enhancement 
1. MTX toxicity prediction model 
One of the major achievements of the study is to have identified and categorised the 
MTX toxicity risk factors through a comprehensive review of literature. This 
undertaking examined the risk factors of MTX toxicity in RA. The framework for 
MTX toxicity prediction models was established by constructing a Bayes Net model 
utilizing the identified risk factors. 
 
However, the literature review failed to pin down the probability data which quantifies 
the MTX toxicities based on its risk factors and toxic effects, therefore the MTX 
toxicity prediction model has not been implemented during the study. Nevertheless, 
the model construct provides a foundation for future model development and 
implementation. The lack of probability data in the literature identifies where research 
is needed to quantify probability with regard to frequencies of drug toxicity that can be 
used to manage risks of toxicity. 
 
2. Guideline evaluation   172
Preliminary evaluation of the guidelines as computed by the CDSS yielded positive 
outcomes with regard to concordance with decisions of the eRA clinic rheumatologists 
accustomed to applying rules. While the Rules for Changes in Dose/Agent are not 
without some complexity, the Drug Toxicity Monitoring Rules developed based on my 
literature review and consultations with clinical experts are far more complex. It was 
hypothesized that there would be poor concordance with these complex rules as proved 
to be the case. 
 
A limitation of the study was that the questionnaire had restricted number of patient 
cases and limited participations. As a consequence, the study was not able to conduct 
compliance analysis on categorised levels of experience among the participants, or to 
perform guideline evaluation by case study. For further enhancement, conducting 
studies to evaluate the developed CDSS on patient outcomes and clinicians’ 
performance will yield further insights into application and effectiveness of the CDSS. 
 
3. Terminology reference 
The study did not address any aspects of the standard clinical terminology reference 
such as SNOMED CT, because it was not in the scope of this project. However, for 
future development, the study should incorporate the standard terminology reference 
wherever possible. 
 
4. Data mining 
A CDSS has the potential to apply data mining tools to determine the type and 
frequency of breaches to automated guideline recommendations. Frequency patterns 
and their associated data can be submitted to clinical experts for interpretation. This 
information is extremely valuable for the evaluation and improvement of guidelines, 
and can be used to promote a continuous improvement model in healthcare practice. 
 
Due to a lack of probability data available in the literature, the study failed to extract 
the probability data that quantifies the MTX toxicity presence according to the 
patient’s risk factors and existing drug toxic effects. However, through integration with 
special data mining tools, a CDSS can help to collect the probability data from the   173
users (clinicians). These data can potentially feed Bayes Net model and realise the 
drug toxicity prediction model. 
 
What this study adds to the topic? 
Unlike most CDSS projects which implemented already available clinical guides, this 
study adopted a novel approach of Knowledge Engineering into the development of a 
CDSS for assisting decision-making in the management of RA. The Knowledge 
Acquisition processes through which the evidence-based RA management rules have 
been established have more general utility. 
 
Significant contributions to knowledge are summarised as follows: 
1. The Knowledge Acquisition processes embraced by the study facilitated not only 
the synthesis of high quality clinical evidence for RA management, but also 
underpin the establishment of the RA management guideline. Clinical evidence is 
the key ingredient which forms the knowledge base of a CDSS. Identifying clinical 
evidence through comprehensive literature review was an important aspect of the 
study. This study also interactively engaged the local clinical experts. A think-
aloud strategy was used to elicit clinical expertise. Encouraging clinicians to 
articulate their premises (knowledge, beliefs) and inferences proved useful in 
formulating treatment rules. 
 
2. The establishment of the computer interpretable model underpinned the success of 
the automation of guidance during the CDSS development. The computer 
interpretable model (dynamic model) facilitated the implementation of highly 
complex CPGs. This model is unique compared to other guideline models, because 
it models unpredictable state transitions during the RA management pathway. State 
transitions are a typical characteristic of chronic disease management and 
accordingly the model architecture has more general utility. 
 
3. The questionnaire explored the level of concordance between guidelines and 
rheumatologists responding to care scenarios. The gaps between guideline 
recommendations and physician responses allowed a number of inferences to be   174
made. These included an endorsement of the effectiveness of the computational 
model as evidenced by better concordance by clinicians familiar with Rules for 
Changes in Dose/Agent. This analysis also underlined the potential importance of 
computer aided guidance in the application of highly complex rule as evidenced by 
poor concordance with the Drug Toxicity Monitoring Rules, including physicians 
familiar with the eRA approach. 
 
4. Drug toxicity prediction model was another unique modelling approach of the 
study. Exhaustive literature review identified a complete list of MTX toxicity risk 
factors in RA, which formed the knowledge base of the MTX toxicity prediction 
model. However due to the lack of required conditional probability data from the 
literature, the drug toxicity prediction model has not yet to be realised. Therefore 
the preliminary version of the eRA-CDSS only implemented the clinical guideline 
models. Nevertheless, this study takes tangible steps toward the ultimate goal of 
developing a specifically designed, clinically sophisticated Knowledge-based 
CDSS with the feature of computerising highly complex CPGs that deliver 
evidence-based recommendations. 
 
With today’s aging population, the high prevalence of chronic diseases and increased 
changes in the use of medications, clinical decision-making is becoming more complex. 
In order to make better decisions in increasingly complex circumstances, we need 
sophisticated systems to assist with decision-making. CDSSs were introduced more 
than two decades ago to assist with clinical decision-making, yet more effort is 
required to optimise systems. I believe that in addition to ‘workflow’, ‘clinical 
sophistication’ is also a key to the development of effective CDSSs, while Knowledge 
Acquisition is fundamental to the process of system development. 
 
Medical practice inevitably will diverge to some extent from knowledge and new 
evidence. Substantial work is needed to realise the full potential of CDSSs to close the 
‘evidence-practice gap’ through the delivery of knowledge and guidance to the 
clinician at point of care. As new evidence continually arises from research, including 
that arising from the outcome data collected by CDSSs, and accumulated clinical   175
experience, the design of CDSSs not only needs to allow for an analysis of clinical 
inputs, but also needs to be amenable to system refinements based on an analysis of 
system performance and emergent scientific information. 
 
Looking to the future, there is another application for CDSSs, which has implications 
for quality of care and also for the rising cost of new treatments. This application 
increases the use of CDSS guidance to provide a background of response-contingent 
best practice care with consistent actions in response to out of range blood results and 
drug intolerances, during the evaluation of novel therapeutic additions to usual 
combination therapies for chronic diseases. This application should displace prevailing 
comparison between new drugs and minimum acceptable comparators which inflate 
the apparent value of new treatments. The resulting perceptions of efficacy then 
became translated into high prices based on inappropriately flattering cost-benefit 
analyses. Thus CDSSs should have a place both in the better delivery of established 
management strategies and in the evaluation of novel treatments.   176
Appendices
Study Timetable 
Time Frame  Events
September 2004 – December 2005  1. Reviewing literature on RA management 
2. Investigating the eRA clinic database 
January 2005 – March 2005 
1. Reviewing literature on CDSSs 
2. Observing the eRA clinic consultation  
3. Analysing clinical protocol compliance 
(Dose Modification Protocol) 
4. Drafting research proposal 
April 2005 – June 2005  1. Analysing clinical workflow 
2. Performing stakeholder analysis 
3. Analysing clinical decision-making process 
July 2005 – August 2005  1. Reviewing literature on MTX toxicity risk 
factors in RA 
2. Consulting local clinical experts for clinical 
expertise in managing RA 
September 2005 – December 2005  1. RA management rule development 
2. Establishing Drug Toxicity Monitoring Rules 
3. Establishing Rules for Changes in 
Dose/Agent 
January 2006 – March 2006  1. Reviewing literature on clinical guideline 
modelling 
2. Analysing the complex RA management 
Rules (rule break down) 
April 2006 – June 2006  Establishing computer interpretable guideline 
model – a dynamic model 
July 2006 – August 2006  1. Reviewing literature on Bayes’ Theorem and 
Bayes Net 
2. Developing MTX toxicity prediction model 
September 2006 – December 2006  1. On leave 
2. CDSS implementation (Alcidion 
corporation) 
January 2007 – March 2007  1. Questionnaire study 
2. Reviewing patient case note for case data 
3. Drafting questionnaire and recruiting 
participants 
April 2007 – June 2007  1. Distributing Questionnaire 
2. Collecting, analysing and reporting 
questionnaire data 
July 2007- December 2007  Thesis writing   177




We are asking you to assist in a research project to evaluate the early Rheumatoid 
Arthritis Clinical Decision Support System (eRA-CDSS). The CDSS automates 
comprehensive ERA clinical rules, generates recommended drug regimen, dosage and 
patient monitor plan. The purpose of this evaluation is to ensure wide applicability for 
the future use of the CDSS in the ERA Clinic or in other clinic settings. 
 
Along with this letter is a questionnaire which includes sixteen patient cases. We ask 
that you use the clinical information provided to make a decision as to whether 
treatment should change and if so how. Completion of the questionnaire enclosed will 
enable us to evaluate the CDSS tool with regard to broader clinical acceptability. The 
cases are real case abstracts, which have been carefully chosen from the ERA Clinic 
database as they are suitable for testing our clinical decision rules. Each case abstract 
has two copies; one copy includes minimum CDSS input, the other copy provides 
extra patient information. If you choose to participate in our questionnaire, please 
respond to both copies of each case, then move on to next case. Your responses will 
not be identified with you in any way and you will not be named in any report. In other 
words, your responses will be treated in a very confidential manner. Only summarized 
data will be included in a formal report. 
 
This questionnaire should take you about 45 minutes to complete. We appreciate your 
time and effort towards this study and we would kindly request you return it to Ning 
Pan by 13
th April 2007. If you have any questions about the questionnaire, you may 
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Ning Pan 
(PhD student 
Health Informatics Unit 
The University of Adelaide) 
 
Dr Susanna Proudman 
Prof. Les Cleland 
(Royal Adelaide Hospital) 
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Questionnaire Sample 
UR:  1183623  DOB:    6 Feb 1961    SEX:  Female 
Age: 45    Weight:  54.9kg 
Patient Current Medications 
 methotrexate 10 mg orally per week  
 folic acid 0.5 mg orally daily  
 sulfasalazine EN 1.0 G orally bd   
 hydroxychloroquine 400 mg orally daily 
Clinical Information 
Duration of the therapy:  6 weeks 
Tender Joint Count:    8 
Swollen Joint Count:    2 
Patient  pain:    20 
Morning stiffness:    0 minute 
Fatigue:    25 
ESR:     26   
CRP:     1.1   
Patient Remarkable Symptoms 
Patient GI side effects:   Nil 
 
Laboratory Results 
  Latest Lab  Prior Lab 
neutrophils (1.80-7.50)  4.73  4.8 
ALT (0-55)  34  27 
AST (0-45)  -  26 
creatinine (50-120)  63  67 
creatinine Clearance  (84.4752)     180
Physician’s Response Detail (Please use block letters) 
Need dose modification? 
Yes    
No    
If Yes 
Increase    ____________ dose ________ 
Reduce   ____________ dose ________ 
Hold      ____________ 
Restart      ____________ dose ________ 
Stop (can not resume)  ____________ 
Consider adding any new medication? 
__________________________________________________________ 
Patient monitor plan 
Repeat lab test in _____ weeks 
See patient in _____ weeks 
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Questionnaire Sample (with extra patient information) 
UR:  1183623  DOB:    6 Feb 1961    SEX:  Female 
Age: 45    Weight:  54.9kg 
 
Patient Current Medications 
 paracetamol 500 mg tds  
 glucosamine  
 vitamins  
 methotrexate 10 mg orally per week Saturday night (began 30/8/06) 
 folic acid 0.5 mg orally daily  
 sulfasalazine EN 1.0 G orally bd (began 30/8/06)   
 hydroxychloroquine 400 mg orally daily (began 30/8/06) 
Patient Remarkable Symptoms & Other Patient Info 
Patient GI side effects:   Nil 
 
Clinical Information 
  Current Visit  Prior Visit 
Duration of the therapy  6 weeks  3 weeks 
Tender Joint Count  8  13 
Swollen Joint Count  2  6 
Patient pain  20  24 
Morning stiffness  0 minute  60 minutes 
Fatigue 25  37 
ESR 26  46 
CRP 1.1  6.6 
Blood Pressure  120/70  110/65   182
Laboratory Results 
  Latest Lab  Prior Lab 
neutrophils (1.80-7.50)  4.73  4.8 
ALT (0-55)  34  27 
AST (0-45)  -  26 
Haemoglobin (135-175)  115  113 
WCC (4.00-11.0)  7.46  7.5 
Monocyte (0.20-0.80)  0.33  0.27 
Lymphocyte (1.00-3.50)  2.29  2.29 
MCV (80.0-98.0)  65.9  66.2 
Platelet (150-400)  223  257 
creatinine (50-120)  63  67 
creatinine Clearance  (84.4752)   
 
Physician’s response detail (Please use block letters) 
Need dose modification? 
Yes    
No    
If Yes 
Increase    ____________ dose ________ 
Reduce   ____________ dose ________ 
Hold      ____________ 
Restart      ____________ dose ________ 
Stop (can not resume)  ____________ 
  
Consider adding any new medication? 
__________________________________________________________ 
Patient monitor plan 
Repeat lab test in _____ weeks 
See patient in _____ weeks 
   183 
Tables of MTX Toxicity Risk Factors 
Overall MTX Toxicity Risk Factors 
Reference Specific  Patient 














496 patients from 11 
placebo controlled 
and comparative 
MTX clinical trials; 
341(69%) patients  
less than 60 years old 
 A  meta-analysis  age,  renal 
impairment 
Lower Creat CL at baseline 
assessment is associated with 
higher rates of overall  toxicity 
( P=0.027);  
Odds Ratio for severe toxicity 
and respiratory toxicity were 
increased from 3 to 6.9 times 
in those with renal 
impairment ; Patients in older 
age group (65-69, >=70) were 











et al., [112], 
1991 
92 RA patients with 
MTX 7.5mg/week 
orally (renal function 





  2 patients had a fatal outcome 
because of an unexpected renal 
deterioration  
Not recorded  Impaired renal 
function   184 
Mean age of 58 with 
range from 30 to 81 
years 
McKendry, 
R.J. et al., 
[111], 1993 
144 RA patients; 
Sub group: 50 
patients with adverse 
reaction and duration 













No significant different 
between groups with respect to 
the variables; 
Discontinuation of therapy due 









R., et al., 
[113], 1993 




age  Advanced age (>=65) was a 
significant predictor of drug 




Advanced age (>= 65) 
Wolfe, F. et 
al., [122], 
1991 
235 RA patients; 
184 patients aged 
over 65 (>65); 51 
patients less than 65 
(<= 65) 
June, 1976 




age More  gastrointestinal 
complaints and more 
pulmonary complaints in older 
age group 
 ² statistic; 
Wilcoxon rank 
sum test 
Advanced age (>65) 
Kent, P.D. et 
al., [143], 
2004 
481 RA patients 




  Lack of folate (P<0.001) and 
increased BMI (P<0.03) were 
associate with permanent 
discontinuation of MTX; 
Hypoalbuminemia was 
associate with temporarily 
Wilcoxon rank 





Lack of folate, 
untreated 
hyperlipidemia, 
increased BMI were 
the risk factors for 
transaminase   185 
withdrawal of MTX; 




increased creatinine (P<0.03) 
and male sex (P<0.04) were 
the risk factors for increased 
abnormal AST; Multivariate 





Pearson  ² test 
elevation; 
Hypoalbuminemia 
was a risk factor for 
thrombocytopenia 
Hoekstra, M., 
et al., [126], 
2003 
411 RA patient; 
Folate 
supplementation 
group: (n = 274); 
Placebo group: (n = 
137) 
48 week  A randomise 
clinical trial 
  Lack of folate (P<0.001), High 
BMI (P=0.02) were associated 
with hepatotoxicity; 
Prior GI events (P=0.03) were 
associated with GI toxicity; 
Hepatotoxicity and GI toxicity 






Lack of folate, high 
BMI were the risk 
factors for 
hepatotoxicity; 
Prior GI events was 
the risk factors for GI 
toxicity 
Morgan, S.L., 
et al., [125], 
1990 
32 patients were 
included in trial of 
folic acid 
supplementation 
during low-dose MTX 





  Folate supplement group had 
significant lower toxicity 






Lack of folate 
supplementation is a 
risk factor for MTX 
toxicity   186 
therapy; 
16 patients in folate 
supplement group 
(folate 1mg/day) and 
16 patients in placebo 
group 
Ortiz, Z., et 
al., [128], 
1998 
7 trials (307 patients); 
147 were treated with 
folate 
supplementation (67 
with folic, 80 with 
folinic acid) 
 A  systematic 
review 
Liver enzyme 




A 79% reduction in mucosal 
and GI side effects was 
observed for folic acid group 
(OR=0.21); 




 ² test 
Lack of folate 
supplementation is a 
risk factor for MTX 
mucosal and GI 
toxicity 
van Ede, A.E., 
et al., [127], 
2001 
A total of 434 RA 
patients were included 
in the study to 
compare the effect of 
folic or folinic acid 
supplementation on 
MTX toxicity; 
411 were included in 
the ITT population: 
137 in placebo group, 
133 in the folic acid 
group, and 141 in the 




controlled trial  
 Toxicity-related  MTX 
discontinuation occurred in 
38% of the placebo group, 
17% of the folic acid group 
and 12%of the folinic acid 
group; 
There was a significant 
difference between placebo 
group and folate 
supplementation group in 
incidence of elevated liver 
enzyme 




rank test, and 
Wilcoxon’s 
tests 
Lack of folate 
supplementation is a 
risk factor for liver 
enzyme elevation   187 
folinic acid group; 





(can be allowed up to 
25mg/week, folate 
dosage were doubled 
once MTX reached 
15mg/week)   188 
MTX Haematological Risk Factors 
Reference Specific  Patient 










A. et al, 
[152], 
1993 
15 cases of 
pancytopenia(12 
RA, 2 PsA, 1 
psoriasis); 








1981-1991 Case-control  dose,  age, 
concomitant 
medications, renal 
function and MCV 
A MTX therapy duration matched 
controls shows significant 
difference with respect  to age, renal 
function and MVC; Pancytopenia 
group had more advanced age, 
impaired renal function and 
elevated MCV; 
A 2
nd age and sex match control 
shows BUN and creatinine were 





 ² statistic 
Renal function, MCV, 
advanced age 
Weinblatt, 
M.E. et al, 
[153], 
1989 
23 RA patients 
receiving low-dose 





MCV  MCV of the patients who developed 
toxicity was significantly higher 
than those without toxicity 
(P<0.02); 
Elevated MCV was associated with 
an increased probability of 














(68 reported in 


















M. et al, 
[155], 
1986 
47 years old white 
woman with RA 
treated with 
MTX12.5mg/week 
  Case report    Developed megaloblastic 
pancytopenia shortly after 
trimethoprim/sulfamethoxazole 
was added to the regimen 
  MTX treatment with 
trimethoprim 
/sulfamethoxazole   190 
MTX Hepatotoxicity Risk Factors 
Reference Specific  Patient 
Group/Sample Size 







W.J., et al., 
[141], 1988 
Total 538 MTX treated Patients 
who underwent liver biopsy 
from Jan.1979 to Jan.1988, 
including 210 RA patients with 




6 patients with RA 
and Grande III liver 
biopsies: 
Sex (M/F): 1/5 
Mean age: 59 (50-68) 





Diabetes mellitus: 3/6 
Obesity: 5/6 
Renal insufficiency: 0/6 
Alcohol usage: 1/6 
Elevated LFT results: 1/6 









J.M. et al, 
[139], 1989 
29 MTX treated RA patients 







In 27 patients 




A worsening hepatic 
histology reflecting by an 
increase in the mean 
histological grade over total 
of six years of MTX therapy;  
There was a significant 
association between alcohol 
assumption and increase in 
biopsy grade,  













enzymes   191 
Total duration of MTX 
therapy was significantly 
longer in patient with grade 
IV biopsy than those not; 
Total cumulative MTX dose 
was correlated with fibrosis 
development; 
Elevated liver enzyme is 
correlated with liver 
histological deterioration; 
There was a significant 
association between age and 




Q.E. et al, 
[140], 1991 
A total of 636 patients 
including 334 RA patients) 
from 15 studies 
A meta-analysis    Patients who were heavy 
drinker (at lease 100g alcohol 
per week) were more likely to 
show histological progression 
and advanced changes; Liver 
histological progression was 
correlated with the 








A.M., et al., 
24 cases of cirrhosis and liver 
failure with positive liver 
Case-control 
study 
  Age at first MTX use and 
time since initiation of MTX 
tabular 
analysis, 
Age, dose and 
duration, elevated   192 
[144], 1993  biopsy were identified by 
rheumatologists from 16600 
RA patients receiving MTX for 
5 years or more. 39 sex, race 
and treatment history matched 
controls were found for 16 
cases; 8 cases had no matched 
controls.  
therapy were the strongest 
predictor of liver failure and 
cirrhosis; 
AST and serum albumin 
discriminated well between 
cases and controls (creatinine 







D.O., et al., 
[116], 1989 
A 38 years old woman with 12 
years RA receiving MTX for 4 
years+ (started with 
7.5mg/week, increased to 
15mg/week) 
Case report    Biopsy revealed chronic 
active hepatitis which was not 
found on biopsy 2 years 
earlier. The patient developed 
serious liver failure (ascites) 
while continuing MTX 
treatment. However the 
patient recovered after the 
MTX therapy was 
discontinued 
 MTX-related  hepatic 
Kujala, 
G.A., et al., 
[117], 1990 
58-year-old white woman with 
22 years RA 
Case report    A liver biopsy revealed 
chronic hepatitis with 
bridging fibrosis and 
piecemeal necrosis. Upon 
discontinuation of MTX, the 
patient’s ascites resolved 
 MTX-related  hepatic   193 
MTX Pulmonary Toxicity Risk Factors 
Reference Specific  Patient 
Group / Sample Size 
Study Type  Result  Analysis 
Method 
Identified Risk Factor 
Searles, G. 
et al, [130], 
1987 
reported 4 cases and 
reviewed 6 published 
cases in the literature 
Case reports and a 
review of the 
literature 
Clinical features of 10 cases: all had dyspnea and most 
of them had cough and fever; 
Profile of possible risk factor: six patients had a 
history of smoking and four patients had pre-existing 
pulmonary diseases 
Not recorded  Smoking, pre-existing 
pulmonary diseases 
Golden, 
M.R., et al., 
[132], 1995 
93 women and 32 men 
with RA treated with 
MTX for any period 
of time between Jan. 
1980 and Jul. 1989 
case-review study  MTX pneumonitis occurred in 4 of 77 (5.2%) patients 
without pre-existing lung disease and 5 of 29 (17.2%) 
patients with pre-existing lung disease (P=0.0610, 
Fisher’s exact test). There are no differences between 
those developing pneumonitis cases and those not 
developing pneumonitis in age, sex, accumulation of 
MTX dose and duration of therapy. The clinical 
characteristics of the 9 MTX pneumonitis patients are 








G.J., et al., 
[107], 1994 
12 patients with MTX 
pneumonitis were 
compared with 24 
age/sex matched 
controls 
case-control study  A shorter duration of MTX treatment and a higher 
incidence of pre-existing lung disease were observed 
in MTX pneumonitis cases, but no significant 
statistical differences. Two groups have no difference 
in smoking, RA duration, MTX dosage, and creatinine 
clearance 
Not recorded  pre-existing lung disease   194 
Alarçon, 
G.S., et al., 
[131], 1997 
29 patients with MTX 
pneumonitis from 
1981 to 1993 were 
compared with 82 
controls 
case-control study  Case-patients were more likely be advanced in age, 
smoker, with rheumatoid pleuropulmonary 
involvement, with previous use of antirheumatic drugs 




Advanced age, smoking, 
rheumatoid 
pleuropulmonary 
involvement, previous use 
of antirheumatic drugs and 
low serum albumin 
Kremer, 
J.M., et al., 
[136], 1997 
27 RA patients with 
MTX lung injury and 
2 with probable MTX 
lung injury between 




review and extracted 
from the English 
medical literature 
Symptoms are normally present for several weeks 
before diagnosis. Earlier recognition and drug 
withdrawal may avoid serious outcomes 
Not recorded  Clinical features including 
shortness of breath, cough 
and fever, sputum 
production, tachypnea, rales 
on examination 
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